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Chapter I 
SITUATION AND AIM 
 
With the discovery of cytokines and their mechanism of action, there is an increasing interest 
in their therapeutic use as mucosal immune modulators. Mucosal delivery of cytokines would 
allow exerting a local effect, resulting in fewer side effects than systemic administration. This 
requires the production of an oral formulation for cytokine delivery. A conventional 
formulation of recombinant cytokines is extremely expensive (purification, etc.). Besides this 
approach suffers from many other technical obstacles e.g. the cytokines extreme sensitivity 
towards intestinal fluids, its poor local delivery resulting in the requirement of large, repeated 
doses making this method unsuitable due to both cost and availability of the cytokines. This 
emphasises the need for an alternative delivery system. Steidler et al. (2000) described the 
advantageous use of recombinant Lactococcus lactis strains for the in situ delivery of 
cytokines. These genetically modified (GM) food grade organisms, used as a live bacterial 
vector, produce therapeutic proteins in vivo and provide an elegant tool for targeting those 
proteins to the mucosae. This concept has two applications.   
• Some cytokines can be used for their counter-inflammatory characteristics. As 
interleukin-10 (IL-10) plays a central role in down-regulating inflammatory cascades, it 
looked a promising candidate to treat Crohn’s disease, a severe, chronic intestinal 
inflammation. However IL-10 given through the systemic route is not effective. A local 
delivery of the cytokine seems more promising.  
• Some cytokines exhibit immune stimulation capacities. They could be very useful in the 
area of vaccination. To improve efficacy, safety and ease of administration, the development 
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of new vaccine delivery technologies is intensively investigated. More specifically, mucosal 
vaccination is an expanding field in the domain of vaccination. It prevents the need for 
specially trained personnel and instruments, avoids discomfort, allows easy administration 
and precludes the risk of disease transmission associated with parenteral administration. In 
contrast to parenteral vaccination, mucosal vaccination allows, besides systemic immunity, 
effective induction of the mucosal immune system. Induction at the site of infection, e.g. the 
small intestine, results in a mucosal immune response, which provides the main protection 
against mucosal infections and is characterised by the production of secretory IgA (sIgA). 
Mucosal immunity against enteric pathogens can therefore best be obtained by local exposure 
of the antigens to the Peyer’s Patches (PP) of the gut-associated lymphoid tissue (GALT).  
Besides the growing interest in the development of human mucosal vaccins, a veterinary 
model has been chosen in this research project. Enterotoxigenic Escherichia coli (ETEC) 
infections occur in neonatal piglets, during the suckling period or within the first week after 
weaning, through specific adherence of the E. coli's F4 fimbriae (F4+ ETEC) on the intestinal 
mucosae of the piglets, resulting in diarrhoea and mortality. The development of an efficient 
vaccine can lead to a strong decrease in economic loss. However, attempts to induce intestinal 
immunity in pigs before or around weaning by oral administration of inactivated ETEC or F4 
fimbriae as antigen have met with little or no success, due to insufficient activation of the 
protective immune mechanisms. Co-administration of the cytokine producing L. lactis could 
increase the efficacy of mucosal vaccination.  
In this research, the first aim was the development of an oral formulation of recombinant 
Lactococcus lactis with maintenance of its capacity to produce immune modulators, for which 
the microorganism has been genetically modified. Since L. lactis is available as a liquid 
suspension after cultivation and the cytokine production is strictly related to its viability, a 
suitable drying technique had to be selected, with maintenance of an acceptable viability. 
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Besides, for an effective delivery of the immune modulators, the viability and involving 
metabolic activity of L. lactis must be ensured at the target site. This implied the development 
of an enteric-coated formulation that protects the bacteria from the detrimental gastric fluid 
and bile salts. For human application, L. lactis should be targeted specifically to the ileum as 
the bile salt concentration is at lowest there because of their active ileal reabsorption. 
Moreover for mucosal vaccination, Peyer's patches are most prominent in the terminal ileum 
and for patients with Crohn’s disease, the site of inflammation is mainly localised in the 
ileum. Therefore the development of a coatable dry dosage form for targeting L. lactis to the 
ileum was required. The suitability of the available coating polymers for ileal targeting had to 
be evaluated. To avoid high costs, environmental and safety problems as well as detrimental 
effects of organic solvents on the viability of L. lactis, aqueous based coating polymers were 
required.  
For the administration of L. lactis and F4 fimbriae to suckling pigs, a multi-particulate 
formulation (~1 mm) had to be developed as it has to be mixed with their creep feed. The L. 
lactis’ viability and the F4 biological activity (immune stimulating capacity) had to be 
maintained. Moreover, the formulation had to be enteric-coated to protect both L. lactis and 
the F4 fimbriae against the gastric fluid, bile salts and digestive enzymes and more 
specifically the F4 fimbriae against the neutralising anti-bodies, present in the mother's milk. 
Finally, L. lactis and the F4 fimbriae had to be targeted to the pig’s jejunal Peyer’s patches, 
the major inductive sites of the F4-specific intestinal immune response.  
REFERENCES 
Steidler, L., Hans, W., Schotte, L., Neirynck, S., Obermeirer, F., Falk, W., Fiers, W., Remaut, 
E., 2000. Treatment of Murine Colitis by Lactococcus lactis secreting Interleukin-10. Science 
289, 1352—1355.   
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Chapter II 
INTRODUCTION 
 
II.1 INTRODUCTION 
The recombinant Lactococcus lactis has two applications as alternative delivery vehicle of 
immune modulators (Cf. Chapter I), i.e. for treatment of Crohn’s disease and in the area of 
mucosal vaccination. These two applications as well as the biosafety aspects of the 
recombinant L. lactis will be highlighted in this chapter. Furthermore the stabilisation of live 
bacteria in dry formulations, the application fields of these formulations, the drying 
techniques used and the stabilisation mechanisms will be discussed. Finally, the techniques 
reported in literature for drying and formulation of L. lactis will be reviewed.    
II.2 CROHN’S DISEASE 
Crohn’s disease is, like ulcerative colitis, an inflammatory bowel disease (IBD) and is 
characterised by a chronic, discontinuous, transmural intestinal inflammation. It predominates 
the lower part of the small intestine (ileum), but may occur in any area of the gastro-intestinal 
tract and can be associated with many extra-intestinal manifestations. The prevalence ranges 
from 10 to 70 per 100 000 and is much more common in industrialised countries. 25 to 30% 
of Crohn’s disease patients develop the disease before the age of 20. Although its aetiology 
remains poorly understood, IBD is thought to arise from interaction of genetic (Hugot et al., 
2001) and environmental (infectious agents present in the gut, hygiene) factors and may 
involve abnormal T-cell responses to commensal microflora (Duchmann and Zeitz, 1999). 
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The symptoms during the relapse periods include abdominal pain, especially right lower 
quadrant abdominal pain as more than 70% of Crohn’s disease patients have involvement of 
the terminal ileum. Thereby, the patients also suffer from diarrhoea, weight loss and general 
malaise. The situation can lead to fistulae, abscesses and bowel obstructions. As currently no 
medical or surgical cure exists, the goals of medical treatment are to suppress the 
inflammatory response, to relieve symptoms and to induce remissions of the disease. 
Commonly used medicines include aminosalicylates (in mild active disease and to maintain 
remission), corticosteroïds (in more severe active disease), immune suppressants and 
antibiotics. Approximately 70% of the patients require surgery at some time during their life. 
However, the disease is not curable by surgical resections and recurs at a rate of 90% in very 
long-term follow-up, even 50% after 1 year. Death can result, in extreme cases, from 
malnutrition, dehydration and anaemia (Stites et al., 1994).  
There is a need for novel therapies that effectively induce remissions in patients that are 
resistant to current medical treatment, and that alter the natural course of the disease. A large 
number of studies demonstrated abnormal cytokine production in patients with Crohn’s 
disease. Crohn’s disease does not only involve excessive immune activation by enhanced 
production of the pro-inflammatory cytokines, but also involves defective anti-inflammatory 
mechanisms. In patients with Crohn’s disease, the capacity to restrain mucosal inflammation 
may be limited either due to insufficient production of anti-inflammatory mediators (IL-10 
and IL-4) relative to levels of inflammatory cytokines (IL-1, 6, 8, 12 and TNF-α produced by 
the macrophages and IL-2, IFN-γ produced by the T-cells) or due to a resistance to anti-
inflammatory mediators (Duchmann and Zeitz, 1999). 
Several animal models of inflammatory bowel disease have shown the importance of IL-10 
for the regulation of mucosal inflammation, e.g. gene-targeted IL-10-deficient mice develop a 
severe transmural inflammation of the small and large bowel, reminiscent of Crohn’s disease. 
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This inflammation could be prevented by the administration of IL-10, suggesting that IL-10 is 
candidate for therapeutic suppression of mucosal inflammation in Crohn’s disease (van 
Deventer, 1997). Van Deventer et al. (1997) evaluated this in humans. Active steroid-resistant 
Crohn’s disease patients were treated with recombinant human IL-10 and showed that the 
treatment with short-term (7 days) intravenous administration of IL-10 is not only safe and 
generally well tolerated (0.5-25 µg/kg), but also clinically efficient. At the end of the study, 
Crohn’s disease activity scores were 179 in IL-10 treated patients and 226 in patients 
receiving placebo. The proportion of patients who experienced a complete remission at any 
time during the 3-week follow-up period was 50% in the IL-10 group and 23% in the placebo-
treated patients. 
However, Fedorak et al. (1998) showed a bell shaped dose response curve for IL-10, having 
an optimum at about 5 µg/kg. At doses higher than 10 µg/kg, patients started to have adverse 
effects, including fever. Moreover, data from Tilg et al. (2002) strongly indicated that IL-10 
administered at a high dose (20 µg/kg) increased the production of IFN-γ by peripheral blood 
lymphocytes, indicating IL-10’s immuno-stimulatory mode of action. No clinical efficacy was 
observed in patients with active Crohn’s disease at this dose, and side effects including fever 
and headache were observed. This suggests that its pro-inflammatory effects limit the use of 
systemically administered IL-10. This problem may be circumvented by approaches that 
result in effective mucosal delivery without causing an increase in systemic IL-10 
concentration. Steidler et al. (2000) tested a new approach of mucosal delivery of IL-10, i.e. 
in situ synthesis by recombinant Lactococcus lactis. It was shown in two mouse models that 
the therapeutic dose of IL-10 can be reduced by localised delivery. In addition, daily intra-
gastric administration of IL-10 secreting L. lactis caused a 50% reduction in colitis in mice 
treated with dextran sulphate sodium (curing) and prevented the onset of colitis in IL10-/- mice 
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(prevention). They showed that the therapeutic effect was due to mIL-10 synthesised de novo 
by IL-10 secreting L. lactis.  
Next to hIL-10, TNF-neutralising strategies have been used as immuno-modulatory therapy in 
Crohn’s disease. Infliximab, a TNF neutralising antibody for intravenous use is approved by 
the FDA for treatment of active Crohn’s disease (van Deventer, 2000). 
II.3 MUCOSAL IMMUNITY  
II.3.1 THE MUCOSAL IMMUNE SYSTEM 
The major ports of entry for microorganisms into the human body are the mucosal surfaces of 
the intestinal, respiratory and urogenital tract, with a total surface of 36 m2. Next to non-
immunological barriers such as e.g. gastric acidity, proteolytic enzymes, peristalsis, 
commensal microflora and mucus specifically for the gastro-intestinal tract, an 
immunological barrier protects the intestinal, respiratory and urogenital mucosae from 
potentially harmful antigens by a complex system of immuno-competent cells named the 
mucosa-associated lymphoid tissue (MALT). The MALT provides resistance to infectious 
agents and the potential to differentiate between harmful agents and innocuous substances 
(Simecka, 1998). The MALT comprises the gut-associated lymphoid tissue (GALT), the 
bronchus-associated lymphoid tissue (BALT), the nasal-associated lymphoid tissue (NALT) 
and the urogenital-associated lymphoid tissue, which all show more or less the same 
characteristics. Here, the mechanism of mucosal immunity will be explained at the level of 
the mucosal immune system of the gastro-intestinal tract (Gilligan and Po, 1991) (Fig. 1).  
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Ingested antigen 
↓ 
Uptake by M-cells of PP or isolated 
lymphoid follicles 
Induction Site         ↓ 
Antigen ingestion and presentation by 
antigen presenting cells (APC) 
↓ 
Activation of B- and T-lymphocytes 
↓ 
Migration to mesenteric lymph nodes 
                           ↓  Thoracic duct** 
Systemic circulation 
Effector site   ↓              ↓ 
             Homing          Common mucosal    
immune system 
↓ 
*sIgA secretion by B-lymphocytes  
*  Effector T-cells  
 
Figure 1 Events following oral administration  Figure 2 Structure of the Peyer’s patches (A) and            
of an antigen (**: activated B- and                    detailed structure of M-cells (B). Adapted                                 
T-lymphocytes migrate directly to the rom        from Clark et al., 2001. 
                systemic cirulation in pigs,without  
                passing the thoracic duct) 
 
The GALT is distributed in four anatomical regions (Gilligan and Po, 1991) 
a) the lamina propria which contains a large number of plasma cells as well as macrophages, 
neutrophils, etc.  
b) the intraepithelial lymphocytes which are dispersed between the epithelial cells of the 
mucosal membrane; 
c) the isolated lymphoid follicles, present throughout the intestine and colon; and 
d) the Peyer’s patches (PP) which are clusters of lymphoid follicles found along the wall of 
the small intestine. 
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II.3.1.1 The induction of the immune response 
An immune response is elicited through the lymphoid tissue of the PP (d) and the isolated 
lymphoid follicles (c). At present, there are thought to be two main pathways for antigen 
uptake from the intestine. The first involves the epithelium overlaying the lymphoid follicles, 
isolated throughout the intestine and colon or clustered along the wall of the small intestine to 
form distinct structures such as the PP and appendix. This epithelium is known as the follicle-
associated epithelium (FAE) and is distinguished from the intestinal epithelium by the 
presence of the specialised antigen sampling M-cells (Gilligan and Po, 1991). The M-cells 
are, contrary to regular epithelial cells, characterised by short irregular microvilli, a thin 
surface glycocalyx, reduced quantities of sIgA and mucus to facilitate the accessibility of the 
M-cells’ apical membranes. Moreover, they have few lysosomes and a large number of 
endocytic vesicles for uptake and transport.  
The other pathway for antigen uptake involves the normal epithelium overlaying the diffuse 
lymphoid tissue, including the lymphoid tissues of the lamina propria (a) and intraepithelial 
lymphocytes (b). However, this pathway is less understood and will not be further discussed 
(Nugent et al., 1998, Snoeck et al., submitted).   
After transport of the antigens from the mucosal surfaces into the underlaying lymphoid 
tissues by the M-cells, the antigens are internalised and processed by antigen presenting cells 
(APC) such as dendritic cells and macrophages, located in the subepithelial dome of the PP 
(Fig. 2). This region of the PP is enriched with B-cell follicles surrounded by T-cells, next to 
macrophages and dendritic cells. So the PP include all possible cells necessary for induction 
of an adequate immune response. Dendritic cells are extremely potent APC’s and play an 
important role in the activation of the immune response by presentation of the antigen to B- 
and T-lymphocytes through expression of major histocompatibility complex molecules on 
their cell surfaces. This results in the induction of CD8+ cytotoxic T-lymphocytes and CD4+ T-
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helper cells, which upregulate cytotoxic T-cells and stimulate the B-cells for differentiation to 
IgA+ B-cells, through the secretion of interleukins. These hormone-like immune response 
influencing messengers are also produced by M-cells for stimulation of B- and T-cells.  
II.3.1.2 Effect of the immune response 
After migration to the lymph nodes, where the lymphocytes further differentiate and maturate, 
and next to the systemic circulation via the thoracic duct, the stimulated lymphocytes migrate 
preferentially to mucosal tissues, mediated by the expression of adhesion molecules on 
lymphocytes and on cells associated with mucosal tissues (Fig.1). A unique adhesin molecule 
is MAdCAM-1 (mucosal addresin cell adhesion molecule I) (Simecka, 1998). The lymphoid 
cells partly home to the mucosal site where the immune response has been elicited. There, 
humoral and cellular mucosal immunity is effected in the lamina propria and intraepithelial 
lymphocytes (both named the diffuse lymphoid tissue), respectively. IgA+ B-cells proliferate 
and differentiate to sIgA secretory plasma cells. This results, through stimulation by IL-6, IL-
2 and TGF-β, in local sIgA production. The effects of sIgA include (Holmgren, 1991) 
• immune exclusion by inhibition of bacterial adherence, colonisation and penetration, of 
toxin-binding and -action, of viral attachment and infection and of food AG uptake; 
• interference with microbial growth (e.g. iron utilisation); 
• stimulation of immune response through the facilitation of AG uptake by M-cells into the 
PP.  
Besides to IgA production, IgE responses are also associated with mucosal immunity. IgE 
responses are important in combating parasitic diseases. However, IgE responses can also 
mediate potentially life-threatening immune reactions. Through mast-cell activation, 
responses like increased vascular permeability, vasodilatation and increased mucus 
production can localise and promote clearance of the antigen that triggered the response. 
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However, IgE-mediated immune reactions may also result in hypersensitivity reactions (e.g. 
food allergies) (Simecka, 1998).  
Next to the humoral mucosal immune response by the sIgA-secretion, the cellular mucosal 
immunity is effected by the intraepithelial T-lymphocytes, which exert natural killer activity 
and cell mediated toxicity. So, they are major effectors for the elimination of antigen infected 
cells by e.g. Salmonella.  
Evidence from many studies has confirmed that stimulation of the mucosal immune system at 
one mucosal site can lead to sIgA production in the local as well as distal mucosal surfaces 
(Chen, 2000). This inter-connected mucosal system has been given the name common 
mucosal immune system (CMIS). 
II.3.1.3 Immunologic memory 
Memory is an important component of mucosal immunity. The intestinal sIgA response to 
antigen exposure is of relative short duration (a few months in humans). However, this 
response exhibits a long-lasting memory. This could be explained by the immunological 
memory by specific memory B-cells, that can be rapidly and efficiently triggered by repeated 
antigen exposure (Holmgren, 1991).   
II.3.1.4 Oral tolerance 
Although infection with mucosal pathogens leads to active immunity, oral administration of 
soluble antigens can lead to a phenomenon called oral tolerance (Simecka, 1998). This is 
characterised by a lack of immune response upon a second challenge with the same antigen. 
Although oral tolerance does present a problem for oral immunisation, its purpose may be to 
prevent the development of inappropriate immune responses e.g. immune responses against 
normal intestinal flora resulting in chronic inflammatory responses and responses against food 
antigens leading to food allergies. Thus the oral tolerance’s ability to prevent adverse 
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reactions may be used to treat a variety of immunologic and inflammatory diseases, including 
auto-immune diseases or rejection of organ transplants.   
II.3.2 ORAL VACCINATION 
Generally, vaccines can be classified into cellular or complete vaccines and acellular or 
subunit vaccines. Cellular vaccines are inactivated or attenuated microorganisms, whereas 
acellular vaccines contain purified antigens, responsible for eliciting the immune response. 
Acellular vaccines are isolated from the microorganism (e.g. chemically inactivated toxins, 
purified polysaccharides from encapsulated bacteria) or prepared by recombinant DNA 
technology (e.g. hepatitis B surface antigens). Live attenuated vaccines are considered by 
many to be the most successful of all human vaccines because they confer long-lasting 
immunity after one or two immunisations. Thereby, they generate both humoral and cellular 
immune responses. The main disadvantages of live vaccines include the risk of reversion to 
virulence and hence production of disease, and manufacturing concerns including instability 
of live vaccines during storage, and the scale-up of cell culturing and freeze-drying processes. 
Despite these drawbacks, live vaccines have proven to be remarkably safe and effective and 
have an outstanding benefit-to-risk ratio.  
Most of the currently available licensed vaccines are administered parenterally (IM, SC, ID). 
The parenteral route of immunisation ensures that an adequate amount of the vaccine reaches 
the systemic circulation, giving an effective systemic immune response to most invading 
pathogens.  
However, parenteral immunisation fails when a protective immune response at the mucosal 
surfaces of the body is required. The route of vaccination should mirror the pathway by which 
infections occur naturally. As the major pathogens of man gain access to the body via the 
mucosal sites, mucosal vaccines are preferred unlike parenteral vaccines. For vaccination 
against enteric diseases in particular, it has been shown that oral administration of vaccines is 
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much more effective than parenteral administration (Holmgren, 1991). Moreover, during 
production, the quality of oral vaccines is easier to control than that of parenteral vaccines. 
Oral vaccines are also easier and safer to administer to large population groups since they do 
not require any medically trained personnel, making it ideal for mass immunisation. Oral 
vaccines avoid the pain and discomfort associated with injections, eliminate possibility of 
infections caused by inadequately sterilised needles or needle re-use. As they are less 
invasive, they produce very few side effects and imply larger public acceptance and patient 
compliance. Based on the concept of common mucosal immune system (CMIS), there is 
currently also much interest in the possibility of developing oral vaccines against infections in 
the respiratory and urogenital tracts (Holmgren, 1991; O’Hagan, 1998; Russel-Jones, 2000). 
The best known oral vaccine is the Sabin live attenuated polio vaccine (licensed for human 
use since ’60 but not longer available on the Belgian market). Next, on the Belgian market the 
oral vaccine against typhoid fever, manufactured by Swiss Serum and Vaccine Institute 
(Berna) and marketed as Vivotif Berna (Salmonella typhi) is well known. Other oral 
vaccines on the Belgian market include Broncho-vaxom by Fournier (H. influenzae, K. 
ozaenae, K. pneumoniae, N. catarrhalis, S. pneumoniae and Staphylococcus), Buccaline by 
Qualifar (H. influenzae, S. pneumococcus and Staphylococcus) and Uro-vaxom by Fournier 
(E. coli). However, their efficacy has never been proven.  
Most antigens given by the oral route are poorly immunogenic as a consequence of 
degradation or denaturation in the GI tract, limited absorption and inefficient delivery to the 
MALT. To increase immunogenicity of oral vaccines and hence to decrease the dose and the 
frequency of dose administration, several strategies have been used. 
1. Enteric-coating polymers have been used to protect the vaccines against the detrimental 
gastric environment (O’Hagan, 1998). Klipstein et al. (1983) formulated the B subunit of 
Escherichia coli heat-labile enterotoxin by tabletting the freeze-dried toxin and 
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subsequent enteric-coating. Jain et al. (1996), Wong et al. (1992) and Flanagan et al. 
(1996) described the coating of ovalbumin, Vibrio anguillarum, and heat-killed E. coli, 
respectively on non-pareil seeds and subsequent coating with aqueous Eudragit L30D-
55. The attenuated live strain of Salmonella thyphi (S. thyphi Ty21a) is registered as oral 
vaccine for human use against thyphoid fever. It is available as freeze-dried powder in 
acid resistant capsules.  
2. In order to enhance retention of the vaccine at the target site, bioadhesive polymers have 
been used, e.g. chitosan (Jenkins, 1999). 
3. Particulate delivery systems have been used as they offer the antigen some protection 
against proteolytic enzymes and induce enhanced immune responses following oral 
immunisation as they are taken up with greater efficiency by the M-cells in the Peyer’s 
patches (PP) than soluble molecules, thus providing a higher local antigen concentration. 
Moreover, some induce an adjuvant effect. It is generally accepted that particles with a 
size < 10 µm are taken up by the M-cells in the PP and particles < 5 µm leave the PP to 
the enteric mesenteric lymph nodes. Moreover, several antigens can be administered 
simultaneously and adjuvants can be incorporated as well (Gilligan and Po, 1991; 
O’Hagan, 1998).  
• Biodegradable micro- and nano-particulate delivery systems have shown some 
potential for oral immunisation. Release properties of the antigen can be tailored for 
sustained immune response in order to develop a single-dose vaccine enhancing 
compliance. The most promising are the poly (lactide-co-glycolide) (DL-PLG) particles. 
These are biodegradable and biocompatible and have been used safely in humans for 
many years. Others include alginate microspheres and microspheres produced using 
polymethacrylic acid copolymers (Nugent et al., 1998). 
• Liposomes are composed of a biomolecular sheet of phospholipids forming an enclosed 
vesicle surrounded by an aqueous solution and can act as immuno-adjuvantia for the 
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induction of humoral and cell-mediated immunity (Nugent et al., 1998). The antigen 
may be incorporated either into the phospholipid bilayer (lipid-soluble agents) or into the 
central aqueous space (water-soluble antigens). While liposomes are susceptible to 
degradation within the gut lumen, stability may be increased by modifying their 
chemical composition or by the use of polymerised liposomes.   
• ISCOMS (immuno-stimulatory complexes) are three-dimensional cage-like structures of 
30-70 nm in diameter and are formed by mixing lipids, cholesterol, and Quil A. Quil A 
is a mixture of Quillaja saponins and is a potent immuno-adjuvant. Hydrophobic 
antigens can be incorporated into the ISCOMs by hydrophobic interactions in their cage 
like structure (Chen, 2000).  
• Proteosomes are formed from meningococcal outer membrane proteins (Jenkins, 1999). 
• Virosomes are virus like particles and enhance intracellular antigen delivery resulting in 
the induction of cell-mediated immunity.  
However, there are some drawbacks associated to particular delivery systems. For the 
production of PLG particles and liposomes, high temperature, high shear forces and organic 
solvents are required leading to antigen inactivation. Moreover, only five oral vaccine studies 
in mice with disease-related antigens in PLG demonstrated evidence of protective immunity. 
All other studies were performed with antigens of limited predictive value (O’Hagan, 1998). 
In the successful oral mice studies, the doses of antigen are still too high and the immune 
outcomes too low. So there is not much evidence that antigens in particles can induce 
adequate protective immune responses compared to antigens in solution (Brayden, 2001). 
Importantly, due to lack of data on human tissue, there is difficulty in relating particle uptake 
data in mice to man. There is little evidence to date that a relevant antigen in any polymeric 
system given orally has any real likelihood of making a successful product for man. Human 
studies have so far offered limited encouragement. Moreover, publication bias must be taken 
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into consideration. The major consideration is the poor particle uptake by M-cells and this is 
mainly due to the small portion of FAE occupied by M-cells (10% in human PP).   
4. Particle absorption by the M-cells can be enhanced by altering the particle size, 
hydrophobicity and surface charge. However, a more reliable method for delivery to 
intestinal M-cells is the use of receptor-mediated M-cell targeting. Bioadhesins suitable 
for targeting to intestinal M-cells must satisfy a number of criteria including (1) suitability 
for conjugation to either the biologically active agent or to the delivery vehicle used to 
carry the active agent included, (2) stability in the gut, (3) non-immunogenicity, (4) non-
toxicity, (5) compatibility with other gut luminal contents such as food digests and 
commensal flora (Clark et al., 2001). Three classes of bioadhesins are sited below 
• lectins, which bind to surface exposed carbohydrate residues within the glycocalyx of 
human M-cells, e.g. lectins derived from Sambucus nigra and Viscum album. 
• microbial adhesins, e.g. from Yersinia (invasin), Salmonella, V. cholerae. 
• Immunoglobulins, e.g. IgA and IgG selectively adhere to M-cell apical membranes. 
5. A large number of microorganisms target to and exploit M-cells as a route of host 
invasion. Consequently, live attenuated microorganisms could potentially act as M-cell 
specific mucosal delivery vehicles. Contrary to killed microorganisms, live cultures elicit 
a stronger immune response. Owen et al. (1986) showed that bacterial viability was 
required for efficient uptake by M-cells of Vibrio cholerae. Live attenuated 
microorganisms also offer a number of potential advantages as delivery vehicles for 
mucosal vaccines over synthetic particulates. Appropriate microorganisms are stable in 
the gut, able to cross the mucus blanket to gain access to cell surface receptors and 
possess the innate capacity to bind to M-cell apical membranes without the need for 
targeting ligands. Moreover, it might be predicted that the commercial cost of producing 
live microbial vaccines is likely to be less than required for the bulk production of ligand-
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targeted synthetic delivery vehicles. Live microorganisms have the disadvantage that they 
are associated with serious safety implications, and adequate attenuation is essential. 
However, there is still the danger that pre-existing antibodies may interfere with vaccine 
function.  
Extensively investigated candidates to target to M-cells are the attenuated Salmonella 
species e.g. enteric pathogen S. thyphi (primates), S. thyphimurium (mice) and more 
especially the less pathogenic mutant S. typhi Thy21a, as there is evidence that the M-cells 
are the major site of Salmonella infections in man. They cannot only be used for 
protection against typhoid, but this species can also be genetically manipulated to act as a 
live recombinant bacterial vector for the delivery of heterologous antigens e.g. H. pylori 
and Shigella and they may be suitable as oral delivery systems for DNA vaccines. Other 
proposed vaccine vectors include attenuated strains of Vibrio cholerae, Shigella flexneri, 
Listeria monocytogenes and mycobacteria. In addition, viral vectors can also be used e.g. 
adenovirus (Nugent et al., 1998; Chen, 2000; Clark et al. 2001).  
The development of recombinant bacteria as antigen delivery system has so far been 
focused on the use of live, attenuated strains. These attenuated strains of bacteria have 
proven to be highly effective vaccines, but their efficacy depends on their capacity to 
establish a limited infection in the host. It is this residual level of invasiveness, which may 
be of concern for immunisation of paediatric, geriatric or partially immuno-suppressed 
individuals. Furthermore, the strong immune response elicited against these attenuated 
bacterial carriers may reduce the effectiveness of booster doses of vaccine. 
In a search for safer vaccines, attention has been turned to the use of non-pathogenic 
Gram-positive bacteria such as commensal lactobacilli. However, the lactobacilli have 
proven to be poorly amenable to genetic manipulation. Therefore, the bacterium 
Lactococcus lactis has been proposed as vaccine delivery vehicle. It is a Gram-positive, 
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facultative anaerobic, non-colonising, non-pathogenic, food-grade bacterium and L. lactis 
is classified as “generally regarded as safe” (GRAS) following its long history of use in 
the human food chain as a consequence of its use in starter cultures for cheese and 
fermented milk products without evidence of pathogenicity. The very little information 
that has been published concerning the immune status of L. lactis indicates its low innate 
immunogenicity. Thereby, it could be repeatedly used for vaccination. As it does not 
colonise the digestive tract of man or other animals, anticipation has been made that its 
use would require in vitro antigen gene expression to preload the bacteria with antigen 
prior to administration. The antigen-loaded bacteria constitute 1 µm particles and thus 
they resemble antigen loaded micro-particles or liposomes. However, they can be 
prepared at very low cost and without risk of antigen denaturation. The immunogens 
expressed by recombinant bacteria are presented to the immune system in particulate 
form and should therefore be more immunogenic and less likely to induce oral tolerance 
than soluble antigens. Moreover, the antigens within L. lactis are protected against direct 
contact with gastric acid and proteolytic enzymes.    
It has been shown that recombinant L. lactis can be pre-loaded in vitro with high levels of 
the heterologous antigen tetanus toxin fragment C (TTFC). Very encouraging are the 
results that show that they are, despite this lack of invasiveness, capable of delivering 
antigens to antigen presenting cells resulting in both mucosal (sIgA) and systemic (IgG) 
humoral immune responses following oral (Robinson et al., 1997) and intranasal (Norton 
et al., 1995) immunisation of mice. This resulted in protection against subsequent 
challenge with lethal quantities of tetanus toxin, as previously shown by Wells et al. 
(1993) after subcutaneous immunisation of mice. Norton et al. (1995) showed that when 
cholera toxin was co-administered as an adjuvant, significant quantities of enteric sIgA 
were formed after intranasal inoculation.     
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In order to improve mucosal vaccination, Steidler et al. (1998) constructed strains of L. 
lactis, which accumulate the TTFC antigen within the cytoplasmic compartment and also 
secrete either biological active murine interleukin-2 (IL-2) or IL-6. When mice were 
immunised intranasally with these strains, the anti-TTFC antibody titers increased more 
rapidly and were substantially higher than in mice immunised with the TTFC loaded L. 
lactis without IL-2 or IL-6 secretion. This adjuvant effect was lost when the recombinant 
strains were killed, indicating that the enhancement of the immune response to the 
coexpressed heterologous antigen could be attributed to the secretion of IL-2 or IL-6. No 
increase of antibody titer against L. lactis itself was observed. 
6. Recent findings are in contrast to the belief that all antigens are non-specifically 
phagocyted by the M-cells. Mucosal binding proteins (e.g. pili, many bacterial toxins, 
tomato lectins, plant toxins) can bind to the intestinal epithelium, rather than to the M-
cells and stimulate those enterocytes to endocytose and shunt them to underlying cells. 
Those binding proteins can be conjugated to the antigen (e.g. antigen-loaded 
microparticles linked to lectins) to form bioconjugates (Russel-Jones, 2000). Moreover, 
enterocytes offer a greater surface area than the M-cells. This can largely compensate the 
relatively inefficient particle absorption across epithelia compared to that across the FAE, 
mediated by M-cells. 
7. In order to potentiate the immune response, a mucosal adjuvant can be administered co-
currently with an antigen (Chen, 2000). 
• Bacterial enterotoxins e.g. cholera toxin (CT) and E. coli heat labile toxin (LT) target 
innate immune pathways for activation of specific immunity pathways. Their use in 
humans is limited due to their toxicity. However, their adjuvant role has been separated 
from the enterotoxic effect. 
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• Aluminium salts enhance the uptake by APC through denaturation and precipitation of the 
antigens.  
• Mineral oils are used to create a slow release antigen depot.  
• CpG oligonucleotides have shown some promise as vaccine adjuvants in recent years 
(Chen, 2000).     
• Perdigon et al. (1999) showed that some lactic acid bacteria (LAB), when orally 
administered, can induce an enhancement of the gut immune response namely an increase 
of the IgA+ B-cells at intestinal level by a dose depending effect. Moreover, the LAB, 
with the exception of L. acidophilus, were able to enhance IgA+ B-cells at bronchial level, 
being also this effect dose dependent.  
8. Since the recent discovery that intra-muscular injection of plasmid DNA, that encodes for 
a protective immunogen, resulted in expression and production of the protective 
immunogen in the host cells and subsequent induction of antibody and cell-mediated 
immune response, the concept of using DNA as a vaccine has been extensively explored. 
Efficacy of mucosal DNA vaccination in mice has been shown but must be proven in 
large animal models (Nugent et al., 1998; Chen, 2000). 
II.4 BIOSAFETY ASPECTS OF THE RECOMBINANT LACTOCOCCUS LACTIS 
Because of their economic importance in food fermentation, an intensive research effort has 
been made over the last decades to characterise the lactic acid bacteria at a genetic level and 
to develop methods that would ultimately allow improvement of commercially important 
strains. Lactococcus lactis is a model LAB; many genetic tools have been developed and its 
complete genome was recently sequenced (Bolotin et al., 2001). As a result of this research, 
lactococci have now become more accessible to genetic manipulation. However, the release 
of genetically modified organisms (GMO’s) in the environment raises safety concerns in three 
aspects 
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1. the uncontrolled dissemination of the GMO in the environment  
2. the dissemination of genetic modifications to other microorganisms 
3. the dissemination of antibiotic selection markers. 
In the laboratory of the Department of Molecular Biomedical Research (DMBR) and the VIB, 
a strategy has been developed to address these problems. 
1. The thymidilate synthase gene, thyA, which is essential for the growth of L. lactis as it 
plays an essential role in its DNA synthesis, was replaced by the expression cassette of 
hIL-10. As expected, the resulting strain was dependent on thymidine or thymine for its 
growth and its survival. It has been shown that this strain is self-limiting because when 
this strain is deprived of thymidine or thymine, its viability dropped by several orders of 
magnitude (107-fold decrease in CFU after 72 h in the absence of thymidine), essentially 
preventing its accumulation in the environment. This biological containment system was 
validated in vivo in pigs (Steidler et al., 2003). 
2. The risk of dissemination of the genetic modification through lateral gene transfer is 
minimised because the hIL-10 gene is integrated in the L. lactis chromosome. If the 
unlikely event takes place that the engineered L. lactis acquires an intact thyA gene from a 
donor such as L. lactis subsp. cremoris, the transgene would be eliminated from the 
genome. 
3. As the expression unit is integrated in the bacterial chromosome, stable inheritance of the 
transgene is guaranteed and circumvents the need for antibiotic resistance genes. 
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II.5 STABILISATION OF LIVE BACTERIA IN DRY (PHARMACEUTICAL) FORMULATIONS 
II.5.1 APPLICATION FIELDS OF DRY LIVE BACTERIA FORMULATIONS 
II.5.1.1 Dairy and food industry  
Strains, and mainly Lactic Acid Bacteria (LAB) (Lactobacillus plantarum, Lactobacillus 
rhamnosus, Lactobacillus bulgaricus, Lactobacillus acidophilus, Streptococcus thermophilus, 
Streptococcus cremoris, Lactococcus lactis,  …) are selected as starter cultures in dairy 
industry for the production of cheeses and yoghurt because of their highly desirable 
technological properties i.e. high acid-producing activity, moderated proteolytic activity and 
high resistance to bacteriophage infection. Next to enterococci (E. durans and E. faecalis), 
lactococci play an important role in ripening, aroma, flavour and texture development in 
several cheeses. LAB also play a crucial role in the production of other fermented food 
products including vegetables, meat (sausages) and wine.  
In the dairy industry, starter cultures were initially supplied in the liquid form (109 CFU/ml). 
However, they could not be used for direct inoculation of the cheese vats and the cheese-
makers had to prepare the intermediate and bulk starters to produce sufficient inoculum to add 
to the cheese vat (1-2% (v/v)). Moreover, liquid cultures have a limited shelf life and are not 
easily transportable. Advances in biotechnology of biomass production brought more 
convenient forms of dairy starter cultures. Two forms are available on the market: frozen and 
freeze-dried concentrates. They can eliminate the subculturing step and have been used 
successfully for the direct inoculation of milk. The frozen concentrated cultures contain 90% 
water, are heavy and bulky, and require sub-zero temperatures for shipment and storage; they 
must be maintained in a freezer at –45°C or in liquid nitrogen during storage at the plant. 
Owing to the risks of thawing during transportation or storage of the frozen cultures, freeze-
dried concentrates seem to be a promising alternative for the direct inoculation of cheese-
making milk (Champagne et al., 1991). Moreover, dried preparations have advantages of 
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long-term preservation and convenience in handling, storage, marketing and consumption, but 
are costly to produce. Maximum survival of LAB starters during drying and subsequent 
storage is of vital importance, technologically and economically. However, next to the 
viability, the lactic acid production capacity is important for starter cultures. The lag time 
before acidification begins is longer for the freeze-dried than for the frozen cultures. Spray-
drying has been extensively investigated as a method to replace the usual liquid bulk starters. 
Despite its low cost in comparison to e.g. freeze-drying, it has not been developed 
commercially, mainly because of low survival rates during drying. Acceptable results are only 
achieved with some thermoduric lactics. However, most of the mesophilic lactics (mainly 
used for cheeses e.g. Lactococcus lactis) are very sensitive to spray-drying. Starters could also 
be vacuum-dried, although survival rates may be inferior to those of freeze-dried starters.  
II.5.1.2 Probiotics 
The definition of “probiotics” implies that this term is restricted to products which 
(1) contain live microorganisms e.g. as freeze-dried cells or in a fermented product, 
(2) improve the health status of men or animals and 
(3) can have its effect in the oral cavity or gastro-intestinal tract (e.g. in food or capsules), the 
upper respiratory tract or in the urogenital tract.  
Owing to their properties, probiotics are incorporated in functional foods. As some lactic acid 
bacteria have probiotic characteristics, they are therefore widely used in the manufacturing of 
fermented dairy products in order to obtain probiotic cheese and yoghurts. For that purpose, 
they are available as highly concentrated frozen or freeze-dried cultures. In the functional 
foods, no minimum levels of live bacteria are depicted but it has been recommended that 
probiotic functional foods should contain at least 107 live microorganisms per g or per mL 
(Ishibashi and Hinamura, 1993). Even if this recommendation is followed, there is no 
guarantee that the product contains this level at the time of consumption because of its limited 
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shelf-life. A dry product could better serve these needs and allow for easier reconstitution by 
the consumer. Besides, this application form is more readily transportable to distant markets 
at low cost. Probiotics can also be used in non-dairy products e.g. cereal products. Next, 
probiotics are available in dietary supplements i.e. in special formulations like capsules or 
tablets, or as a fermented milk beverage (e.g. Actimel (1010 Lactobacillus casei/100 ml)) or 
added to fresh milk without any fermentation (Sanders, 2003). There is an enormous diversity 
among the dietary supplements and a lack of standardisation.  
Few pharmaceutical formulations containing viable probiotics have been reported in the 
literature. Maggi et al. (1994, 2000) developed a formulation for vaginal administration of 
different strains of lactobacilli in order to restore the normal vaginal flora as a new approach 
for therapy and prevention of urogenital tract infections in the female population. Freeze-
drying was used to obtain a microbial powder preparation. Next, this powder (mixture of three 
strains) was compacted in tablets consisting of two layers with different release properties: 
one is effervescent that ensures a rapid and complete distribution of the active ingredient over 
the whole vaginal surface; while the second is a sustained release composition capable of 
releasing the lactobacilli over a longer period of time. This formulation showed the feasibility 
of industrial production and a good bacterial viability in the final dosage form.   
Stadler and Viernstein (2003) developed a gastric juice resistant tablet formulation containing 
Lactobacillus acidophilus in order to successfully implant probiotics in the gastrointestinal 
tract for exerting beneficial effects. Freeze-dried powder was mixed with 
hydroxypropylmethylcellulose acetate succinate and sodium alginate and compacted to tablets 
and resulted in a formulation with good protective qualities against artificial gastric juice. It 
must be concluded that oral formulations of L. lactis lack in literature. Because of their 
colonising capacity and superior resistance to the detrimental gastric fluid and bile salts, 
lactobacilli are preferred as probiotic strains for oral administration.  
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II.5.1.3 Vaccines 
Live microorganisms are currently being actively evaluated for human pharmaceutical use in 
the development of new vaccines and the use of live organisms as delivery vehicles for 
protein antigens or for gene therapy. There is much interest in the use of live oral vaccines to 
develop protection against a number of enteric diseases such as typhoid fever, as well as 
Shigella, V. cholerae, and enterotoxigenic E. coli gastroenteritis. However, very few live oral 
vaccines are currently registered. In order to produce a safe and efficacious vaccine, the right 
balance must be found between attenuation of the bacteria for safety and maintaining 
immunogenicity. Bacterial pathogens are registered as oral vaccines for human use, including 
attenuated live strains of Salmonella typhi (S. typhi Ty21a) and Vibrio cholerae (V. cholerae 
CVD 103-HgR) against typhoid fever and cholera, respectively. Depending on the country, 
Ty21a, grown to stationary phase, mixed with excipients, and freeze-dried is available in acid 
resistant capsules or as a liquid formulation stored in a double-chambered aluminium foil 
packet sachet; one chamber contains the freeze-dried bacteria, while the other contains a 
neutralised buffer (sodium bicarbonate-ascorbic acid). The vaccine is reconstituted by mixing 
the powders in both chambers with water. The enteric-coated capsules are stable for up to 24 
months, while the sachet formulation is stable for 15 months during storage under 
refrigeration. CVD 103-HgR is presented only in the liquid formulation. Both vaccines have 
been proven to be immunogenic and efficacious in a wide range of pre- and post-marketing 
clinical studies. 
Considerable interest has also been generated by the use of live attenuated bacteria as oral-
delivery vehicles of either surface antigens or DNA plasmids introduced by genetic 
engineering for gene therapy. For example, there has been much work done with bacterial 
recombinant carrier strains expressing foreign antigens in S. typhi and V. cholerae. The 
successful use of live attenuated viral and bacterial vaccines depends not only on the proper 
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choice and delivery of microorganisms, but also on maintaining the sufficient potency 
required for an immune response. The inherent lability of live organisms present a particular 
formulation challenge in terms of stabilising and preserving vaccine viability during 
manufacturing, storage and administration. This has required the implementation of a system 
– the so-called “vaccine cold chain” system – that ensures that vaccines are kept cold during 
transportation and storage in order to maintain their potency. Especially in developing 
countries, maintaining a proper cold chain is still a significant logistical challenge. 
Live vaccines for parenteral injection (subcutanously or intramuscularly) are usually stored in 
vials or prefilled syringes. For oral administration, live vaccines are typically formulated to 
protect the microorganisms from degradation from gastric acid. One exception is the oral 
administration of the polio vaccine; in this case, the virus is sufficiently acid-stable to allow 
direct administration. Tablet or capsule formulations with enteric coatings have been used for 
oral delivery of gastric acid-sensitive, live bacterial vaccines (cf. p. 13). Nasal delivery is also 
an attractive route and typically occurs through metered-spray devices. Typically in the 
pharmaceutical industry, a freeze-drying process is employed to dry live vaccines and store 
them in the solid state.   
II.5.2 OVERVIEW OF THE DRYING TECHNIQUES OF BACTERIA 
II.5.2.1 Freeze-drying 
The freeze-drying procedure consists of two separate processes: solidification (freezing of the 
materials to be dried) and drying of the frozen materials under reduced pressure (vacuum).  
Originally, freeze-drying was designed for long-term preservation of biological materials, 
pharmaceuticals, and other compounds that are unstable when dissolved or dispersed in a 
solvent. As an industrial process it dates from the time during World War II when the demand 
for human blood plasma reached critical proportions.  
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Nowadays, besides for the preparation of solid protein pharmaceuticals (Carpenter et al., 
1997; Wang, 2000; Arakawa et al., 2001), freeze-drying is the most commonly used method 
for preparing dry live (attenuated) bacteria or viruses as vaccines (Burke et al., 1999; Worrall 
et al., 2001) or for food application (Champagne et al., 1991). 
II.5.2.2 Spray-drying 
Spray-drying is the most used dehydration method in food industry e.g. to process milk, 
cheese, whey, coffee, tea, eggs, encapsulated flavours. Thereby, a variety of heat sensitive 
biological materials are currently spray dried. These include enzymes, sera, plasma, 
microorganisms and yeasts.  
Spray-drying has been used extensively in the pharmaceutical industry, primarily in the 
production of raw drug materials (e.g. antibiotics) and excipients (e.g. spray-dried lactose). 
Other well established pharmaceutical applications include granulation and 
microencapsulation processes (Broadhead et al., 1992). The production of powders for dry 
powder aerosols by spray drying has also some potential because of the ability to produce 
particles of controlled size and shape.  
Interest in developing novel delivery systems for protein and peptide drugs (e.g. cytokines, 
human growth hormones, plasminogen activator) and vaccines has focused attention on spray-
drying as a mean of processing these thermolabile materials. Spray-drying may be a useful 
alternative to freeze-drying as it is less time-consuming and expensive. It has been estimated 
that the cost of spray-drying is six times lower per kilogram of water removed than that of 
freeze-drying.  
II.5.2.3 Vacuum-drying 
Vaccum-drying involves the removal of water from the product by evaporation at low 
pressure (i.e. under vacuum). When compared to freeze-drying, an advantage of vacuum 
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drying is the avoidance of the freezing step, the reduced cost and the lower energy 
consumption.  In comparison with spray-drying, it is a slow process. However, the drying 
temperature can be adjusted close to room temperature by pressure reduction, which is an 
advantage over spray-drying.    
Dehydration of microorganisms by vacuum drying has the potential drawback that the 
microorganisms are exposed to a liquid-state environment during drying, potentially for 
relatively long periods of time. These are conditions in which some live vaccines may be 
inactivated. This is contrary to freeze-drying, where the water is removed from the solid, 
frozen state, resulting in the drying of a live vaccine under frozen (and presumably more 
stable) conditions.  
II.5.3 STABILISATION MECHANISMS 
In nature, both plants and microorganisms can be exposed to extreme environmental 
conditions such as temperature (heat and cold), pH and high ionic strength, and low water 
activity (dehydration). Before considering pharmaceutical approaches to stabilise biological 
drugs and vaccines for long-term storage via freezing and freeze-drying, it is of interest to 
consider the ways in which nature responds and provides preservation under conditions of 
external environmental stress. Two basic strategies of adaptation to stress have been identified 
(Burke et al., 1999):  
• adjusting macro-molecules to withstand environmental conditions (e.g. enzymes from 
thermophilic microbial sources have subtle changes in amino-acid sequence, leading to 
increased conformational rigidity)  
• synthesising compatible solutes such as unique macro-molecules (anti-freeze and heat-
shock proteins) or small molecules (osmolytes and sugars such as sucrose and trehalose) 
that protect the proteins and membranes of the organisms against stressful environmental 
conditions. The best-studied is the use of sugars such as sucrose and trehalose by plants 
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and microorganisms to prevent damage during dehydration by desiccation and 
subsequent long-term storage. Water is usually thought to be required for the living 
state, not only for the metabolic reactions, but also for the structural stability of cellular 
constituents or organelles. However, numerous organisms are nevertheless capable of 
surviving essentially complete dehydration. The dry organisms may remain in the unique 
living state, which is known as anhydrobiosis. When water again becomes available, 
they rapidly resume metabolism.  
Two mechanisms have been proposed for the protective effects of sugars upon dehydration 
(Crowe et al., 1992). 
1. First, drying of macromolecules in the presence of sugars results in an amorphous, 
glassy state of very high viscosity. This vitrification of macromolecules embeds them 
into a “rocky candy” type of glassy state, inhibiting chemical and biochemical reactions 
since mobility/diffusion is of the order of micrometers per year. The amorphous 
structure is characterised by the glass transition temperature (Tg). When the amorphous 
material is exposed to a temperature above Tg, it will collapse, resulting in a rubbery 
state and loss of stabilising capacity. When the material is exposed to a temperature 
below Tg, it occurs in a glassy state. However, Tg is an unsatisfactory indicator for the 
temperature below which molecular motions and hence chemical and physical 
degradation reactions are zero (Yu, 2001). T0 rather than Tg should be used as a practical 
guide for selecting the storage temperature, as only below this temperature zero mobility 
is obtained. T0 is at least 50°C below Tg (the Tg – 50°C rule). Next, the amorphous state 
of a material is unstable and crystallisation can occur, leading to loss of stabilising 
power (Franks, 1999). 
2. Second, sugars can replace water in the dried state, thus satisfying hydrogen-bond 
interactions of proteins and lipid bilayers, which are necessary in maintaining the native 
II. Introduction                   30
conformation of proteins (Carpenter et al., 1989) and lipid bilayers (Crowe et al., 1987). 
This “water-replacement” hypothesis does not exclude the formation of glassy states 
upon drying, but rather asserts that glassy states in themselves are not sufficient and a 
direct interaction between sugar and macromolecules is required. Removal of hydrogen-
bonded water from the head group region of phospholipid bilayers increases the head 
group packing and forces the acyl chains together, increasing the probability of Van der 
Waals interactions. As a result, the lipid may undergo a transition from liquid crystalline 
to gel phase (Fig. 3).  
 
Figure 3 Mechanism by which trehalose stabilises dry phospholipids bilayers as proposed by Crowe et 
al. (1992) (Trehalose: ∆; water: •) 
Upon rehydration, dry membranes, which are in gel phase at room temperature, undergo 
a transition from gel to a liquid crystal phase. As the membranes pass through this phase 
transition there are regions with packing defects, making the membranes leaky. Adding 
a disaccharide such as trehalose before drying lowers the transition temperature TM of 
the dry membranes by replacing the water between the lipid head groups, preventing the 
phase transition and its accompanying leakage upon rehydration (Fig. 3). In addition, 
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the ability to stabilise proteins during drying results from the disaccharides, forming 
hydrogen bonds with the proteins when water is removed, thus preventing protein 
denaturation.  
II.5.4 LITERATURE OVERVIEW OF THE LACTOCOCCUS LACTIS DRYING TECHNIQUES AND 
FORMULATIONS  
In the literature, spray-drying (Fu and Etzel, 1995; To and Etzel, 1997; Mauriello et al., 1999) 
and freeze-drying (Champagne et al., 1991, 1992; Cárcoba and Rodríguez, 2000; To and 
Etzel, 1997) are mentioned as drying techniques of Lactococcus lactis for use in the dairy 
industry as starter culture.  
In general, for the spray-drying of L. lactis, it can be concluded that cell viability after spray-
drying decreased with increasing inlet and outlet-air temperature. To and Etzel (1997) 
observed a viability of 2.95 ± 0.07% to 0.35 ± 0.07% after spray-drying at 65 and 90°C 
outlet-air temperature, respectively. Fu and Etzel (1995) also obtained the highest viability at 
the lowest outlet-air temperature (77°C) and with the highest cell concentration in the feeding 
suspension (1.1 x 1011/ml) (78%). Mauriello et al. (1998) showed a viability of 8-12% at the 
lowest inlet-air temperature (160°C), independent of the feeding suspension used (skim milk 
or whey).  
According to Fu and Etzel (1995), storage at 4°C for 3 months caused a 54% loss of viability. 
Mauriello et al. (1998) showed a loss of more than 99% after storage for 2 months at 4°C.  
Concerning metabolic activity after spray-drying, To and Etzel (1997) showed a delay in 
lactic acid production after spray-drying. Contrary, Fu and Etzel (1995) showed that the lactic 
acid production was similar for frozen, freeze-dried and spray-dried cultures made from a 
single cell paste and concluded that the lag-time before lactic acid production was apparently 
an inherent characteristic of each specific cell paste. Mauriello et al. (1998) evaluated the 
bacteriocin producing capacity of Lactococcus lactis strain for their use as starter and 
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protective cultures reducing risk of growth and survival of pathogens and spoilage 
microorganisms. They found no loss of ability to produce bacteriocin or any loss of 
bacteriocin activity after spray-drying.  
For freeze-drying of L. lactis, several studies have been performed in order to improve 
viability after freeze-drying. Contrary to spray-drying, the process parameters during freeze-
drying were not altered. But in most studies, different substances were added to the freeze-
drying matrix. Cárcoba and Rodríguez (2000) showed that supplementing reconstituted skim 
milk with β-alanine enhanced the highly-protective effect of skim milk 1.4 times (44.3% 
without and 62% with β-alanine) and led to a reduction in lag phase before acidification of 
1.02 times. To and Etzel (1997) showed a survival of Lactococcus lactis subsp. cremoris of 
63 ± 6% in a maltodextrin solution. Font de Valdez (1983) showed the protective effect of the 
amino acid sodium glutamate and the polyols glycerol and β-glycerophosphate on 
Streptococcus lactis after freeze-drying.    
However, these techniques result in a powder formulation. So the development of a final 
pharmaceutical formulation is lacking.  
In the literature, immobilisation of Lactococcus lactis has been described and is of interest to 
the dairy industry since it facilitates cell removal, improving the control of the fermentation 
process in the production of cheese and yoghurt. Since the cells can be recovered and reused, 
high inoculation rates are possible reducing fermentation time. Removal of immobilised 
cultures would reduce or eliminate residual activity in the refrigerated product, extending its 
shelf-life. Moreover, immobilisation tends to stabilise cells, potentially enhancing viability 
and stability in the production, storage and handling of lactic cultures. Next, it reduces the 
chance of phage contamination. Steenson et al. (1987) showed that by immobilisation of 
Streptococcus lactis in calcium alginate, the bacteria were protected from attack by virulent 
bacteriophages. Another application of immobilisation of L. lactis is the control of the 
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development of psychrotrophic bacteria in raw milk, leading to spoilage of the dairy product. 
However, the addition of LAB to raw milk is generally not performed as the numbers of LAB 
that have to be added exceed the established microbiological standards for raw milk. The use 
of immobilised LAB could reduce the levels of free LAB in raw milk and thus help extend 
this practice to non-fermented dairy products. Champagne et al. (1990) showed that addition 
of 107/ml Lactococcus lactis and 108/ml Lactobacillus helveticus, immobilised in calcium-
alginate beads, reduced the development of psychrotrophic bacteria in raw milk with 
approximately 50%. The advantage of immobilisation using natural polymers like alginate is 
that the reagents are non-toxic and the procedures are gentle to the microorganisms. However 
cell release from such beads is undesirable in some applications. Alternatively, the cells were 
micro-encapsulated, involving immobilisation within an ultrathin, semipermeable membrane. 
Larisch et al. (1994) micro-encapsulated L. lactis within alginate/poly-L-lysine (alg/PLL), 
nylon or crosslinked polyethylene imine membranes. Toxic effects were observed with 
solvents and reagents used in nylon and PEI membrane formation. Alg/PLL encapsulation as 
a result of the coating of Alg beads with PLL resulted in viable and active cell preparations 
but acidifying rate less than free cell population. However, there was still a need for stronger 
membranes to prevent cell leakage. Hyndman et al. (1993) used an alternative micro-
encapsulation technique, which involves a single step process i.e. interfacial polymerisation. 
Lactococci were encapsulated within gelatin membranes cross-linked with toluene-2,4-
diisocyanate at an oil/water interface. The micro-encapsulated cells resulted in a similar 
acidification rate of milk as the free cell preparation. Groboillot et al. (1993) also used the 
interfacial polymerisation technique for micro-encapsulation of Latococcus lactis within 
cross-linked chitosan membranes. Although the technique results in less permeable beads, 
loss of cell activity was seen following micro-encapsulation due to the toxicity of the cross-
linking agents (4 log decrease in viability of lactococci) and the free chitosan (polycations 
generally exhibit antimicrobial properties).  
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II.5.5 CONCLUSIONS 
From this literature review it can be concluded that no techniques are available or described 
for the production of an enteric-coated (multi-particulate) formulation of L. lactis. This 
implies the development of a new formulation. 
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III.1 INTRODUCTION 
The aim of Chapter III was the development of an enteric-coated formulation of recombinant 
Lactococcus lactis for ileal mucosal delivery of human interleukin-10. The following strategy 
has been followed in this Chapter:  
1. Since L. lactis is available as a liquid suspension after its cultivation, a suitable drying 
technique had to be selected with maintenance of an acceptable L. lactis’ viability and 
hIL-10 producing capacity. Freeze-drying has been chosen as drying technique as it is the 
most common method for the preservation of bacteria. Chapter III.2 describes the 
development of a freeze-dried powder formulation of viable, hIL-10 producing 
recombinant L. lactis.   
2. Besides, for an effective mucosal delivery of hIL-10, L. lactis’ viability and hIL-10 
producing capacity must be ensured at the target site. This implied the development of an 
enteric-coated formulation that protects the bacteria from the detrimental gastric fluid and 
bile salts. For human application, for both mucosal vaccination and treatment of patients 
with Crohn’s disease, L. lactis should be targeted specifically to the ileum as the Peyer's 
Patches and the site of inflammation are mainly localised in the ileum, respectively. A 
coating polymer, suitable for enteric-coating and ileal targeting had to be selected 
(Chapter III.3). As it is the final aim of this Chapter to develop a multi-particulate 
formulation, the polymers will be evaluated after fluid-bed coating on pellets. 
3. Next, an enteric-coated formulation of L. lactis had to be developed for an in vivo study in 
pigs. As at that stage of the research, the development of a multi-particulate formulation 
was still ongoing and L. lactis was only available as freeze-dried powder, an enteric-
coated capsule formulation had to be developed (Chapter III.4). 
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4. In Chapter III.5 a multi-particulate formulation (~1 mm) of L. lactis was developed in 
order to enhance gastric emptying and ease of swallowing in case of large dose 
administration (human application) and for administration to suckling pigs (veterinary 
application). A production technique had to be selected with maintenance of L. lactis’ 
viability and hIL-10 producing capacity and the formulation had to be enteric-coated.   
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III.2 DEVELOPMENT OF A FREEZE-DRIED POWDER FORMULATION CONTAINING VIABLE, 
INTERLEUKIN-10 PRODUCING RECOMBINANT LACTOCOCCUS LACTIS  
III.2.1 INTRODUCTION 
As bacteria are available as a liquid suspension after cultivation, the first step in the 
development of an enteric-coated formulation is the solidification of this liquid suspension. 
Preservation of bacteria and more specifically of Lactic Acid Bacteria (LAB) is widely used, 
mainly in the food industry to facilitate their use as starter cultures in fermentation processes 
(Gehrke et al., 1992; Champagne et al., 1991) and more recently for their application as 
probiotics (Ishibashi and Hinamura, 1993). The most common method for preservation of 
starter cultures to guarantee long-term viability is freeze-drying (Champagne et al., 1991).  
Although freeze-drying is commonly used, this technique can cause cell damage as microbial 
cell survival throughout drying and storage is dependent on many factors including growth 
conditions, growth medium, cell preparation method, physiological state of the bacteria, drying 
medium, freezing rate, cell density, storage conditions (temperature, atmosphere, light, 
humidity), etc. (Champagne et al, 1991; Carvalho et al., 2004).  
In literature, numerous studies report about the freeze-drying of lactic acid bacteria and about 
the improvement of the survival during freeze-drying and subsequent storage. However, full 
comparison of the experimental data from distinct studies is difficult for a number of reasons.  
 Survival studies showed that the survival after freeze-drying is strain dependent (Sinha et 
al., 1974; El-Sadek et al., 1975; Kilara et al., 1976; Bozoglu et al., 1987; Kim and 
Bhowmik, 1990; Champagne et al., 1991; Gehrke et al., 1992; Souzu, 1992; To and Etzel, 
1997; Andersen et al., 1999; Carcoba and Rodriguez, 2000). Thereby, the influence of each 
protective agent on the survival of each LAB strain in the dried stage should be determined 
on a case-to-case basis. 
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 Most studies are mainly conducted in the dairy or food industry and only report about the 
rate of acidification of the dried product while lacking precise data on initial viability. 
However for probiotics, viability data are required as it is recommended that the products 
contain at least 107 live microorganisms /g (Ishibashi and Shimamura, 1993). Also in case 
of hIL-10 producing L. lactis, accurate viability data are essential to ensure therapeutic 
activity.  
 Most reports focused on survival during drying but not during storage.  
 None of the studies report on freeze-drying of bioengineered bacteria and/or maintenance of 
their properties achieved by recombinant technologies. 
This implies that data available from reported studies are rarely useful for the optimisation of 
the freeze-dried formulation of other specific bacteria. 
The aim of this study was to develop a freeze-dried L. lactis Thy12 formulation with 
preservation of its viability and hIL-10 producing capacity in combination with an acceptable 
shelf life of the dry powder. In a first part of the study, the influence of the freeze-drying 
matrix, physiological state and rate of freezing was determined on the viability using the wild 
strain L. lactis MG1363. Next, in order to determine the best storage condition of the freeze-
dried powder, short (1 week)- and long-term (6 months) stability tests were performed. Then, 
further optimisation experiments were performed for culture preparation, cell density and 
incorporation of nutrients in the freeze-drying matrix. In a last part, protective agents 
(antioxidants and additional carbohydrates) have been added to the freeze-drying matrix in 
order to improve viability after freeze-drying and storage.  
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III.2.2 MATERIALS AND METHODS 
III.2.2.1 Strains used in this study 
Lactococcus lactis subsp. cremoris MG1363 (Gasson, 1986) and L. lactis Thy12 (hIL-10 
producing L. lactis MG1363) (Steidler et al., 2003)  
III.2.2.2 Preparation of the cell suspensions 
The non-bioengineered L. lactis subsp. cremoris MG1363 culture was prepared by 
inoculating a stock suspension, stored at –20°C in glycerol/GM17 (50/50), 1/1000 in growth 
medium (further specified). To prevent further activity or growth after culture preparation, the 
culture was kept on ice until use and in between all manipulations.  
To investigate the influence of the freeze-drying matrix, two growth media were used: M17 
broth (Difco, Becton Dickinson, Erembodegem, Belgium) supplemented with 0.5% glucose in 
order to obtain GM17 or 10% (w/v) skim milk (Difco, Becton Dickinson, Erembodegem, 
Belgium) supplemented with 0.5% glucose and 0.5% casiton (Casiton® Difco, Becton 
Dickinson, Erembodegem, Belgium) to obtain GC-milk. The influence of the physiological 
state was investigated by growing the bacteria in GC-milk for 3 h or overnight to obtain the 
logarithmic and stationary phase, respectively. The culture in the logarithmic phase had a 
viable count of about 107 cfu/ml, while the culture in the stationary phase had ± 109 cfu/ml.  
In further experiments, L. lactis MG1363 was grown overnight in GM17 and collected by 
centrifugation at 3000g for 10 min at 4°C. To investigate the influence of culture preparation, 
the L. lactis MG1363 pellet was suspended in fresh GC-milk, with or without a previous wash 
step with PBS. As a reference, L. lactis MG1363 was grown in GC-milk until the stationary 
phase. To determine the influence of L. lactis MG1363 density, the cell pellet was suspended 
in different volumes of fresh GC-milk i.e. the initial volume of culturing, 1/5th, 1/10th, 1/100th 
and 1/200th of the initial volume in order to obtain different densities of L. lactis: initial 
density (2.3x109 cfu/ml), ~5 times concentrated (9.5x109 cfu/ml), ~ 10 times concentrated 
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(3.3x1010 cfu/ml), ~100 times concentrated (2x1011 cfu/ml) and ~200 times concentrated 
(4x1011 cfu/ml), respectively.  
L. lactis Thy12 was inoculated in 10% skim milk supplemented with 0.5% glucose, 0.5% 
Casiton® (Difco, Becton Dickinson) and 50 µg/ml thymidine (GCT-milk) or in GM17 
supplemented with 50 µg/ml thymidine (GM17T) and prepared as cited above. The cell pellet 
was resuspended in skim milk at about 1010 cfu/ml (10 times concentrated). To evaluate the 
influence of feed components in the freeze-drying matrix on L. lactis’ Thy12 viability, the cell 
pellets were resuspended in the initial volume (this is the same volume as in which the cells 
were cultured) of fresh skim milk, T-milk (skim milk supplemented with 50µg/ml thymidine) 
or GCT-milk. To evaluate the influence of an antioxidant in the freeze-drying matrix on L. 
lactis’ Thy12 viability, the cell pellet was resuspended in the initial volume of GCT-milk with 
1.25% vitamin C (Federa, Braine-l’Alleud, Belgium). As a reference the cell pellet was 
suspended in the initial volume of GCT-milk without any antioxidant added. To evaluate the 
influence of an additional carbohydrate in the freeze-drying matrix on L. lactis’ Thy12 
viability, the cell pellet was resuspended in the initial volume of GCT-milk with 5 or 10% 
(w/v) trehalose (Sigma-Aldrich, Bornem, Belgium), with 5% (w/v) inulin EXL (Sensus, 
Roosendaal, the Netherlands) or in the initial volume of 10% inulin (w/v).  As a reference the 
cell pellet was resuspended in the initial volume of GCT-milk without any additional 
carbohydrate added.  
III.2.2.3 Freeze-drying of L. lactis    
Approximately 2 g L. lactis culture was filled in vials (glass type 1, Gaash Packaging, 
Mollem, Belgium). The vials were covered with a freeze-drying stopper (V9032 FM 257/2 
SAF1, bromobutyl with magnesium silicate as filler, kindly donated by Helvoet Pharma, 
Alken, Belgium). Prior to freeze-drying, the vials were kept on ice.  
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The vials were loaded on the precooled shelves (- 25°C) of the freeze-dryer (Leybold GT4, 
Finn-aqua, Sohlberg, Germany). The samples were frozen to - 45°C over 105 min at 
1000 mbar. The primary drying (12 h) was performed at - 15°C and 0.8 to 1 mbar and the 
secondary drying (9 h) at 10°C and 0.1 to 0.2 mbar. After freeze-drying, the vials were closed 
under vacuum or dry nitrogen. To determine the influence of freezing rate, some vials were 
instantly frozen, accomplished by immersing them into liquid N2 (-196°C) prior to freeze-
drying. All freeze-drying runs were performed in triplicate (n=3), except if mentioned. To 
evaluate the influence of the additional carbohydrate inulin in the freeze-drying matrix on L. 
lactis’ Thy12 viability, a modified freeze-drying process was used. The vials were loaded on 
the precooled shelves (- 25°C) of the freeze-dryer and kept at this temperature for 1 h 
(1000 mbar). The primary drying (12 h) was performed at - 25°C and 0.1 to 0.2 mbar and the 
secondary drying (3 h) at 10°C and 0.05 to 0.2 mbar. 
III.2.2.4 Storage of the freeze-dried powder in vials  
To evaluate the influence of storage parameters on stability, vials containing the freeze-dried 
L. lactis MG1363 (closed under vacuum) were stored for 1 week at different conditions i.e. 
8°C/10% RH, 8°C/vacuum, 8°C/N2, RT/10% RH, RT/60% RH, RT/vacuum and RT/N2. 10% 
relative humidity (RH) was reached by opening the vials and placing them above silica gel for 
desiccation (Sigma, Bornem, Belgium) in a plastic container. 60% relative humidity (RH) was 
reached by opening the vials and placing them above a saturated sodium bromide solution. 
The nitrogen atmosphere was reached by opening the vials and flushing them with dry 
nitrogen for 60 s before closing.  
The long-term stability of freeze-dried L. lactis Thy12 in vials was evaluated at low 
temperature (8°C) and 10% RH, N2 (the vials were closed under dry nitrogen) and 20% RH 
(above a saturated potassium acetate solution). Analysis was performed after 1, 2, 3 and 6 
months. To evaluate the influence of the culture preparation method, cell density and 
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nutrients, freeze-dried L. lactis Thy12 was stored for 1 week at 8°C/10% RH. To evaluate the 
influence of the protective agents (antioxidants and carbohydrates), freeze-dried L. lactis 
Thy12 was stored for 1 week at 8°C/ 10% RH and RT/10% RH. 
III.2.2.5 Analysis of the freeze-dried L. lactis cultures 
III.2.2.5.1 Determination of viability of L. lactis  
The viability of the bacteria was determined by the Department of Molecular Biomedical 
Research (DMBR, Ghent University, Technologiepark 927, 9052 Ghent (Zwijnaarde), 
Belgium) by following the growth of standards and samples in an automated turbidimeter 
(Bioscreen C, Oy Growth Curves AB Ltd, Helsinki, Finland). The viability of the starting 
culture was set at 100%. In order to prepare the standards, different dilutions of the starting 
culture were made (from undiluted (=100% viability) to 1/20 (=5% viability)), inoculated 
1/100 in fresh GM17 with (for L. lactis Thy12) or without (for L. lactis MG1363) thymidine 
and loaded in triplicate onto micro-titer plates. The growth of all standards was followed at 
30°C for 21 h and the equation was determined of the linear part of each growth curve 
(y=ax+b, Fig. 1). Using this equation, the time necessary (T50%) to reach an optical density 
OD50%, half way the minimum (ODmin) and maximum (ODmax) OD of the growth curve was 
calculated. All these T50% values were plotted against the natural logarithm of the viability 
(from 1.6 (=ln5) until 4.6 (=ln100)) and the equation of the standard curve was calculated 
(Fig. 2). For the samples, T50% was similarly determined as for the standard curve, based on 
the growth curves (Fig. 3). Based on the standard curve of the starting culture, viability was 
calculated and expressed as % of the theoretical value.   
The viability of the samples determined by this method corresponded very well with the 
results obtained by the traditional plate count method and offers the advantage of a broad 
dynamic range and small error bars. For determining the viability in the freeze-dried powder, 
0.1 g powder was dissolved in 1 ml sterile water. When concentrated cultures were used, the 
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powder was diluted further accordingly. Three replicas of each sample were analysed and of 
each replica, three dilutions (1/100, 1/200 and 1/400) were loaded in duplicate. Viability after 
storage was expressed as % of viability after freeze-drying (relative viability).  
a 
b 
Figure 1 Growth curve of two standards i.e. 100% standard (Fig. 1a) and 40% standard (Fig. 1b) and 
explanation of the determination of T50% i.e. 1: determination of the equation of the linear part of the 
growth curve (y=ax+b) 2: determination of OD50%,, (= an optical density half way the minimum 
(ODmin) and maximum (ODmax) OD of the growth curve) 3: calculation of T50% by using OD50%  and 
the equation from 1.  
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Figure 2 Example of a standard curve (T50% (min) against the natural logarithm of the viability (%)).  
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Figure 3 Example of growth curves of three different dilutions of a sample.  
III.2.2.5.2 Determination of water content 
The water content of the freeze-dried culture was determined using a Mettler DL35 Karl 
Fisher titrator (Mettler-Toledo, Beersel, Belgium). The samples were stirred in the reaction 
medium for 80 s. Afterwards the water was titrated with Hydranal® Composite 5 (Riedel-de 
Haën, Seelze, Germany). The analysis was performed in triplicate. 
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III.2.2.5.3 Determination of hIL-10 production 
A sample that had been used for determining the viability was diluted 1/25 in GM17 and 
incubated for 3 h at 30°C. The cultures were then centrifuged for 10 min at 1650g, the 
supernatant was removed and the bacteria were resuspended in BM9. BM9 is buffered GM9 
growth medium (GM9 growth medium containing per liter: 6 g of Na2HPO4, 3 g of KH2PO4, 
1 g of NH4Cl, 0.5 g of NaCl, 2 mmol of MgSO4, 0.1 mmol of CaCl2, 5 g of glucose, 5 g of 
peptone), prepared by addition of carbonate to 50mM and set at the desired pH value by the 
appropriate ratio of NaH2CO3/Na2HCO3. The cultures were incubated for another 3 h at 30°C. 
A sample of 1 ml was removed and centrifuged for 3 min at 16000g. The supernatant was 
removed to determine the hIL-10 concentration in a sandwich ELISA. Maxisorp F96 plates 
(Nunc, Roskilde, Denmark) were coated with 2 µg/ml rat anti-human IL-10 (Pharmingen). 
The plates were blocked with a 0.1% casein solution. A ½ dilution series of hIL-10, starting 
from 1 ng/ml and appropriate dilutions of the samples were loaded on the plates. Between 
each step the plates were washed with PBS + 0.05% Tween-20. The bound hIL10 was 
detected with 1/1000 biotinylated rat anti-human IL10 (Pharmingen) combined with 1/1000 
horseradish peroxidase coupled streptavidine. The plates were developed with TMB substrate 
(Pharmingen). The reaction was stopped after 30 min with 1M H2SO4. The absorbance was 
measured at 450 nm, with 595 nm as reference wavelength. The amount of hIL10 present in 
each sample can be calculated, but for the moment we cannot correlate the hIL-10 production 
with the viability of L. lactis Thy12 e.g. cell lysis could occur after freeze-drying or storage, 
resulting in the release of the precursor-protein from the cells. As the current ELISA cannot 
differentiate between hIL-10 and the non-active precursor-hIL10, this may lead to an 
overestimation of the hIL-10 concentration. Only qualitative information can be concluded 
from the hIL-10 determination test i.e. the hIL-10 production capacity is maintained or not.    
Huyghebaert et al., Eur. J. Pharm. Biopharm, submitted. 
III.2 Development of a freeze-dried powder formulation of recombinant of Lactococcus lactis  52
Determination of the glass transition temperature 
Tg was determined using a model 2920 modulated DSC (TA Instruments, Brussels, Belgium). 
Approximately 7 mg of sample was placed in an aluminium pan that was hermetically sealed. 
The sample was heated from –40°C to 100°C with an underlying heating rate of 2°C/min, a 
modulation period of 60 s and modulation amplitude of 0.5°C. Tg was reported as the 
midpoint of the transition. The analysis was performed in duplicate. 
III.2.2.6 Statistical analysis 
Viability values (mean of values obtained from three freeze-drying cycles) were statistically 
evaluated with a one-way ANOVA. The values obtained in the short (1 week) and long-term 
(6 months) stability studies were evaluated with a two-way ANOVA. Both tests were 
performed at a significance level of 0.05. The normality of the data was checked by means of 
a Kolmogorov-Smirnov test and the homogeneity of variances by means of the Levene test. A 
multi comparison among pairs of means was performed using a Scheffé test with p<0.05 as a 
significance level. All analyses were performed with SPSS 11.0 for Windows. 
III.2.3 RESULTS AND DISCUSSION  
There is no universally applicable protocol for the successful freeze-drying of bacteria. 
Viability loss of lactic acid bacteria, freeze-dried in the same matrix, can vary from 1 log unit 
for Streptococcus thermophilus to 2 log units for Lactobacillus bulgaricus (Kim and 
Bhowmik, 1990). This means that for each individual type of bacterium a matrix has to be 
optimised. Moreover, depending on the cryoprotective agents added, survival after freeze-
drying can range from e.g. less than 1 to 67% for S. thermophilus (Kilara et al., 1976). 
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III.2.3.1 Influence of freeze-drying matrix, physiological state and rate of freezing on 
viability of L. lactis MG1363  
L. lactis MG1363 was freeze-dried in GM17 (n=1). This resulted in a viability of only 9.3 ± 
0.8%. Viability of L. lactis MG1363 grown and freeze-dried in GC-milk was significantly 
higher (60.0 ± 18.0%, n=17) than in GM17. The obtained viability is in accordance with the 
viability data reported by Cárcoba and Rodríguez (2000) for L. lactis subsp. lactis CECT5130 
(44.3%) and Kilara et al. (1976) for L. cremoris (63%), both freeze-dried in skim milk. 
Despite all attempts to standardise the freeze-drying procedure, batch-to-batch variability 
could not be avoided. Andersen et al. (1999) experienced the same problem. The low viability 
obtained in the GM17 matrix can be explained by the collapsed structure of the freeze-dried 
product. This problem was overcome by freeze-drying L. lactis MG1363 in skim milk, a 
medium used by many investigators to freeze-dry lactic acid bacteria. It is thought to offer 
beneficial properties because of its proteins, calcium ions and lactose (Sinha et al., 1974; El-
Sadek et al., 1975; Kilara et al., 1976; Champagne et al., 1991; Cárcoba and Rodríguez, 
2000). This resulted in a glassy matrix (Tg: 71.7 ± 5.5°C). In nature, sugars are accumulated 
by desiccated structures (Aguilera and Karel, 1997). Their mechanism to stabilise biological 
materials under desiccation is linked to their ability to form glasses, a first requirement for 
stabilisation. Moreover, Crowe et al. (1996) concluded that direct interaction between the 
sugar and polar groups, e.g. in proteins and phospholipids, is a second stabilisation 
requirement. The proposed mechanism is that sugars replace the water molecules removed 
during desiccation, which is referred to as the “water replacement theory”.  
From Table 1, it is clear that the viability after freeze-drying is dependent on the physiological 
state of the bacteria: viability after freeze-drying of L. lactis MG1363 in the stationary phase 
was significantly higher than after freeze-drying in the logarithmic phase. These results are in 
accordance with the data published by Bergère (1968) for Lactococci. However, in literature, 
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there is disagreement about the influence of the physiological state of the bacteria on the 
viability after freeze-drying. Souzu (1992) reported an increasing resistance of E. coli as cell 
growth approached its stationary phase. While Gehrke et al. (1992) reported that E. coli 
shows a better resistance against freezing, the most detrimental step of the freeze-drying 
process when the cells are taken from the logarithmic growth phase as compared to the late 
stationary phase.  
The rate of freezing is also a critical parameter in the freeze-drying process (Souzu, 1992). In 
our study, two freezing rates were evaluated: slow freezing by loading the filled vials on the 
precooled shelves (-25°C) or instant freezing by immersion of the vials in liquid N2     (-
196°C) before loading them on the precooled shelves. After freeze-drying, there was no 
significant difference in viability of L. lactis, frozen at both freezing rates studied (Table 1). 
Gehrke et al. (1992) found that the percentage of living cells decreased dramatically during 
the freezing process and that the optimal cooling rate depends mainly on cell properties (size, 
membrane and structure). An optimum has to be found as rapid freezing of cells leads to 
formation of intra-cellular ice-crystals, which results in cell damage. This can be avoided by 
slow cooling (Champagne et al., 1991; Tan, 1997; Mazur, 1977). However at slow cooling 
rates the cells loose water from the cell cytoplasm. This leads to high salt concentrations in 
the cell, which can damage the cell membrane and cause protein denaturation. The optimum 
freezing rate varies from one genus to another (Champagne et al., 1991). It can be concluded 
that freeze-drying of L. lactis MG1363, grown until the stationary phase in GC-milk, without 
a previous freezing step resulted in the highest survival.    
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Table 1 Influence of physiological state and rate of freezing on the viability (%) of L. lactis MG1363 
after freeze-drying (1): L. lactis grown and freeze-dried in GC-milk, (2): L. lactis grown until stationary 
phase in GC-milk and freeze-dried in GC-milk  
Physiological state (1) Viability (%) Rate of freezing (2) Viability (%) 
Logarithmic phase 24.1 ± 8.0a (n=3) Slow 67.0 ± 18.2c  (n=8)  
Stationary phase 60.3 ± 20.0b  (n=3) Fast (liquid N2) 67.1 ± 16.5c (n=8)   
a,b,c: Groups with the same superscript are not significantly different from each other (p>0.05) (one-way    
ANOVA). 
 
III.2.3.2 Stability of freeze-dried L. lactis  
Next to a high viability after production, the product should have an acceptable shelf life. In 
literature it is mentioned that during storage, contact with oxygen and moisture should be 
avoided. Moreover, light seems also highly detrimental (Champagne et al., 1991). In a first 
screening study, the viability of freeze-dried L. lactis MG1363 was evaluated after 1 week 
storage at different conditions (Table 2). Preliminary studies showed that storage at room 
temperature and 60% RH for 1 week resulted in a complete loss of viability. The increased 
water content of the freeze-dried powder (from 2.2 after freeze-drying to 10.5% (w/w)) can 
explain this viability loss. As water acts as a plasticiser, the Tg of the glassy matrix, in which 
the bacteria are stabilised (71.7 ± 5.9°C) decreased to –2.8 ± 3.6°C and resulted in a collapse 
of the freeze-dried powder. It is known that the stability of biological systems held in rubbery 
state decreases remarkably (Aguilera and Karel, 1997). In further studies, this storage 
condition was excluded.  
To compare viability data after storage, the relative viability values were used since absolute 
viability values were batch dependent. Two main storage factors (temperature and 
atmosphere) were evaluated for their influence on viability. From Table 2 it can be concluded 
that the storage temperature has a significant influence on the viability, in contrast with the 
storage atmosphere. Although not statistically significant, viability tended to be higher after 1 
week storage at RT and vacuum or N2 than at 10% RH. This can be explained by the absence 
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of oxygen. Moreover, the water content of the powder increased from 2.2 ± 0.7% (vacuum 
and N2) to 3.2 ± 0.2% (10% RH), but this did not cause a significant change in Tg (from 71.7 
± 5.9°C to 65.8 ± 7.8°C). No significant interaction was seen between storage temperature 
and storage atmosphere (two-way ANOVA). 
Table 2 Relative viability (%) of L. lactis MG1363 (mean ± S.D.), grown in GC-milk until the 
stationary phase and freeze-dried in GC-milk after 1 week in function of storage conditions.  
Relative viability (%) of L. lactis MG1363 stored at different temperatures 
 8°C n RT n Main Atmosphere* n 
10% RH 85.4 ± 24.2 9 13.6 ± 11.9 9 49.5 ± 41.3 c 18 
Vacuum 81.5 ± 31.4 3 26.0 ± 19.6 3 53.7 ± 38.4 c 6 
N2 74.4 ± 25.0 6 28.2 ± 13.2 6 51.3 ± 30.7 c 12 
Main Temperature** 81.1 ± 24.5 a 18 20.6 ± 14.7 b 18 50.8 ± 36.6 36 
a,b,c: Groups with the same superscript are not significantly different from each other  (p>0.05) (two-way 
ANOVA, post hoc Scheffé). 
*: global effect of atmosphere, irrespective of temperature 
**: global effect of temperature, irrespective of atmosphere  
 
From these data it was clear that long-term stability (1 year) of L. lactis MG1363, freeze-dried 
in the skim milk matrix could not be achieved at room temperature. After 1 week storage at 
8°C, viability has already decreased with 20% of the initial viability after freeze-drying.  
A long-term stability test was performed at 8°C to further investigate the rate of decrease in 
viability. In contrast to the short-term stability test, the long-term stability test (6 months) was 
performed with the recombinant strain (L. lactis Thy12), grown and freeze-dried in GCT-milk 
(n=3). An additional storage condition was included i.e. 20% RH as this is an acceptable 
condition for further processing of the freeze-dried powder into capsules. Figure 4 shows the 
viability profile as a function of time. A significant effect of storage time was observed (Table 
3). Moreover, viability decreased remarkably after 1 month, followed by a slower decrease in 
viability during the subsequent months of storage (logarithmic trend). Storage under dry N2 
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atmosphere resulted in a significantly higher viability than storage at 10 or 20% RH. The 
results of the short-term stability test indicated that the viability tended to be higher after 
storage under vacuum or N2 atmosphere than at 10% RH and were now confirmed by the 
results of the long-term storage at 8°C. The water content of the powder stored at 10 and 20% 
RH was similar and this was reflected in a similar viability. The water content increased 
slightly after 6 months when the samples were stored at 10% RH. This could be explained by 
water penetration through the plastic container in which the vials were stored. This proved 
again that it is essential to protect against moisture, especially during storage in the 
refrigerator, in which a high relative humidity exists (77%).  
Although the water content remained constant (2.2 ± 0.4%), Tg (71.7 ± 5.9°C) was high and 
oxygen was absent, a decrease in viability was also observed when stored under an inert N2 
atmosphere. This confirms that Tg is a poor indicator for temperatures below which molecular 
motions and hence chemical and physical degradation reactions are zero (Yu, 2001). T0 rather 
than Tg should be used as a practical guide for selecting the storage temperature, as only 
below this temperature zero mobility is obtained. T0 is at least 50°C below Tg. Although, in 
this study the difference between the storage temperature (8°C) and Tg (71.7 ± 5.5°C) is 63°C, 
viability decreased. Deleterious metabolic and/or enzymatic reactions, which progress at this 
low storage temperatures and water content are probably the cause of the decrease in viability 
(Souzu, 1992).  
In this study it was also shown that the hIL-10 producing capacity was maintained after 
freeze-drying. To the best of our knowledge, we are the first to prove maintenance of a 
recombinant characteristic after freeze-drying.    
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Figure 4 Long-term stability at 8°C (6 months) of L. lactis Thy12, grown in GCT-milk until stationary 
phase and freeze-dried (n=3): relative viability (%) (mean ± S.D.) (—) and water content (%) (mean ± 
S.D.) (---) under N2 atmosphere (●), at 20% RH (▲) and 10%RH (). 
Table 3 Long-term stability at 8°C (6 months) of L. lactis Thy12, grown in GCT-milk until stationary 
phase and freeze-dried: relative viability (%) in function of storage time and atmosphere.  
Relative viability (%) of L. lactis Thy12 stored at different atmospheres 
 N2 n 10% RH n 20% RH n Main Time* n 
1 week 93.9 ± 20.2  3 75.5 ± 19.3  3 91.6 ± 23.3  3 87.0 ± 20.2 c 9 
1 month 63.2 ± 7.8 2 44.5 ± 20.6 2 40.8 ± 7.8 2 49.5 ± 15.0 d 6 
2 months 56.2 ± 6.8 3 36.2 ± 17.1 3 34.7 ± 12.4 3 42.4 ± 15.2 de 9 
3 months 42.5 ± 10.2 3 20.5 ± 10.3 3 20.8 ± 9.5 3 27.9 ± 13.9 de 9 
6 months 32.5 ± 22.5 3 7.3 ± 4.6 3 15.6 ± 16.4 3 18.5 ± 18.0 e 9 
Main Atmosphere** 57.2 ± 26.0 a 14 36.3 ± 27.8 b 14 40.7 ± 31.2 b 14 44.7 ± 29.4  42 
a,b,c,d,e: Groups with the same superscript are not significantly different from each other (p>0.05) (two-way 
ANOVA, post hoc Scheffé). 
*: global effect of time, irrespective of atmosphere  
**: global effect of atmosphere, irrespective of time  
 
III.2.3.3 Influence of culture preparation 
In this experiment, the influence of the culture preparation on the viability after freeze-drying 
was evaluated. As a reference, L. lactis MG1363 was grown in GC-milk and freeze-dried in 
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this matrix (I). As alternative culture preparation method, L. lactis MG1363 was grown in 
GM17 and harvested by centrifugation. Next, the cell pellet was resuspended in fresh GC-
milk (II). To ensure removal of all possible toxic metabolic products, the cells were subjected 
to a washing step before resuspension in fresh GC-milk and freeze-drying (III). No significant 
differences are seen immediately after freeze-drying or after storage for 1 week at 8°C and 
10% RH (Fig. 5). It can be concluded that the time-consuming washing step is not 
advantageous and can be omitted. Furthermore, although the viability of L. lactis grown and 
freeze-dried in GC-milk tends to be higher after 1 week storage at 8°C and 10% RH, it can be 
concluded that L. lactis tolerated the centrifugation step. This offers the advantage to increase 
the concentration of the bacteria in the freeze-dried powder. Moreover, the bacteria could be 
resuspended in a fresh matrix, so avoiding metabolites, which could create GMP problems on 
large-scale production. From these data we can conclude that the growth environment of L. 
lactis has no reflection on the tolerance to freeze-drying stress.   
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Figure 5 Influence of the culture preparation on the initial (absolute) viability of L. lactis MG1363 
after freeze-drying () and relative viability* after storage (1 week, 8°C and 10% RH) () (mean ± 
S.D.) (n=3) a,b: Groups within the same series with the same superscript are not significantly different from each 
other (p>0.05) (one-way ANOVA, post hoc Scheffé). *: relative viability = (absolute viability after storage 
/ absolute viability after freeze-drying) * 100.  
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III.2.3.4 Influence of culture density 
In literature bacterial concentration is reported to affect viability after freeze-drying, 
especially during freezing (Souzu, 1992). Our data showed no significant influence of cell 
density on viability immediately after freeze-drying (Fig. 6). After 1 week storage at 8°C and 
10% RH, viability decreased significantly with increasing cell density (Fig. 6). It can be 
concluded that increasing the cell density of L. lactis by a factor 10 seems an acceptable limit 
(no significant decrease). Bozoglu et al. (1987) explained the observed higher viability for a 
higher cell load by the fact that by increasing the initial bacterial load, the interactions 
between microorganisms decreased the exposed area of each cell to the environment and 
therefore prevented possible damage. However, a too high cell load (1012 cfu/ml) would be 
harmful because of an unbalanced osmotic pressure.  
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Figure 6 Influence of density of L. lactis MG1363 in the matrix on the initial viability of L. lactis 
MG1363 after freeze-drying () and relative viability* after storage (1 week, 8°C and 10% RH) () 
(mean ± S.D.) (n=3)  a,b,c: Groups within the same series with the same superscript are not significantly 
different from each other  (p>0.05) (one-way ANOVA, post hoc Scheffé) *: relative viability = (absolute 
viability after storage / absolute viability after freeze-drying) * 100. 
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III.2.3.5 Influence of nutrients in the freeze-drying matrix 
L. lactis Thy12 is dependent on three different nutrients: glucose, amino acids and thymidine. 
The microorganism lacks the genes for lactose and protein digestion because the essential 
plasmides are lost by protoplasting and lacks the genes for thymidilate synthase (cf. Chapter 
II.4) to ensure its biocontainment. To ensure viability and metabolic activity of the bacteria in 
vivo, the essential nutrients were freeze-dried together with L. lactis Thy12. We observed no 
significant difference in viability between the three freeze-drying matrices immediately after 
freeze-drying and after 1 week storage at 8°C and 10% RH (Fig. 7). However, the 
incorporation of glucose and casein hydrolysate (amino acids) in the freeze-drying matrix 
tended to negatively influence the viability after 1 week storage at 8°C and 10% RH 
(p=0.091). It can also be concluded that the thymidine dependent strain (L. lactis Thy12) was 
stable in dry state without its essential.  
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Figure 7 Influence of nutrients incorporated in the freeze-drying matrix on the initial viability of L. 
lactis Thy12 after freeze-drying () and relative viability* after storage (1 week, 8°C and 10% RH) 
() (mean ± S.D.) (n=3) a,b: Groups within the same series with the same superscript are not significantly 
different from each other  (p>0.05) (one-way ANOVA, post hoc Scheffé) *: relative viability = (absolute 
viability after storage / absolute viability after freeze-drying) * 100. 
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III.2.3.6 Influence of antioxidant in the freeze-drying matrix 
Vitamin C (ascorbic acid) is often added to the suspension medium prior to freeze-drying as it 
helps in increasing viability (Font de Valdéz et al., 1986). Fig. 8 shows that the addition of 
1.25% (w/w) vitamin C to the skim milk matrix had no influence on viability after freeze-
drying. However, after storage for 1 week at RT/10% RH, the addition of vitamin C resulted 
in a significantly higher viability. No difference was seen after storage at 8°C/10% RH. It can 
be concluded that the influence of the vitamin C after 1 week is only seen at the most stressful 
storage condition. Probably, the influence at 8°C/10% RH will only been seen after longer 
storage time. However, from this experiment we cannot rule out that vitamin C has a 
protective effect on its own. By addition of vitamin C to the skim milk solution, the pH 
decreased and could contribute to the protective effect.  
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Figure 8 Influence of vitamine C incorporated in the freeze-drying matrix (GCT-milk) on the initial 
viability of L. lactis Thy12 after freeze-drying () and relative viability* after storage for 1 week at 
8°C/10% RH () and at RT/10% RH () (mean ± S.D.) (n=3) a,b,c,d: Groups within the same series with 
the same superscript are not significantly different from each other  (p>0.05) (one-way ANOVA, post hoc 
Scheffé) *: relative viability = (absolute viability after storage / absolute viability after freeze-drying) * 
100. 
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III.2.3.7 Influence of additional carbohydrates (trehalose and inulin) in the freeze-drying 
matrix 
In literature, trehalose is mentioned as the golden standard for stabilisation of biomaterials 
during anhydrobiosis. Based on evidence, Crowe et al. (1996) concluded that direct 
interactions between the sugar and polar groups in proteins and phospholipids occur in the dry 
state. In literature, this is referred to as the “water-replacement” theory since the removed 
water is replaced by the sugar. Moreover, trehalose has the ability to form a glass, another 
requirement for stabilisation (Crowe et al., 1996). Amorphous structures have a very high 
viscosity and hence a low mobility. This slows down detrimental chemical and physical 
reactions. In addition, trehalose has a high Tg (115°C), compared to other sugars (Crowe et al., 
1996). Lactose however, also has a high Tg (105°C) (Franks, 1999), but it shows a high 
tendency to crystallise. Our results confirmed the stabilising capacity of trehalose. Addition of 
10% (w/v) trehalose in the 10% (w/v) skim milk matrix resulted in a viability of L. lactis 
Thy12 (1010 cfu/ml) after 1 week storage (RT, 10% RH) that was twice as high as obtained in 
the 10% (w/v) skim milk without additives or with only 5% trehalose added (n=3) (Fig. 9). 
However, this difference was not statistically significant.  
As the high price of trehalose is disadvantageous, inulins having a high Tg were evaluated for 
their potential as stabilising matrix. Inulins are fructose oligomers with varying molecular 
weight. As the Tg of the inulins is related to its chain length, it offers the advantage that Tg 
can be adjusted to 154.4°C. Hinrichs et al. (2001) showed that inulin EXL meets the 
physico-chemical characteristics to successfully act as a protectant for proteins. They showed 
that 50% of the activity of alkaline phosphatase, freeze-dried in inulin EXL (Tg: 154.4°C), 
was maintained after storage at 60°C for 6 days, whereas the activity of alkaline phosphatase 
in trehalose was completely lost. In order to evaluate the stabilising capacity of inulin for L. 
lactis Thy12, a suitable freeze-drying process was set-up in order to obtain a product with 
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Figure 9 Influence of trehalose incorporated in the freeze-drying matrix (GCT-milk) on the initial 
viability of L. lactis Thy12 after freeze-drying () and relative viability* after storage for 1 week at 
8°C/10% RH) () and at RT/10% RH () (mean ± S.D.) (n=3) a,b,c: Groups within the same series with 
the same superscript are not significantly different from each other  (p>0.05) (one-way ANOVA, post hoc 
Scheffé) *: relative viability = (absolute viability after storage / absolute viability after freeze-drying) * 
100. 
satisfying water content. The viability of L. lactis Thy12 (1010 cfu/ml) after freeze-drying in 
10% GCT-milk (reference), in 10% inulin and in 10% GCT-milk + 5% inulin as alternative 
matrices (n=3) showed no significant difference. After subsequent storage for 1 week at 
8°C/10% RH, the 10% inulin matrix did not show the same stabilising capacity as the 10% 
milk matrix, although inulin has a higher Tg (Fig. 10). This could be explained by the 
requirement of milk proteins for successful stabilisation and/or by the better stabilising 
capacity of lactose (disaccharide) than inulin (polysaccharide). However, addition of 5% 
inulin to the 10% milk matrix resulted in a significant increase in stabilising capacity of the 
10% milk matrix during storage of freeze-dried L. lactis Thy12 (Fig. 10). This could be 
explained by the higher Tg of this matrix (90,5°C) compared to that of 10% milk without 
inulin added (71,7°C) and is supported by the collapse of the freeze-dried 10% skim milk 
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matrix after storage at RT and 60% RH, contrary to the 10% milk + 5% inulin matrix that 
remained an amorphous cake. It could be concluded that addition of 5% inulin to the 10% 
milk matrix significantly increased the stability of freeze-dried L. lactis Thy12 during storage.   
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Figure 10 Influence of inulin incorporated in the freeze-drying matrix (GCT-milk) on the initial 
viability of L. lactis Thy12 after freeze-drying () and relative viability* after storage for 1 week at 
8°C/10% RH) () and at RT/10% RH () (mean ± S.D.) (n=3) a,b,c,d,e: Groups within the same series with 
the same superscript are not significantly different from each other  (p>0.05) (one-way ANOVA, post hoc 
Scheffé) *: relative viability = (absolute viability after storage / absolute viability after freeze-drying) * 
100. 
In further experiments, the individual findings that incorporation of 1.25 vitamine C, 10% 
trehalose or 5% inulin resulted in a significant better viability after storage can be combined 
resulting in a complex matrix. A long-term stability test has to be performed to prove the 
benefits of this optimised matrix. 
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III.2.4 CONCLUSIONS 
From this study it can be concluded that a freeze-dried powder formulation of L. lactis Thy12 
with acceptable viability and maintenance of hIL-10 production capacity can be obtained by 
growing the bacteria in GM17 broth, subsequent centrifugation and resuspension in 1/10th of 
the initial volume of skim milk. In order to reach an acceptable stability, the powder should be 
stored at low temperature (8°C) and N2 atmosphere. However, this storage condition was not 
applicable once the powder has been filled in capsules at 20% RH. Since storage at 20% RH 
resulted in an unacceptable loss of viability, storage temperature could be decreased (-20°C). 
Next, 1.25% vitamine C, 10% trehalose or 5% inulin can be added to the freeze-drying skim 
milk matrix as this study has shown that this improved storage stability.  
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III.3 IN VITRO EVALUATION OF DIFFERENT COATING POLYMERS FOR HUMAN ILEAL 
TARGETING  
III.3.1 INTRODUCTION 
As mentioned in Chapter II (Introduction), a strain was constructed in which the essential gene 
encoding for thymidylate synthase is knocked out to assure self-containment of the bacteria and 
to meet the biosafety issue raised with the use of genetically modified human interleukin-10 
(hIL-10) secreting Lactococcus lactis (Steidler et al., 2003). For in vitro growth until saturation, 
5.106 cfu of this strain require 2.45 µg thymidine. When this strain is devoid of thymidine, its 
viability (cfu) drops six orders of magnitude in approximately 60 h. This system of biological 
containment was found to be functional in vivo in pigs (Steidler et al., 2003). To enable in vivo 
hIL-10 production and hence effective treatment of Crohn’s disease, a co-formulation of hIL-10 
producing L. lactis and thymidine should be developed.  
Although Crohn’s disease can occur in any area of the gastro-intestinal tract, the site of 
inflammation is mainly localised in the more distal regions of the small intestine i.e. the ileum 
(Both et al., 1983). For effective delivery of hIL-10, the viability and involving metabolic 
activity of L. lactis at the target site must be ensured. Klijn et al. (1995) showed that only up 
to 2% of the amount of L. lactis consumed are recovered in the faeces, indicating that the 
gastrointestinal environment negatively influences its viability. This implies development of a 
formulation that protects the bacteria from the detrimental gastric fluid and the bile salts. 
Because of their active ileal reabsorption, the bile salt concentration is at lowest in the distal 
part of the small intestine (Northfield and McColl, 1973). Therefore the development of a 
formulation targeting L. lactis to the ileum is required. Besides, specific ileum targeting of 
thymidine is required to ensure the availability of thymidine for the survival and hence hIL-10 
production by L. lactis Thy12.  
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To avoid penetration of the detrimental gastric fluid into the formulation because of 
prolonged gastric residence time, pellets were chosen as a multi-particulate formulation 
(Krämer and Blume, 1994). These particles with a diameter of 1 mm show a gastric emptying 
comparable to liquids since they are released through the pylorus, independent of the feeding 
status (fed or fasted) of the subject.  
Contrary to colon-targeting, no specific strategies are reported in literature to obtain ileum-
specific delivery. In this study, a pH-dependent approach, based on the increasing pH along 
the gastro-intestinal tract (from stomach until the ileum), will be used in an attempt to obtain 
ileum targeting by coating pellets with polymers with different pH solubility and different 
coating thickness (Harris and Ghebre-Sellassie, 1997). However, as the formulation of L. 
lactis was still under development, thymidine pellets were used for adequate evaluation of the 
coating polymers as this molecule is easier to monitor and quantify (UV-spectrophotometry). 
Moreover, because of its high water-solubility (5.5 g / 100 ml) and its pH-independent release 
(at all pH values ranging from 2.5 to 7.4, 80% thymidine was released within 20 min from 
microcrystalline cellulose pellets), thymidine has excellent properties for adequate evaluation 
of enteric properties of the pellets, coated with several coating polymers.  
The main objective of this study was to evaluate the suitability of the available coating 
polymers for enteric-coating and ileal targeting of thymidine. On the basis of the thymidine 
release data, the polymers will be discussed for their gastric protection and ileal targeting 
properties of L. lactis in order to ensure its viability at the target site if administered in the 
same pellet formulation. 
Huyghebaert et al., Int. J. Pharm., submitted 
III.3 In vitro evaluation of different coating polymers for human ileal targeting  71
III.3.2 MATERIALS AND METHODS 
III.3.2.1 Production of pellets 
Pellets were prepared with a thymidine concentration of 1% (w/w). Thymidine (7 g) (Alkemi, 
Lokeren, Belgium) and microcrystalline cellulose (693 g) (Avicel PH 101, FMC, Brussels, 
Belgium) were blended and granulated with 700 ml demineralized water in a planetary mixer 
(Kenwood Major Classic, Hampshire, UK). Extrusion was performed in a single screw 
extruder (Dome extruder lab model DG-L1, Fuji Paudal, Tokyo, Japan) at 45 rpm, through a 1 
mm perforated screen. 600 g extrudate was spheronized on a spheronizer (Caleva model 15, 
Sturminster Newton, UK), using a cross-hatched friction plate, operating at 1000 rpm with a 
residence time of 5 min. 600 g wet spheres were dried in a fluid bed dryer (GPCG1, Glatt, 
Binzen, Germany) for 90 min at an inlet air temperature of 35 °C. The 700 to 1250 µm 
fraction was separated using a sieve shaker (VE 1000, Retsch, Haan, Germany) for 20 min at 
an amplitude of 2 mm. 
III.3.2.2 Preparation of coating dispersions 
III.3.2.2.1 Aqoat AS-HF 
Three different coating dispersions of Aqoat were prepared using Aqoat AS-HF powder 
(Shin-Etsu Chemical Co., Tokyo, Japan) (Table 1). The coating dispersion A was prepared by 
dissolving triethyl citrate (TEC, plasticiser) (Sigma-Aldrich, Bornem, Belgium) and sodium 
lauryl sulphate (wetting agent) (Federa, Brussels, Belgium) in water, according to the 
producers guidelines. Next, Aqoat AS-HF and than talc (glidant) (Alpha pharma, Nazareth, 
Belgium) were gradually added while stirring. The dispersion was mixed with a high speed 
mixer (Silverson, Bucks, England) for additionally 10 min. The coating dispersions B and C 
were prepared by dissolving TEC in water (Nykänen et al., 1999). Next, Aqoat AS-HF and 
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magnesium stearate (glidant) (Alpha pharma, Nazareth, Belgium) were gradually added while 
stirring. The dispersions were mixed with a high speed mixer for additionally 10 min.  
Table 1 Composition of coating dispersions containing Aqoat AS-HF  
 A   B   C  
 Total (g) Dry (g)  Total (g) Dry (g)  Total (g) Dry (g) 
Aqoat AS-HF powder  10 10  10 10  10 10 
Mg-stearate - -  3 3  3 3 
Talc 2 2  - -  - - 
Triethyl citrate 3.5 3.5  3.5 3.5  5 5 
Sodium lauryl sulphate 0.2 0.2  - -  - - 
Water 83.5 -  83.5 -  83.5 - 
Polymer content (%, w/w)   10.1          10.0   9.9  
Solid content (%, w/w)        15.8          16.5   17.7  
 
III.3.2.2.2 Eudragit FS 30 D and Eudragit L30D-55  
The composition of the coating dispersions containing Eudragit FS 30 D and Eudragit 
L30D-55 is shown in Table 2. To prepare the Eudragit FS 30 D coating dispersion, a 30 % 
(w/w) aqueous Eudragit FS 30 D dispersion was used (Röhm, Darmstadt, Germany). 
Polysorbate 80 (wetting agent) (Tween® 80, Alpha pharma, Nazareth, Belgium) and glyceryl 
monostearate (glidant) (Federa, Braine-l’Alleud, Belgium) were added to water and stirred for 
10 min with a high-speed mixer until a fine, homogenous dispersion was obtained. This 
dispersion was gently added to the Eudragit FS 30 D dispersion and mixed by magnetic 
stirring. For the Eudragit L30D-55 coating dispersion, the preparation was identical, except 
that TEC was used as a plasticiser. For the Eudragit FS 30 D coating dispersions no 
plasticiser was required since this polymer exhibits a minimum film-forming temperature 
(MFT) of 14°C.  
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Table 2 Composition of coating dispersions containing Eudragit FS 30 D, Eudragit L30D-55 and a 
mixture of Eudragit FS 30 D/L30D-55 
 Eudragit FS 30 D  Eudragit L30D-55  Mixture  
 Total (g) Dry (g)  Total (g) Dry (g)  Total (g) Dry (g)
Eudragit FS 30 D (30% aq. disp.) 55 16.5  - -  42.4 12.7 
Eudragit L30D-55 (30% aq. disp.) - -  51 15.3  10.6 3.2 
Glyceryl monostearate 1.3 1.3  1.3 1.3  1.3 1.3 
Tween 80 (33% aq. sol.)  1.6 0.5  1.6 0.5  1.6 0.5 
Triethyl citrate - -  3.1 3.1  0.6 0.6 
Water 41.7 -  43 -  45 - 
Polymer content (%, w/w)                 16.6          15.3   15.7  
Solid content (%, w/w)                      18.4          20.2   18.0  
 
III.3.2.2.3 Eudragit S  
The composition of the coating dispersions containing Eudragit S is shown in Table 3. The 
three dispersions differ in plasticiser type and content: 60% TEC in A, 40% TEC in B and 
60% dibutyl sebacate (DBS) (Sigma-Aldrich, Bornem, Belgium) in C. To prepare the 
Eudragit S coating dispersion A and B, Eudragit S powder (Röhm, Darmstadt, Germany) 
was dispersed in water. Drop-wise addition of 1M ammonia to the aqueous suspension over 5 
min resulted in neutralisation of 15% of the carboxyl groups of the polymer. A milky latex was 
formed. After additional stirring for 1 h, TEC was added. After overnight stirring, a glyceryl 
monostearate (GMS)-dispersion (prepared by homogenising GMS for 10 min in a polysorbate 
80-water mixture using a high-speed mixer) was added to the polymer dispersion. To prepare 
the Eudragit S coating dispersion C, DBS was mixed with the Eudragit S powder using a 
mortar and pestle. After overnight standing, the powder mixture was dispersed in water.   
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Table 3 Composition of coating dispersions containing Eudragit S  
 A  B  C  
 Total (g) Dry (g) Total (g) Dry (g) Total (g) Dry (g) 
Eudragit S powder  15 15 15 15 15 15 
Water 97.3 - 97.3 - 97.3 - 
Ammonia 1M 7.6 - 7.6 - 7.6 - 
Triethyl citrate 9.2 9.2 6 6 - - 
Dibutyl sebacate - - - - 9.2 9.2 
Glyceryl monostearate 1.2 1.2 1.2 1.2 1.2 1.2 
Tween 80 (33% aq. sol.) 1.5 0.5 1.5 0.5 1.5 0.5 
Water 15 - 15 - 15 - 
Polymer content (%, w/w)   10.2           10.4  10.2  
Solid content (%, w/w)         17.6           15.8  17.6  
 
III.3.2.2.4 Mixture Eudragit FS 30 D/L30D-55  
The composition of the coating dispersion containing a mixture of Eudragit FS 30 D/L30D-
55 (80/20, w/w) is shown in Table 2. The preparation of the dispersion is identical to the 
method described under III.3.2.2.2. The plasticiser amount is calculated as 20% (w/w) on 
Eudragit L30D-55.  
III.3.2.3  Coating of pellets with different coating dispersions 
The coating dispersions were passed through a 0.3 mm sieve before use. Throughout the 
coating process the coating dispersions were stirred using a magnetic stirrer. 300 g of pellets 
were coated in a fluid bed coating apparatus (GPCG 1, Glatt, Binzen, Germany), used in the 
bottom spray mode with the Wurster setup (nozzle diameter 0.8 mm; atomising pressure 1.5 
bar). The spray rate and the product temperature during the coating process with Aqoat AS-
HF were 8.5 g/min (initial 30 min), 10.5 g/min (next 30 min), 11.4 g/min (till the end of the 
process) and 30°C and for coating with the Eudragit-polymers 4 g/min and 23-25°C. Before 
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coating, the pellets were heated to the desired product temperature used during coating. After 
coating, the pellets were cured for 15 min at the same conditions as the coating process. 
Thereafter, they were cured either for 2 or 5 days on trays at room temperature, 40 or 60°C, 
depending on the polymer and coating dispersion. The pellets were coated with 15 to 25% 
(w/w) Aqoat AS-HF (depending on the coating dispersion used), 15 % (w/w) Eudragit FS 
30 D, 10 to 30 % (w/w) Eudragit L30D-55, 15 % (w/w) of the mixture Eudragit FS 30 
D/L30D-55 and 15 to 20% (w/w) Eudragit S.  
III.3.2.4 Dissolution testing 
Dissolution testing (n=3) was performed using the reciprocating cylinder method (USP 
apparatus 3) (Bio-Dis, Vankel, NJ, USA) at a dip rate of 21 dpm using 1 g pellets per vessel 
(250 ml) with two consecutive media: HCl 0.1N (2 h) and consequently a buffer solution 
(phosphate buffer 0.05 M) at pH 5.5, 6.0, 6.5, 6.8, 7.0, 7.2 or 7.4, depending on the polymer 
tested, with a drain time of 10 s in between the two dissolution media. The concentration of 
thymidine was measured spectrophotometrically (Perkin Elmer, Zaventem, Belgium) at 267 
nm.  
III.3.2.5 Scanning electron microscopy 
The morphology of the coating surface and the coating thickness were examined by scanning 
electron microscopy (SEM) (Jeol JSM 5600 LV, Jeol, Tokyo, Japan). Pellets were radially 
sheared and platina coated using a sputter coater (Auto Fine Coater, JFC-1300, Jeol, Tokyo, 
Japan). The coating thickness of five pellets was measured at five sites per pellet. 
III.3.2.6 Modulated differential scanning calorimetry 
Films of Eudragit FS 30 D, Eudragit L30D-55 and the mixture of Eudragit FS 30 
D/Eudragit L30D-55 (80/20, w/w) were prepared by casting a thin layer of pure Eudragit 
FS 30 D dispersion (30% (w/w) aqueous dispersion), pure Eudragit L30D-55 dispersion 
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(30% (w/w) aqueous dispersion) and Eudragit FS 30 D/L30D-55 mixture in a recipient. The 
films were dried for four days at RT.    
Tg of the films was determined using a model 2920 modulated DSC (TA Instruments, 
Brussels, Belgium). Approximately 25 mg of sample was placed in an aluminium pan that 
was hermetically sealed. The sample was heated from –40°C to 80-120°C with an underlying 
heating rate of 2°C/min, a modulation period of 60 s and a modulation amplitude of 0.5°C. Tg 
was reported as the midpoint of the transition. The analysis was performed in duplicate. 
III.3.3 RESULTS AND DISCUSSION 
Specific targeting to the human ileum finds increasing interest, not only in the treatment of 
Crohn’s disease but also in the domain of mucosal vaccination. Recent advances in 
biotechnology made it possible to use live microorganisms, genetically engineered to express 
foreign antigens and/or immune stimulating cytokines at the mucosal target site (Mielcarek et 
al., 2001). Mucosal immunity can best be obtained by local exposure of the antigens to the 
Peyer’s Patches of the gut-associated lymphoid tissue, most prominent in the terminal ileum 
(Chen, 2000; Kato and Owen, 1994).  
In order to obtain specific ileal release, knowledge of the ileal characteristics is required. Table 
4 gives an overview of the ileal pH reported by different authors in healthy people and patients 
with Crohn’s disease. This table shows that the pH in the ileum ranges from 6.6 to 8.3 and is 
not influenced by Crohn’s disease. The mean transit in the small intestine is relatively constant 
and ranges from 3 to 4 h (Friend, 1998; Abrahamsson et al., 1996; Gupta et al., 2001). Davis et 
al. (1986) reported that the residence time of pellets in the jejunum is 2 h, and approximately 
1.5 h in the ileum. In patients with Crohn’s disease, transit time can be dramatically decreased 
because of diarrhoea. Due to the short transit time, variation in gastric emptying and lack of 
specific enzymes and microflora, the only approach to target to the ileum relies on differences 
in pH along the GI-tract.  
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Table 4 pH of the ileum in healthy people and patients with Crohn’s disease  
pH ileum   Reference  
Healthy volunteers Patients with Crohn’s disease 
Evans et al. (1988)  7.5 ± 0.5 (7.0-8.0) (n=58)  
Fallingborg et al. (1989)  7.3 (6.6-7.7) (n=33)   
Fallingborg et al. (1998)  7.4 (6.6-8.1) (n=13)   
Press et al. (1998)    7.0 (4 patients <7.0, of which 1 patient < 6.8) 
(n=12) 
Ewe et al. (1999)  7.7 (n=15)  7.4 (2 patients pH < 6.8, 10 patients pH >7.0) 
(n=12)
Sasaki et al. (1997)  7.7 ± 0.2 (n=4)  7.8 ± 0.5 (n=4) 
Friend (1998)  7.5 ± 0.4 (n=66)   
RANGE  6.6 - 8.1  6.6 - 8.3 
 
To guarantee ileal delivery of thymidine and L. lactis in áll patients, the pH-sensitive polymer 
must dissolve from pH 6.8 (Table 4). Since the transit time in the ileum is approximately 1.5 h 
but can be dramatically decreased in patients with Crohn’s disease and since a sufficient 
amount of thymidine and L. lactis has to be available at the site of inflammation ensuring a 
quick start of the hIL-10 secretion, we premised a second requirement of the polymer i.e. fast 
and complete release within 40 min. Next, to avoid high costs, environmental and safety 
problems as well as detrimental effects of organic solvents on viability of L. lactis, aqueous 
based coating polymers were required. Only two pH-sensitive polymers, dissolving from pH 
6.8 and applicable as aqueous dispersions, are available and pharmaceutically approved: 
Aqoat AS-HF (Shin-Etsu Chemical Co, Tokyo, Japan) and Eudragit FS 30 D (Röhm, 
Darmstadt, Germany). Aqoat AS-HF (Shin-Etsu Chemical Co, Tokyo, Japan) is a polymer 
consisting of hydroxypropylmethylcellulose acetate succinate and is available as a fine 
powder (Fig. 1c). Eudragit FS 30 D (Röhm, Darmstadt, Germany) is an anionic copolymer 
of methyl acrylate, methyl methacrylate and methacrylic acid and is available as a 30% 
aqueous dispersion (Fig. 1b). In another approach to obtain ileal targeting, Eudragit L30D-
55, an anionic copolymer of methacrylic acid and ethyl acrylate (1:1), dissolving from pH 5.5 
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and available as a 30% aqueous dispersion was applied in a thick layer to obtain a lag-phase 
of its dissolution during transit and possibly allow the coated pellets to pass the proximal 
small intestine intact (Fig. 1a).    
 
Figure 1 a: Chemical structure of Eudragit L30D-55: R1(H); R2 (C2H5);  n1:n2 (1:1) and 
Eudragit S: R1(CH3); R2 (CH3);  n1:n2 (1:2). b: of Eudragit FS 30 D. c: of Aqoat AS-HF: 
R: -H, -CH3, -CH2CH(CH3)OH, -COCH3, -COCH2CH2COOH. 
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III.3.3.1 Release of thymidine from pellets coated with Aqoat AS-HF  
Pellets coated with coating dispersion A (15%, w/w) showed sub-optimal enteric properties: 
the release in HCl 0.1N after 2 h (13.6%) was slightly above the limits indicated in the 
European Pharmacopoeia (maximally 10%) (Fig. 2). Increasing the amount of polymer 
applied to 20% (w/w) did not improve the enteric properties (13.1% release in HCl 0.1N after 
2 h). Fig. 3 shows a SEM picture of the cross-section of a pellet coated with 15% (w/w) 
Aqoat AS-HF (coating dispersion A). Despite the high coating thickness (34.8 ± 6.9 µm 
(n=25)), the porous appearance of the coating surface could explain the sub-optimal enteric 
properties. No continuous polymer layer was formed probably due to incomplete coalescence 
and fusion of the polymer droplets during coating and subsequent curing, despite the fact that, 
as recommended, triethyl citrate was used as plasticiser in a concentration of 35% (w/w) to 
the polymer and the product temperature during coating was 30°C. Curing time and 
temperature were increased in an attempt to improve film formation and hence coating 
performance. Increasing curing time to 5 days did not decrease release after 2 h in HCl 0.1 N 
(13.1%). Increasing curing temperature to 60°C slightly decreased release after 2 h in HCl 0.1 
N (10.4%) but the value was still above the limits indicated in the European Pharmacopoeia.  
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Figure 2 Thymidine released (mean ± S.D., n=3) in HCl 0.1N after 2 h from pellets coated with 
different amounts (10, 15, 20, 25 or 30%) of Aqoat AS-HF (dispersion A, B and C), Eudragit FS 30 
D, Eudragit L30D-55, Eudragit FS 30 D / L30D-55 mixture and Eudragit S (dispersion A, B and 
C), cured at RT for 2 days. Insert: Thymidine released (mean ± S.D., n=3) in HCl 0.1N after 2 h from 
pellets coated with 15% (w/w) Aqoat AS-HF (A), Eudragit S (A) and Eudragit FS 30 D / L30D-55 
mixture, cured at different conditions for different periods.   
 
Figure 3 SEM picture of a cross-section of a pellet coated with 15% Aqoat AS-HF (w/w) using 
coating dispersion A (Aqoat AS-HF 10%, talc 2%, triethyl citrate 3.5%, sodium lauryl sulphate 0.2% 
and water 83.5%) and cured at RT for 2 days.  
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Nykänen et al. (1999) suggested using coating dispersion B (containing triethyl citrate, 
Aqoat AS-HF and magnesium stearate (glidant)) for enteric-coating of ibuprofen containing 
granules, but no data were provided on the gastric resistance of the enteric-coated granules. 
When using coating dispersion B, no enteric properties were obtained in this study (Fig. 2). 
Applying more polymer (up to 25% (w/w)) resulted in a decrease of the release rate of 
thymidine in HCl 0.1N, but still 100% was released within 2 h. The low solubility of 
ibuprofen in acidic medium could explain why no problems were reported by Nykänen et al. 
(1999) in relation to enteric-coating efficiency. In contrast, thymidine has a pH independent 
solubility, so it has excellent properties for evaluating enteric-coated formulations and more 
specific formulations of acid sensitive compounds such as L. lactis. The release of thymidine 
in HCl 0.1N gives a good indication of the acid permeability of the enteric-coat during 
passage through the stomach and the possible detrimental effect on L. lactis’ viability.  
On SEM pictures the coating surface appeared porous and discontinuous, similar to dispersion 
A. By varying the plasticiser concentration, the film forming properties of a polymer can be 
modified. Therefore, the thymidine pellets were coated with coating dispersion C, containing 
more plasticiser. However, this formulation did also not meet the requirements for enteric-
coated dosage forms of the European Pharmacopoeia (Fig. 2).  
The poor enteric properties achieved with coating dispersion B and C were probably due to an 
incompatibility between AqoatAS-HF and magnesium stearate as after coating, the pellets 
were covered with a white and dusty polymer layer.  
In this study, the best enteric properties with AqoatAS-HF were achieved using coating 
dispersion A. Before further optimisation of this coating in order to obtain satisfying enteric 
properties, the suitability of the polymer to obtain ileal targeting was evaluated by studying 
the release profiles (Fig. 4). The release rate increased with increasing pH, while the release 
rate decreased by increasing the amount of coating polymer applied on the pellets.  
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From pellets coated with 15% (w/w), as well as 20% (w/w) polymer, 80% thymidine was 
released after 40 min dissolution, even at pH values lower than 6.8. These release data 
indicated the inability of Aqoat AS-HF to obtain ileal targeting for thymidine incorporated in 
pellets. This is in contrast to the data of Nykänen et al. (1999) who reported that after 3 h at 
pH 6.8, only 35% of ibuprofen was released from granules, coated with 20% (w/w) 
AqoatAS-HF. This difference in dissolution profile could be explained by the difference in 
formulation approach as Nykänen et al. (1999) used AqoatAS-HF both as binder and coating 
material to delay drug release from the granules in order to target to the colon.  
From these data it can be concluded that AqoatAS-HF is not suitable neither for enteric-
coating of thymidine pellets, nor for ileum targeting of thymidine from this pellet formulation.  
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Figure 4 Release profiles (mean ± S.D., n=3) of thymidine from pellets coated with 15 (- - -, open 
symbols) and 20% (, filled symbols) Aqoat AS-HF (w/w) using coating dispersion A (Aqoat AS-
HF 10%, talc 2%, triethyl citrate 3.5%, sodium lauryl sulphate 0.2%, water 83.5%, cured at RT for 2 
days) in HCl 0.1N (2 h) and subsequently in buffer solution with pH 6.5 (●), 6.8 (■) or 7.0 (▲). 
III.3.3.2 Release of thymidine from pellets coated with Eudragit FS 30 D  
Fig. 5 shows the release profiles of thymidine from pellets coated with Eudragit FS 30 D. 
After 2 h dissolution in HCl 0.1N less than 10% thymidine (3.0 ± 2.1%) was released, which 
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proves the gastro-resistance of the coating at the applied coating thickness (Fig. 2). Fig. 6 
shows an SEM picture of a cross-section of a pellet coated with 15% (w/w) Eudragit FS 30 
D. The coating thickness was 25.7 ± 3.1 µm (n=25). This is in agreement with Gupta et al. 
(2001), who reported a coating thickness of 47µm on pellets (0.8-1µm) coated with 30% 
Eudragit FS 30 D. Contrary to pellets coated with Aqoat AS-HF, the coating surface had a 
smooth appearance and a continuous polymer layer was formed. At pH 6.8 no release was 
observed after 1.5 h, considered to be the maximal transit time of pellets in the ileum. Release 
was very slow at pH 7.0: only 11% of thymidine was released after 1.5 h. Only at pH 7.2 and 
above, 100% thymidine was released within 1.5 h. At pH 7.2, a lag-time of 20 min was 
observed before the release started. When the requirements of the polymer to allow complete 
release within 40 min from pH 6.8 are considered, it can be concluded that only at pH 7.4 and 
above, thymidine release was completed within 40 min. Below pH 7.0, no thymidine was 
released. At pH 7.2 and 7.4, 42% and 84% was released within 40 min, respectively.  
The pH at which the Eudragit FS 30 D dissolution started (pH 7.2) was not in accordance to 
the value reported in literature (pH 6.8) (Gupta et al., 2001). As the ileal pH can be lower than 
7.2 (Table 4), it is evident that in some patients the thymidine release will not occur in the 
ileum or only at its distal parts. For the co-formulated L. lactis, incomplete and/or delayed 
release will result in insufficient time to become metabolically active and secrete the hIL-10 
at the site of inflammation. This study clearly emphasises the necessity of testing a 
formulation, developed for specific targeting, at a range of pH-values since small variations of 
pH can cause remarkable differences in release profiles.  
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Figure 5 Release profiles (mean ± S.D., n=3) of thymidine from pellets coated with 15% (w/w) 
Eudragit FS 30 D (- - -) and Eudragit S (A, cured at 60°C, 2 days) () after 2 h HCl 0.1N and 
subsequently buffer solution with pH 6.8 (■), 7.0 (▲), 7.2 (●) or 7.4 (✕). 
   
Figure 6 SEM picture of a cross-section of a 
pellet coated with 15% (w/w) Eudragit FS 30 
D.  
Figure 7 SEM picture of a cross-section of a 
pellet coated with 15% (w/w) Eudragit L30D-
55. 
III.3.3.3 Release of thymidine from pellets coated with Eudragit S  
Alternatively, Eudragit S, an anionic copolymer of methacrylic acid and methylmethacrylate 
(1:2), available as a fine powder and redispersable in water by partial neutralisation with 
NH4OH, was tested (Fig. 1a). Rudolph et al. (2001) showed faster release from 5-ASA pellets 
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coated with Eudragit S than coated with Eudragit FS 30 D at pH 7.2 (both from an aqueous 
dispersion), 100% being released within 30 and 360 min, respectively. Fig. 2 shows that the 
release from thymidine pellets, coated with Eudragit S and cured at RT after 2 h in HCl 0.1N 
is higher than the limits indicated in the European Pharmacopoeia. Increasing the coating 
thickness to 20% (w/w) could not improve the coating performance. Since Eudragit S is a 
rigid polymer (Tg 160°C), contrary to the Flexible Eudragit FS 30 D (Tg 30°C), 60% TEC 
was added to reach sufficient plastisation of the polymer. But the hydrophilic characteristics 
of the plasticiser, combined with its high content in the coating layer could lead to pore 
formation and subsequent release of thymidine in the gastric stage (Frohoff-Hülsmann et al., 
1999). Decreasing the plasticiser content (40%) or using a hydrophobic plasticiser (dibutyl 
sebacate) could not improve the coating performance (Fig. 2). However, increasing the curing 
temperature to 40 and 60°C for 2 days markedly improved the coating performance (Fig. 2). 
This can be explained by the fact that due to the rigid properties of the polymer, higher curing 
temperatures are required for complete coalescence and hence film formation.  
Fig. 5 shows that at all pH values, the release profiles of thymidine from pellets coated with 
15% Eudragit S are comparable with the profiles of thymidine from pellets coated with 15% 
Eudragit FS 30 D. When the requirements of the polymer to allow complete release within 
40 min from pH 6.8 are considered, it can be concluded that only at pH 7.4 and above 
thymidine release was completed within 40 min. Below pH 7.0, no thymidine was released. 
At pH 7.0, 7.2 and 7.4, 6%, 45% and 97%, respectively was released within 40 min. 
Moreover, as L. lactis is temperature sensitive, this polymer can not be used for the 
production of an enteric-coated formulation containing this microorganism because curing has 
to be performed for 2 days at minimally 40°C.  
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III.3.3.4 Release of thymidine from pellets coated with Eudragit L30D-55  
In another attempt to obtain ileal targeting, pellets were coated with Eudragit L30D-55. It is 
an anionic copolymer of ethyl acrylate and methacrylic acid (1:1) and is available as a 30% 
aqueous dispersion (Fig. 1a). At a generally proposed coating thickness of Eudragit L30D-
55 for multiple unit formulations (10 to 20% (w/w) polymer weight gain) to reach enteric 
properties, an in vivo dilution and absorption of thymidine will take place before it reaches the 
ileum. Moreover, the co-formulated bacteria would be released in the small proximal bowel 
and this will result in a loss of viability due to the presence of the detrimental bile salts. A 
way to overcome this problem could be the application of a thicker coat of Eudragit L30D-
55 (Harris and Ghebre-Sellassie, 1997). A lag-phase of approximately 2 h must be obtained to 
ensure intact passage through the proximal small intestine. The percentage of thymidine 
released from pellets coated with different amounts of polymer after 2 h in HCl 0.1N is shown 
in Fig. 2. The amount of thymidine released after 2 h decreased with increasing the coating 
thickness (9.1 ± 0.7, 5.7 ± 2.0, 4.2 ± 1.8, 2.8 ± 1.1% for 10, 15, 20 and 30%, respectively). 
For every coating thickness applied, the coated pellets met the requirements of the European 
Pharmacopoeia concerning enteric-coated dosage forms. Fig. 7 shows a SEM picture of the 
cross-section of a pellet coated with 15% (w/w) Eudragit L30D-55. The coating thickness 
was 29.5 ± 2.0 µm (n=25), but 61.3 ± 8.6 µm (n=25) for pellets coated with 30% (w/w) 
polymer. The surface of the pellets coated with Eudragit L30D-55 was smooth. Fig. 8 shows 
the release profiles of thymidine from pellets coated with different amounts of Eudragit 
L30D-55 at pH 5.5, 6.0 and 6.5. At pH 5.5, a very slow thymidine release was observed: 17.5 
% was released after 4 h from pellets coated with 10% (w/w) Eudragit L30D-55. The release 
from pellets coated with a thicker coat was as expected lower (12% after 4 h from pellets 
coated with 30 % (w/w) Eudragit L30D-55). Fig. 8 clearly shows that at pH 6.0, by 
increasing the coating thickness, the release rate decreased. However, only a short lag-phase 
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was obtained (20 min) from pellets coated with 30 % (w/w) Eudragit L30D-55. At pH 6.5, 
increasing the coating thickness did not affect the release rate and in all cases 80 % was 
released within 20 min.  
0
20
40
60
80
100
0 50 100 150 200 250 300 350 400
Time (min)
Th
ym
id
in
e 
re
le
as
ed
 (%
)
 
                       HCl 0.1N                          Buffer solution        
Figure 8 Release profiles (mean ± S.D., n=3) of thymidine from pellets coated with 10% (◆), 15% 
(●), 20% (▲) and 30% (■) Eudragit L30D-55 after 2 h HCl 0.1N and subsequently buffer solution 
with pH 5.5 (, grey symbols), 6.0 (, black symbols) and 6.5 (, open symbols). 
Klein et al. (2002) studied the dissolution of mesalazine from two types of tablets coated with 
Eudragit L30D-55: Claversal and Salofalk. A lag-time in buffer pH 6.8 was reported of 30 
and 150 min, respectively, due to the difference in coating thickness, which was 100 µm and 
250 µm, respectively. In our study, the coating thickness was only 61.3 ± 8.6 µm for pellets 
coated with 30% (w/w) Eudragit L30D-55.   
In this study, Eudragit L 100, dissolving from pH 6.0, is not used as an alternative of 
Eudragit L30D-55. This polymer has a very high Tg (200°C), even higher than Eudragit S. 
Most likely, this polymer will also require high curing temperatures for adequate film 
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formation and hence good enteric properties. However, this is inappropriate for the L. lactis’ 
viability.  
III.3.3.5 Release of thymidine from pellets coated with a mixture of Eudragit FS 30 D 
/L30D-55 
Khan et al. (1999) coated mesalazine tablets using combinations of Eudragit L100-55 and 
Eudragit S100 and showed that the release profile of mesalazine within the pH range of 5.5 
to 7.0 could be manipulated by changing the Eudragit L100-55 and Eudragit S100 ratios. In 
this study, a combination of Eudragit L30D-55 and Eudragit FS 30 D was used as 
separately they resulted in good enteric properties after curing at room temperature. Eudragit 
S was not used in the mixture as this polymer requires high curing temperatures, which is 
inappropriate for the viability of L. lactis. The polymers were used in a ratio of 1/4 as with 
this ratio, Khan et al. showed a lag-time of 45 min at pH 6.5. Fig. 2 shows that pellets coated 
with this combination have no good enteric properties, even after 5 days curing (9.4 ± 2.0% 
release after 2h in 0.1N HCl) or curing at 60°C (10.1 ± 2.9% release after 2h in 0.1N HCl). 
However, pellets coated with Eudragit FS 30 D or L30D-55 only showed good enteric 
properties i.e. 3.0 ± 2.1% and 5.7 ± 2% release after 2h in 0.1N HCl, respectively. Although 
the similarity in chemical structure of both polymers, it was investigated if these polymers 
were compatible by determination of the Tg of several polymer films, prepared by casting the 
coating dispersions (pure or mixture) and subsequently drying and curing (Fig. 9). The pure 
Eudragit FS 30 D and Eudragit L30D-55 films showed a Tg of 32.0 ± 0.6°C (n=2) and 56.4 
± 0.4°C (n=2). A physical mixture of both films showed two Tg signals i.e. the first at 34.0 °C 
and the second at 56.9°C. These values are in accordance with the values obtained from the 
pure films and can be attributed to the Eudragit FS 30 D and Eudragit L30D-55 polymer, 
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respectively. The films, prepared by casting a mixture of Eudragit FS 30 D and Eudragit 
L30D-55 (80/20, w/w) showed only one signal (33.3 ± 4.5°C; n=6).  
Figure 9 MDSC curves (Total Heat Flow (black lines) and Reversing Heat Flow (grey lines)) of pure 
Eudragit FS 30 D (——), pure Eudragit L30D-55 (-----), physical mixture of Eudragit FS 30 
D/L30D-55 (80/20) (—.—.) and of Eudragit FS 30 D/L30D-55 (80/20) film (— —) with Tg 
mentioned on the Reversing Heat Flow curves.   
From these results it can be concluded that these polymers were compatible. A hypothesis for 
the explanation of the increased release after 2h in 0.1N HCl may be that the plasticiser 
included in the polymer mixture results in an increased permeability of the film i.e. addition 
of plasticiser to Eudragit FS 30 D, a polymer that requires no plasticiser because of its 
inherent flexibility, may increase its permeability.  
Release profiles showed a decrease in release rate at pH 6.0, which is comparable with the 
release rate from pellets coated with 30 % (w/w) Eudragit L30D-55, but no lag-phase was 
seen. At pH 6.5 and higher, release is completed within 40 min. A hypothetical explanation 
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for these results can be that although the polymers show compatibility, individual spots of 
pure Eudragit FS 30 D and Eudragit L30D-55 can be identified on the surface of the coated 
pellets. An Eudragit L30D-55 spot dissolves from 6.0 resulting in the formation of pores, 
from which thymidine can be released.   
As Khan et al. (1999) showed only a slight increase in lag-phase from 45 to 60 min by 
changing the ratio of both polymers from 1:4 to 1:5, respectively, other ratio’s have not been 
tested in this study.  
III.3.4 CONCLUSIONS  
From this study, it is clear that Aqoat AS-HF, Eudragit L30D-55 and a mixture of 
Eudragit FS 30 D/L30D-55 dissolve at a pH lower than the pH at the target site (6.8) and 
consequently thymidine will be diluted and absorbed in the proximal small intestine and the 
co-formulated L. lactis will be subjected to the detrimental bile salts present in the jejunum. 
Eudragit FS 30 D and S dissolve at a pH above the pH at the target site. Consequently, 
thymidine and the co-formulated L. lactis will not be released or will only be released in the 
most distal parts of the ileum. This implies that the hIL-10 production will not occur in the 
ileum but in the colon. It can be concluded that none of the tested polymers or polymer 
mixtures can guarantee ileal targeting on his own. To circumvent the issue of high 
gastrointestinal pH variability among individuals, a combination of doses could be used: one 
dose coated with Eudragit L30D-55 while another dose coated with Eudragit FS 30 D. In 
patients with a high GI-pH profile, thymidine and L. lactis will be released in the ileum from 
the formulation coated with Eudragit FS 30 D, while in patients with a low GI-pH profile, 
thymidine and L. lactis will be released in the ileum from the formulation coated with 
Eudragit L30D-55. This approach has been used to deliver biological contained hIL-10 
secreting L. lactis in a safety study in patients suffering from Crohn’s disease.  
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III.4 ALTERNATIVE METHOD FOR ENTERIC-COATING OF HPMC CAPSULES RESULTING IN 
READY-TO-USE ENTERIC-COATED CAPSULES / INCORPORATION OF FREEZE-DRIED 
LACTOCOCCUS LACTIS THY12 
III.4.1 INTRODUCTION  
An in vivo experiment in pigs was performed to prove the principle of the biological 
containment system and the capacity of the genetically modified thyA- hIL10+ Lactococcus 
lactis (L. lactis Thy12) to secrete hIL-10 at the target site (pigs ileum) (Steidler et al., 2003). 
At that stage of the research, L. lactis was available as a freeze-dried powder (Chapter III.2). 
The development of a multi-particulate formulation was still ongoing.  However, L. lactis had 
to be administered in an enteric-coated dosage form to protect it from the detrimental gastric 
fluid, from lysis by bile salts and digestive enzymes and to ensure pig ileal release. An 
enteric-coated capsule, containing freeze-dried L. lactis was selected as the appropriate 
formulation. Because pigs chew their food and would thereby destroy the enteric-coating, a 
fistula was created to access the proximal duodenum, while a second fistula was created to 
sample the ileal content. To ensure easy administration of the capsules through the fistula 
tubing, capsule size 5 was used. This small size is only available in gelatin, the most 
commonly used material for manufacturing capsules. As gelatin softens in contact with water, 
resulting in sticking of the capsules, it was preferred to coat the capsules with organic 
solutions. For safety reasons, the capsules were enteric-coated in a lab scale capsule coater. A 
rotating air stream injected into a glass sphere causes a rotating movement of the capsules 
inside the glass sphere. Simultaneously, a silicone flexible tubing starts to swivel around 
inside the sphere and allows the coating solution to be sprayed onto the capsules. The solvent 
evaporates instantly and the polymer is left behind on the capsules. 
During preliminary experiments, hard gelatin capsules were enteric-coated with an organic 
solution of Eudragit L 100-55 (Röhm Pharma), a copolymer of methacrylic acid and 
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ethylacrylate, available as a fine powder and dissolving above pH 5.5. However this resulted 
in the so-called “orange peel” effect. Moreover, during coating the water present in the gelatin 
capsule wall and acting as a plasticiser, evaporated resulting in shell embrittlement. To 
improve adhesion of the enteric-coat to the smooth hard gelatin capsule surface and to prevent 
the peeling of the enteric-coat and shell embrittlement, a hydroxypropyl cellulose (Klucel 
EF, Hercules) precoat (4 à 5 mg/cm2) was applied using a 7% (w/v) solution in isopropanol. 
Next, Eudragit L 100-55 (8 à 9 mg/cm2) was applied using a 7.4% (w/w) solution in aceton. 
Dibutyl sebacate (15% (w/w) of the polymer) was added as a plasticiser and talc (28% (w/w) 
of the polymer) as a glidant. The capsules used in the pig in vivo study complied the 
requirements of the European Pharmacopoeia for enteric-coated formulations: release in HCl 
0.1N after 2 h was below 10%, while at pH 6.0, release was completed within 40 min.  
Although pre-coating solves the problem of poor adhesion of the enteric-coat to the gelatin 
surface and shell embrittlement (Murthy et al., 1986; Thoma and Bechtold, 1992), it is a time 
consuming and complicated procedure. Moreover, aqueous coating is preferred above organic 
coating because of toxicological, environmental and safety-related drawbacks, with high 
manufacturing costs (Cunningham and Fegely, 2001; Wheatley and Steuernagel, 1997). 
However, the aqueous coating process of gelatin capsules is a very sensitive, time consuming 
and expensive process.  
Enteric-coating of HPMC capsules, since decades used in the dietary supplement industry as a 
vegetarian alternative for gelatin (Ogura et al., 1998), results in good polymer adhesion and 
compatibility (Cole et al., 2002; Scott and Cole, 2001). Contrary to gelatin, aqueous coating 
of HPMC capsules is more feasible. Moreover, HPMC capsules have a natural low moisture 
content (2-5%), contrary to gelatin capsules (13-15%) allowing the maintenance of a low 
water content within the HPMC capsule. Thereby, they maintain mechanical integrity under 
extremely low-moisture conditions. For both these reasons, they are ideally suited to be filled 
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with moisture sensitive compounds and to be stored at low relative humidity conditions. 
Moreover, contrary to gelatin capsules, HPMC has no chemically reactive groups.  
However, a sealing step prior to coating is required to avoid leakage of the capsule content 
into the stomach or vice versa. It can be performed manually using a brush and applying a 
20% (w/w) gelatin solution to overlay the closure of the capsule (Felton et al., 2002). The 
need for manual sealing can be overcome by using the LEMSTM technique (Liquid 
Encapsulation Microspray Sealing), developed by Capsugel for the automatic sealing of 
capsules containing semi-solids or liquids. In this process, a solution of ethanol and water is 
sprayed between the overlap of body and cap, followed by a heating step (40-60°C) to 
complete the fusion of the body and the cap. However, this is still a time-consuming and 
expensive step in the production process. Moreover, from Chapter III.2 it is clear that freeze-
dried L. lactis is temperature and moisture sensitive as after 1 week storage at room 
temperature and 60% RH, viability of L. lactis in the freeze-dried powder dropped to zero. So 
heat sealing could lead to destabilisation of the freeze-dried L. lactis. Therefore, all handling 
of L. lactis at elevated temperatures and at high relative humidity should be limited. 
The aim of this study was to develop an alternative method for the enteric-coating of HPMC 
capsules eliminating the sealing step and providing enteric-coated capsules for incorporation 
of freeze-dried L. lactis, limiting all handling with this heat and moisture sensitive material. 
The enteric-coated capsules were optimised to allow storage at low temperature and low 
relative humidity and allow passage through the stomach avoiding gastric fluid penetration. 
The new method was evaluated in terms of enteric properties of the coated capsules, 
applicability to other polymers, reproducibility, release from the coated capsules and storage 
stability of the coated capsules. To prove the broad application range of the method, capsules 
with different sizes were coated. The freeze-dried L. lactis Thy12 were incorporated in the 
enteric-coated capsules and the viability and hIL-10 production in function of time and 
viability after simulated passage through the stomach have been tested. Moreover, it was the 
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aim to evaluate the suitability of this dosage form for gastric protection and ileum targeting of 
L. lactis Thy12. 
III.4.2 MATERIALS AND METHODS 
III.4.2.1 Preparation of enteric-coated capsules 
III.4.2.1.1 Traditional coating method  
Filling of the capsules 
HPMC capsules 00 (Vcaps) (Capsugel, Bornem, Belgium) were filled with a mixture of 300 
mg freeze-dried reconstituted skim milk (RSM) (good model for the freeze-dried L. lactis) 
and 30 mg thymidine (marker substance) and closed. Thymidine was chosen as marker 
substance because it is freely water-soluble (5.5 g / 100 ml) at all pH values (from pH 2.5 to 
7) and has therefore excellent properties to evaluate the enteric properties of an enteric-coated 
formulation.  
Coating of HPMC capsules with Eudragit FS 30 D and Eudragit L30D-55  
The filled capsules were coated with Eudragit L30D-55, an anionic copolymer of methacrylic 
acid and ethylacrylate (1:1) and Eudragit FS 30 D, an anionic copolymer of methyl acrylate, 
methyl methacrylate and methacrylic acid. Previous experiments showed that Eudragit FS 30 
D dissolves from pH 7.2 and Eudragit L30D-55 from pH 6.0 (Chapter III.3). Both polymers 
are available as a 30% (w/w) aqueous dispersion (Röhm, Darmstadt, Germany). For the 
preparation of the Eudragit L30D-55 dispersion, 4.6 g of triethyl citrate (plasticiser) (Sigma-
Aldrich, Bornem, Belgium) (20% (w/w) calculated on the polymer content) was dissolved in 
103.3 g water. This solution was added to 77.1 g of Eudragit dispersion (30% (w/w)) (Cole et 
al., 2002). Next, the coating dispersion was passed through a 0.3 mm sieve and continuously 
stirred throughout the coating process using a magnetic stirrer. For the preparation of the 
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Eudragit FS 30 D dispersion, only 1.15 g of triethyl citrate was needed (5% (w/w) of the 
polymer) since this polymer exhibits a lower minimum film-forming temperature (14°C) than 
Eudragit L30D-55 (27°C) (Cole et al., 2002). Besides triethyl citrate, 2.3 g of a polysorbate 80 
solution (33%, v/w) (wetting agent) (Tween® 80, Alpha pharma, Nazareth, Belgium) and 1.9 g 
of glyceryl monostearate (glidant) (Federa, Braine-l’Alleud, Belgium) was added to 103.3 g 
water and stirred over a period of 10 min with a high-speed mixer (Silverson, Bucks, England) 
until a fine, homogenous dispersion was obtained. Then, this solution was gently added to 77.1 
g of Eudragit dispersion (30% (w/w)). For the coating experiments, 735 ml of filled capsules 
(total surface area of 0.2 m2) were coated in a fluid bed apparatus (GPCG-1, Glatt, Binzen, 
Germany) using the bottom spray mode with the Wurster setup and the partition for tablet 
coating. The operating parameters are provided in Table 1. Based on theoretical calculation, 10 
mg polymer/cm2 was applied. Contrary to Eudragit L30D-55 coated capsules, capsules coated 
with Eudragit FS 30 D were cured at low relative humidity (20% RH) to prevent sticking as 
this polymer has a low Tg. Coating composition optimisation experiments resulted in a modified 
composition i.e. for the Eudragit L30D-55 dispersion the addition of 2.3 g of a polysorbate 80 
and 1.9 g of glyceryl monostearate and for the Eudragit FS 30 D dispersion an increase of the 
triethyl citrate concentration from 5 to 10% (w/w of the polymer). 
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Table 1 Operating parameters used to coat HPMC capsules with Eudragit FS 30 D, Eudragit 
L30D-55, Aqoat AS-HF and Sureteric 
 Eudragit FS 30 D Eudragit L30D-55 Aqoat AS-HF  Sureteric
Before coating:                     
Preheating to (°C) 25 25 30  38 
Coating:      
Nozzle diameter (mm) 0.8 0.8 0.8  0.8 
Spray rate (g/min) 6 6 10-15  4.6 
Atomising pressure (bar) 1.3 1.3 1.3  1.5 
Inlet air volume (m3/min) 2.43 2.43 2.43  2.43 
Inlet air temp. (°C) 30 30 34-41  44-46 
Product temp. (°C) 25-26 25-26 30  38-40 
Coating time (min) 31 31 23  33 
Curing:      
In fluid bed      
Time (min) 5 5 5  5 
Product temp.(°C) 25 25 30  38 
On Trays ON ON ON  ON 
Temperature (°C) RT RT RT  RT 
Relative Humidity (%) 20 60 60  60 
ON: overnight, RT: room temperature 
III.4.2.1.2 Alternative coating method   
The preparation of the coating dispersions is described below. After preparation, the 
dispersions were passed through a 0.3 mm sieve and continuously stirred throughout the 
coating process using a magnetic stirrer. For the alternative coating method, 30 g of HPMC 
caps or bodies 00 (Vcaps) (total surface area of 0.2 m2) were coated separately in the fluid bed 
apparatus (cf. the traditional coating method). Based on theoretical calculation, 10 mg 
polymer/cm2 was applied. The operating parameters are provided in Table 1. Besides, 24 g 
HPMC caps or bodies 4 (Vcaps), respectively were coated with the Eudragit L30D-55 
coating dispersion using the process parameters provided in Table 1.  
Huyghebaert et al., Eur. J. Pharm. Sci., 21 (2004) 617-623 
III.4 Production of ready-to-use enteric-coated HPMC capsules and incorporation of freeze-dried 
Lactococcus lactis Thy12 
100
Coating of the HPMC caps and bodies with Eudragit FS 30 D and Eudragit L30D-55  
The composition, the preparation of the Eudragit L30D-55 and Eudragit FS 30 D coating 
dispersions and the coating operating parameters were identical to the traditional coating 
method.  
Coating of the HPMC caps and bodies with Aqoat AS-HF  
Aqoat AS-HF is a polymer consisting of hydroxypropyl methylcellulose acetate succinate, 
available as a fine powder and designed to be used in an aqueous system. Previous 
experiments showed that the polymer dissolves at pH 6.5 (Chapter III.3). The coating 
dispersion was prepared by first dissolving 8.1 g of triethyl citrate (plasticiser) (Sigma-
Aldrich, Bornem, Belgium) and 0.7 g of sodium lauryl sulphate (wetting agent) (Federa, 
Brussels, Belgium) in 291.4 g of water. Then, 23.1 g of Aqoat AS-HF (Shin-Etsu Chemical 
Co., Tokyo, Japan) and next 6.9 g of talc (glidant) (Alpha pharma, Nazareth, Belgium) were 
gradually added while stirring.  
Coating of the HPMC caps and bodies with Sureteric 
Sureteric (Colorcon, Kent, UK) is a mixture of PVAP (polyvinyl acetate phthalate), 
plasticisers and other ingredients and dissolves above pH 5.5. To prepare the coating 
dispersion, 0.15 g of simethicone emulsion (anti-foam agent) (30%, USP, Colorcon, Kent, 
UK) was added to 129.8 g of water while stirring. Next, 23.1 g of Sureteric was gradually 
added while stirring. The final dispersion was stirred for at least 30 min before use. 
Filling of the capsules 
The coated bodies 00 and 4 were filled with a mixture of 300 mg freeze-dried reconstituted 
skim milk (RSM)/30 mg thymidine and 40 mg freeze-dried RSM/30mg thymidine, 
respectively and closed manually with the coated caps.  
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III.4.2.2 Evaluation of the enteric-coated capsules 
III.4.2.2.1 Dissolution testing 
To evaluate the enteric properties of the capsules coated with the different polymers, a 
dissolution test (n=3) was performed using the reciprocating cylinder method (USP apparatus 
3) (Bio-Dis, Vankel, NJ, USA) at a dip rate of 21 dpm using 1 capsule per vessel, filled with 
250 ml HCl 0.1N (pH 1) for 2 h. To determine the pH dissolution profile of the coated 
capsules 00, a dissolution test was performed using two consecutive media: first HCl 0.1N for 
2 h and next a buffer solution (phosphate buffer 0.05M) for 4 h at pH 5.5, 6.0 and 6.5 and at 
pH 7.0, 7.2 and 7.4 for capsules coated with Eudragit L30D-55 and Eudragit FS 30 D, 
respectively. To determine the influence of storage on release from the coated capsules 00, a 
dissolution test was performed in HCl 0.1N for 2 h for both polymers and consequently at pH 
6.5 and 7.4, for Eudragit L30D-55 and Eudragit FS 30 D coated capsules, respectively. 
Marker release was measured spectrophotometrically (Perkin Elmer, Zaventem, Belgium) at 
267 nm. 
III.4.2.2.2 Coating composition optimisation 
For the optimisation of the coating composition in order to allow passage through the stomach 
avoiding gastric fluid penetration, the water content of the powder in the capsules coated with 
Eudragit L30D-55 and Eudragit FS 30 D was determined after 2 h dissolution in HCl 0.1N 
using a Mettler DL35 Karl Fisher titrator (Mettler-Toledo, Beersel, Belgium). The samples 
were stirred in the reaction medium for 60 s. Afterwards the water was titrated with 
Hydranal® Composite 5 (Riedel-de Haën, Seelze, Germany). The analysis was performed in 
triplicate. In order to allow storage at low relative humidity and low temperature, the 
Eudragit L30D-55 and Eudragit FS 30 D coated capsules were filled and packed in Alu 
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sachets (LPS, Vapor flex barrier bag, New Jersey, USA), sealed at 20% RH and subsequently 
visually analysed after storage for 1 week at 8°C.  
III.4.2.2.3 Optical microscopy 
Images were taken of HPMC capsules 00, coated using the traditional and alternative method, 
before and after the dissolution test (HCl 0.1N for 2 h) using an Olympus SZX9 
stereomicroscope, fitted to an Olympus Camedia Digital Camera C3030 (Tokyo, Japan).  
III.4.2.2.4 Scanning electron microscopy 
The coating thickness, homogeneity and appearance of the polymer at the inner surface of 
caps and bodies 00 coated with Eudragit L30D-55 and FS 30 D using the alternative coating 
method was examined by scanning electron microscopy (SEM) (Jeol JSM 5600 LV, Jeol, 
Tokyo, Japan) at the open end, in the middle and at the domed end (n=3). The coated bodies 
and caps were longitudinally cut and platina coated using a sputter coater (Auto Fine Coater, 
JFC-1300, Jeol, Tokyo, Japan) before scanning electron microscopy was performed.   
III.4.2.2.5 Reproducibility  
To test the reproducibility of the alternative coating method, three batches of caps and bodies 
00 were coated with Eudragit L30D-55 and FS 30 D, and the enteric properties were 
evaluated.  
III.4.2.2.6 Storage stability  
It was evaluated if the enteric properties and the release form the capsules 00 coated with 
Eudragit L30D-55 and FS 30 D using the alternative coating method were affected by storage 
of the coated caps and bodies prior to filling. Caps and bodies coated with Eudragit L30D-55 
were stored at standard ambient conditions (25°C/60% RH); while those coated with FS 30 D 
were stored at 25°C and 20% RH to prevent sticking. After 12 months the coated bodies were 
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filled and closed with the coated caps. A dissolution test was performed cf. III.4.2.2.1. 
Influence of storage on the enteric properties and the release from filled capsules was also 
evaluated. Therefore, immediately after coating and curing, the coated bodies were filled and 
closed with the coated caps. Capsules coated with Eudragit L30D-55 were stored at standard 
ambient conditions (25°C/60% RH), at 25°C/20% RH (in Alu sachets (LPS, Vapor flex barrier 
bag, New Jersey, USA) sealed at 20% RH), 8°C/20% RH (cf. above) and –20°C/20% RH (cf. 
above), while capsules coated with Eudragit FS 30 D were stored at 25°C/20% RH (cf. 
above), 8°C/20% RH (cf. above) and –20°C/20% RH (cf. above). A dissolution test was 
performed cf. III.4.2.2.1. 
III.4.2.3 Incorporation of L. Lactis Thy12 in the ready-to-use enteric-coated capsules 
III.4.2.3.1 Preparation of the freeze-dried powder formulation 
L. lactis Thy12 was inoculated in GM17 supplemented with 50 µg/ml thymidine (GM17T) 
and grown overnight (ON) to obtain the stationary phase (109 cfu/ml). The cells were 
collected by centrifugation at 3000g for 10 min at 4°C and the cell pellet was resuspended in 
1/10th of the initial volume of skim milk (10 times concentrated, 1010 cfu/ml). Next, L. lactis 
Thy12 was filled in petri-dishes (approximately 60 g/dish). Prior to freeze-drying, the dishes 
were kept on ice. The dishes were loaded on the precooled shelves (- 25°C) of the freeze-
dryer (Leybold GT4, Finn-aqua, Sohlberg, Germany). The samples were frozen to - 45°C 
over 105 min at 1000 mbar. The primary drying (12 h) was performed at - 15°C and 0.8 to 1 
mbar and the secondary drying (9 h) at 10°C and 0.1 to 0.2 mbar. After freeze-drying, the 
dishes were kept on ice until further handling. The freeze-dried L. lactis Thy12 were filled in 
HPMC bodies 00 (Vcaps, Capsugel, Bornem, Belgium), precoated with Eudragit L30D-55 
and Eudragit FS 30 D at 20% RH to prevent sticking of the hygroscopic powder and closed 
with the Eudragit L30D-55 and FS 30 D coated caps, respectively. The capsules were 
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packed in Alu sachets (LPS, Vapor flex barrier bag, New Jersey, US), sealed at 20% RH and 
stored at 8°C and -20°C. Analysis was performed after 1, 2, 3, 6, 9 and 12 months storage. 
III.4.2.3.2 Analysis of the freeze-dried L. lactis Thy12 culture filled in the ready-to-use 
enteric-coated HPMC capsules 
Determination of viability of L. lactis Thy12 
Viability of the bacteria was determined using a turbidimetric method as described in Chapter 
III.2. For determining the viability in the enteric-coated capsules, 0.1 g of the freeze-dried 
powder was dissolved in 10 ml sterile water. For determining the viability in the enteric-
coated capsules after the gastric fluid passage, the capsules were subjected to HCl 0.1N 
(37°C) (1 capsule/30 ml). After 2 h, the content of the capsule was dissolved in 30 ml 
GM17T. Three replicas of each sample were analysed and of each replica, three dilutions 
were loaded in duplicate onto micro-titer plates. Viability after storage was expressed as % of 
viability after freeze-drying (relative viability).  
Determination of water content 
The water content of the freeze-dried powder, stored in the ready-to-use enteric-coated HPMC 
capsules was determined as described in III.4.2.2.2. 
Determination of hIL-10 production 
The hIL-10 production of the bacteria in the enteric-coated capsules after storage and after 
gastric fluid passage was determined using a sandwich ELISA as described in Chapter III.2. 
Determination of the glass transition temperature 
The Tg of the freeze-dried powder in the ready-to-use enteric-coated HPMC capsules after 
storage and passage through the gastric fluid was determined using the method described in 
Chapter III.2.  
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Determination of the amorphous properties 
The amorphous properties of the freeze-dried powder, stored for 9 months in the ready-to-use 
enteric-coated HPMC capsules at 8°C and –20°C were determined by X-ray diffractometry 
(diffractometer D5000 Cu Kα, Siemens, Germany) (Counting time 0.8 s, Step size 0.020 dg, 
Wave length 1.5406 Angstrom) 
Statistical analysis 
Viability values obtained in the stability test were evaluated with a two-way ANOVA, 
performed at a significance level of 0.05. The normality of the data was checked by means of 
a Kolmogorov-Smirnov test and the homogeneity of variances by means of the Levene test. A 
multi comparison among pairs of means was performed using a Scheffé test with p<0.05 as a 
significance level. All analyses were performed with SPSS 11.0 for Windows. 
III.4.3 RESULTS AND DISCUSSION 
III.4.3.1 Traditional coating method 
From literature it is known that in order to coat HPMC capsules, there is a need for prior 
sealing (Cole et al., 2002; Felton et al., 2002). In order to develop an alternative enteric-
coating method avoiding the need for prior sealing, the cause of poor enteric properties 
obtained by the traditional coating method had to be explored. According to Cole et al. 
(2002), the capsules have to be coated with at least 6 and 8 mg/cm2 Eudragit FS 30 D and 
Eudragit L30D-55, respectively to obtain enteric properties. In this study, 10 mg/cm2 
polymer was applied (based on theoretical calculation) to ensure enteric properties. From Fig. 
1a the absence of enteric-coating polymer on the critical area where the cap overlaps the body 
is clear.  
To prevent floating of the capsules, the conventional dissolution apparatus with the rotating 
baskets (USP apparatus 1) was used. However, due to its size, the coated capsule (size 00) 
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was fixed in the basket, and hence disintegration was hindered. Therefore, dissolution testing 
was performed using the reciprocating cylinder method (USP apparatus 3). This prevented 
floating of the capsules, without hampering disintegration. During the dissolution test, a 
rupture appeared at the critical overlap site of the body in 0.1N HCl after 1 h. Due to the 
absence of enteric-coating polymer at this site, the dissolution medium penetrated between 
body and cap and dissolved the HPMC. This led to the disintegration of the capsule (Fig. 1b) 
and 100% thymidine was released in HCl 0.1 N after 2 h. Fig. 1c clearly shows that there was 
no damage at the domed end of the enteric-coated capsule after dissolution testing in HCl 
0.1N for 1 h. This indicated that the coating process was performed efficiently, that good 
polymer/HPMC adhesion was obtained and that a sufficient amount of coating polymer was 
applied. These observations confirmed that the lack of enteric properties was due to leakage at 
the closure between body and cap. 
 
 
a                                              b                                         c 
Figure 1 HPMC capsule coated by the traditional coating method before dissolution (a) and after 1 h 
dissolution in HCl 0.1N at the critical area where cap overlaps the body (b) and at the domed end of 
the cap (c).  
III.4.3.2 Alternative coating method 
In an attempt to prevent disintegration of the enteric-coated HPMC capsules in HCl 0.1N 
without sealing them, bodies and caps were coated separately to ensure coverage of the entire 
surface with polymer, especially where the body and cap overlap. In accordance to the coating 
experiments performed by the traditional method, a theoretically estimated amount of 10 
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mg/cm2 of either Eudragit FS 30 D or L30D-55 was applied to the caps and bodies 00. Caps 
and bodies were coated in a separate process to avoid the caps to slide into the bodies during 
coating.  
The amount of caps or bodies in the apparatus during the coating process was chosen to 
obtain the same total outer HPMC surface as in the traditional coating process. So, the same 
coating parameters could be applied. During the process no problems of excessive spray 
drying or capsule sticking were encountered. The coated caps and bodies had a glossy and 
transparent appearance. No problems were experienced during filling of the coated bodies and 
subsequent closing with the coated caps. Coated caps slid easily over the coated bodies 
without damaging the coat (Fig. 2). No disintegration occurred in HCl 0.1N after 2 h 
dissolution. Moreover, capsules coated with Eudragit FS 30 D, as well as those coated with 
L30D-55 showed a negligible release in HCl 0.1N after 2 h (<1%) and thereby complied with 
the European Pharmacopoeia requirements for an enteric-coated formulation (release < 10% 
in HCl 0.1N for 2 h) (Fig. 3). However, the freeze-dried powder in the Eudragit L30D-55 
coated capsules which had a water content of 4.9 ± 0.3% before the dissolution test, collapsed 
completely after 2 h in HCl 0.1N. Moreover, it had a water content of 21.7 ± 1.6%, contrary 
to the powder in the Eudragit FS 30 D coated capsules which showed no collapse and a 
water content of 10.2 ± 0.7%. As it is known from Chapter III.2.3.2. that collapse of the 
stabilising glassy matrix by increased water content results in a loss of viability. The coating 
dispersion composition was modified by adding the lypophilic agent glyceryl mono-stearate 
(GMS), 8% (w/w), calculated on the polymer content and polysorbate 80 as wetting agent. 
GMS is often used in coating solutions as glidant, but is not necessary for coating of HPMC 
capsules (Cole et al., 2002). This resulted in a significant decrease in water content of 8.6% 
after 2 h HCl 0.1N (13.1 ± 2.6%). The powder showed no or limited collapse. In another 
attempt to decrease the water content, a thicker coat was applied to the caps and bodies. 
Huyghebaert et al., Eur. J. Pharm. Sci., 21 (2004) 617-623 
III.4 Production of ready-to-use enteric-coated HPMC capsules and incorporation of freeze-dried 
Lactococcus lactis Thy12 
108
However, problems were encountered during manual assembly as the coated caps did not 
longer fit on the coated bodies.  
A preliminary test showed that after storage for 1 week at 8°C in Alu sachets (20% RH), 
cracks appeared at both domed ends of caps and bodies of the Eudragit FS 30 D coated 
capsules, contrary to Eudragit L30D-55 coated capsules. Modification of the coating 
dispersion composition by increasing the plasticiser content from 5 (Cole et al., 2002) to 10% 
(w/w) (calculated of the polymer content) yielded good film integrity after 1 week storage at 
low temperature and low relative humidity.  
The coating thickness was measured by SEM. Bodies and caps coated with Eudragit FS 30 
D showed a coating thickness of 31.3 ± 3.4 µm and 29.5 ± 2.0 µm, respectively. The coating 
thickness on caps and bodies coated with Eudragit L30D-55 was 29.5 ± 5.3 µm and 28.5 ± 
3.0 µm, respectively. This indicated that a similar coating thickness on both the caps and the 
bodies was obtained. The values are in accordance with the coating thickness on pellets, 
enteric-coated with 15% (w/w) Eudragit FS 30 D and L30D-55, which was 25.7 ± 3.1 µm 
and 29.5 ± 2.0 µm, respectively (Chapter III.3). This indicated that the alternative coating 
method is a valuable tool for obtaining enteric-coated HPMC capsules. Moreover, from Fig. 
2, it is clear that the coating thickness at the open end (35.2 µm) (Fig. 2c), in the middle (33.2 
µm) (Fig. 2b) and at the domed end (35.7 µm) (Fig. 2a) of the coated cap was similar. The 
same results were obtained for the coated bodies. This proves that the coating method results 
in a homogeneous coating layer on the capsules. It is also clear that this method results in 
coating of the inner surface of the capsules. Fig. 2 shows that the inner coating thickness 
decreases along the cap length: from the open end (24 µm) (Fig. 2c), the middle (12 µm) (Fig. 
2b) to the domed end (5.3 µm) (Fig. 2a). From this, it was estimated that approximately 30% 
of the polymer was found on the inner surface. It can be concluded that the actual outer 
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coating level obtained with the alternative coating method, was approximately 7 mg/cm2, 
rather than the theoretically calculated 10 mg/cm2.  
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Figure 2 HPMC capsule coated by the alternative coating method before dissolution test with inserted 
SEM pictures of cross sections with outer and inner coating thickness at cap domed end (a), in the 
middle (b) and at the cap open end (c). 
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Figure 3 Thymidine released (mean ± S.D, n=3) in HCl 0.1N after 2 h from 3 batches (1(), 2(), 
3()) of capsules coated with 7 mg/cm2 Eudragit L30D-55 and Eudragit FS 30 D, 1 batch of 
capsules coated with Aqoat AS-HF and Sureteric. 
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Additional experiments were performed to evaluate whether the process performance was 
dependent on the polymer tested. Therefore, this method was evaluated using two other 
polymers applicable as an aqueous dispersion: Aqoat AS-HF and Sureteric. For both 
polymers, no data are available about the coating thickness on capsules required to ensure 
gastric integrity. Cole et al. (2002) used Eudragit L30D-55 and FS 30 D, only. For tablets, a 
weight increase of 8% and 10% is recommended for Aqoat and Sureteric, respectively. 
However, formulation dependency is mentioned. In accordance to the Eudragit polymers, 10 
mg/cm2 of each polymer was applied, based on theoretical calculation. During the process, no 
problems of capsule sticking were encountered. However, coating with Aqoat AS-HF 
resulted in excessive spray drying, even at high spray rates. Caps and bodies coated with 
Aqoat AS-HF as well as with Sureteric exhibited a white and dull appearance. During 
filling of the bodies, coated with both polymers and subsequent closing with the coated caps, 
no coating damage was observed. However, for both polymers, a remarkable resistance was 
experienced when closing the coated bodies with the coated caps, which could cause 
problems on an industrial scale. Fine-tuning of capsule filling and closing equipment to 
produce enteric-coated formulations on industrial scale will be necessary. The capsules coated 
with Aqoat AS-HF and Sureteric complied with the European Pharmacopoeia requirements 
for enteric-coated formulations. Capsules coated with Aqoat AS-HF showed a negligible 
release of 1.2% in HCl 0.1N after 2 h, while the release from capsules coated with Sureteric 
was higher (7.3%), but still below 10% (Fig. 3). These data indicated that the alternative 
coating method is applicable to the most commonly used enteric-coating polymers. However, 
from this study it was clear that the Eudragit-polymers resulted in superior enteric-coated 
capsules in terms of coating efficacy (spray drying), aesthetic and enteric properties and in 
ease of handling. These polymers were selected for the evaluation of the reproducibility of the 
method, the pH release profiles and the stability of the coated capsules. Further optimisation 
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of the composition of the Aqoat AS-HF and Sureteric coating dispersions could probably 
solve the problem of higher resistance while closing, but this was not the primary aim of this 
study. 
To evaluate the reproducibility, three batches were compared for enteric properties. For all 
batches, release of marker substance from the HPMC capsules coated with Eudragit L30D-
55 and FS 30 D was below 1% in HCl 0.1N after 2 h (Fig. 3), indicating the reproducibility of 
the method.  
The alternative coating method was also applied to caps and bodies 4. Using smaller caps and 
bodies did not lead to process inconveniences. Besides, after filling, the ready-to-use enteric-
coated HPMC capsules 4 had excellent enteric properties (release in HCl 0.1N HCl for 2 h 
below 1% (0.12 ± 0.01%)), proving that other capsule dimensions could be coated this way as 
well.  
Previous studies revealed that complete release of thymidine from pellets coated with 
Eudragit L30D-55 and FS 30 D occurred within 40 min after the gastric stage (HCl 0.1N 
after 2 h) at pH 6.5 and 40 min at pH 7.4, respectively (Chapter III.3). Therefore, the release 
from the capsules coated by the alternative coating method was investigated at pH values 
around the critical pH of dissolution of the coating polymers, after a simulated gastric stage 
(HCl 0.1N for 2 h) (Fig. 4a and b). From capsules coated with Eudragit L30D-55, no release 
was seen at pH 5.5 for 4 h after the simulated gastric stage. At pH 6.0, a lag-time of 20 min 
was observed before release started and 80% was released after 60 min (T80). At pH 6.5, 
release started immediately after the simulated gastric stage without lag-time and T80 was 35 
min. This is in accordance to the release from the Eudragit L30D-55 coated pellets. Capsules 
coated with Eudragit L30D-55 complied with the specifications of the European 
Pharmacopoeia for gastro-resistant capsules (disintegration within 60 min at pH 6.8). For 
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capsules coated with Eudragit FS 30 D, these specifications are not applicable as the 
polymer does not dissolve at pH 6.8, but only from pH 7.2 (Chapter III.3). From capsules 
coated with Eudragit FS 30 D, no release was seen at pH 7.0. At pH 7.2 and 7.4 a lag-time of 
60 and 40 min, and a T80 of 100 and 60 min was observed after the simulated gastric stage 
(HCl 0.1N for 2 h), respectively. The lag-time values were in accordance with the release data 
obtained by Cole et al. (2002) from capsules coated with 6 mg/cm2 Eudragit FS 30 D at pH 
7.4 (36 min). During dissolution test, after dissolution of the coat, a gelly membrane 
surrounding the drug content was visually observed. This can be explained by the fact that 
next to HPMC, the capsules consist of a gelling agent (gellan gum) and KCl as a gelling 
promoter, both necessary for the production of the HPMC capsules. However, the buffer 
solutions used in this study contain potassium ions, inducing the formation of gelly membrane 
and hence suppressing capsule disintegration. Most probably, this does not lead to delay of in 
vivo release as the membranes are very friable and will be destroyed by the in vivo mechanical 
forces. Human studies on cephalexin (Ogura et al., 1998) and ibuprofen (Cole et al., 2004) 
absorption rates from HPMC and gelatin capsules showed no significant differences in AUC, 
Cmax and tmax. Although, Cole et al. (2004) showed a slower in vivo disintegration time of 
uncoated HPMC capsules (0.69 ± 0.29 h contrary to 0.24 ± 0.14 h for gelatin capsules). This 
can be attributed to the acid conditions of the fasted stomach, hindering the HPMC capsule 
disintegration since its dissolution is pH dependent, contrary to gelatin capsules. However, for 
enteric-coated HPMC capsules this factor can be excluded as they will only disintegrate in the 
small intestine. So the delayed in vivo disintegration in the stomach reported by Cole et al. 
(2004) can be disregarded. The fact that in our study, no lag-time is seen from the Eudragit 
L30D-55 coated capsules at pH 6.5 (Fig. 4.a) could be explained by the almost three times 
lower sodium ion concentration present in this dissolution medium (0.014M), contrary to the 
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medium of pH 7.4 (0.039M). This ion also suppresses the capsule disintegration, although to a 
lesser extent than potassium ions.   
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Figure 4 Release (mean ± S.D., n=3) of thymidine from capsules coated with 7 mg/cm2 Eudragit 
L30D-55 (a) and Eudragit FS 30 D (b) using the alternative coating method in HCl 0.1N after 2 h and 
subsequently 4 h in buffer solution with pH 5.5 (●), 6.0 (■), 6.5 (▲) (Eudragit L30D-55 (a)) and 7.0 
(●), 7.2 (■), 7.4 (▲) (Eudragit FS 30 D (b)).  
Next, it was evaluated if the enteric properties and the release from the capsules coated by the 
alternative coating method were affected by storage. Therefore, the coated caps and bodies 
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were stored prior to filling and after filling. Table 2 shows the release of thymidine from 
Eudragit L30D-55 and FS 30 D coated capsules stored for 12 months prior to filling and 
after filling. It can be concluded that for both polymers the enteric properties were maintained 
after 12 months storage at all conditions for the capsules stored prior to filling as well as for 
those filled prior to storage. The release was below 1% in HCl 0.1N after 2 h with both 
polymers at all storage conditions. T80 and the lag-time did not change in time, except for 
filled capsules coated with Eudragit FS 30 D stored in Alu-sachets at all temperatures (25, 8 
and –20°C), for which T80 increased with 20, 15 and 70 min, respectively. For filled capsules 
coated with Eudragit L30D-55 stored in Alu-sachets at –20°C, T80 and the lag-time 
increased with 40 and 35 min, respectively.  
Table 2 Release of thymidine (mean ± S.D., n=2) from capsules coated with Eudragit L30D-55 and 
FS 30 D immediately after preparation and after storage for 12 months.    
  Release in 0.1N 
HCl after 2 h (%)
Lag-time 
(min) 
 T80  (min) 
 
Eudragit FS 30 D       
 Immediately after coating  0.66 ± 0.07  40 ± 01  60 ± 01 
 Stored for 12 months      
    Prior to filling (25°C/20% RH)  0.31 ± 0.07 40 ± 01  60 ± 01 
    After filling (Alu sachets 25°C/20% RH)  0.36 ± 0.07 40 ± 01  80 ± 141   
    After filling (Alu sachets 8°C/20% RH)  0.93 ± 0.27 40 ± 01  75 ± 211 
    After filling (Alu sachets -20°C/20% RH)  0.12 ± 0.03 100 ± 01  130 ± 141 
Eudragit L30D-55      
 Immediately after coating  0.52 ± 0.06 /  35 ± 02 
 Stored for 12 months      
    Prior to filling (25°C/60% RH)  0.42 ± 0.07 /  20 ± 02 
    After filling (25°C/60% RH)   0.97 ± 0.05 /  30 ± 02 
    After filling (Alu sachets 25°C/20% RH)  0.98 ± 0.21 /  30 ± 02 
    After filling (Alu sachets 8°C/20% RH)  0.93 ± 0.27 /  30 ± 02 
    After filling (Alu sachets -20°C/20% RH)  0.16 ± 0.01 35 ± 72  70 ± 142 
1: at pH 7.4, 2: at pH 6.5 
Huyghebaert et al., Eur. J. Pharm. Sci., 21 (2004) 617-623 
III.4 Production of ready-to-use enteric-coated HPMC capsules and incorporation of freeze-dried 
Lactococcus lactis Thy12 
115
As the most remarkable increase in the lag-time is observed at –20°C and 20% RH for both 
polymers, it could be concluded that the release rate decrease could be attributed to a low 
temperature and/or low relative humidity effect. No literature is available on the influence of 
low storage temperature on release rate. However, the data obtained in this study should be 
interpreted with care i.e. a dissolution test does not mimic in vivo mechanical forces and so in 
vivo release tests have to reveal if this change in lag-time and T80 is of any significance.  
III.4.3.3 Viability of L. lactis Thy12 in ready-to-use enteric-coated capsules  
Besides the protection against the detrimental gastric fluid and bile salts, the enteric-coating 
should allow targeting of L. lactis Thy12 to the human ileal mucosae for treatment of Crohn’s 
disease. L. lactis Thy12 is genetically modified for in situ hIL-10 production, a down-
regulator of the inflammatory cascade. From previous experiments, in which all commercial 
available polymers were evaluated for their ileum targeting properties, it could be concluded 
that none of the polymers or mixtures of polymers are suitable for specific targeting to the 
ileal mucosae (Chapter III.3). A possible solution for this problem could be the administration 
of a combination of doses, namely one dose coated with Eudragit L30D-55 and another 
coated with Eudragit FS 30 D. This explains why in the next section, the viability of L. lactis 
Thy12 after storage and gastric fluid passage was determined in capsules coated with both 
Eudragit L30D-55 and Eudragit FS 30 D. 
III.4.3.3.1 Viability and hIL-10 production of L. lactis Thy12 after storage for 12 months at 8 
and –20°C 
Fig. 5 shows the viability of freeze-dried L. lactis Thy12 in capsules coated with Eudragit 
L30D-55 as a function of time and storage temperature. L. lactis Thy12 in capsules coated 
with Eudragit FS 30 D showed a comparable viability profile. Two main storage factors 
were evaluated, storage time and temperature. They both had a significant influence on 
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viability as a function of storage (Table 3). A logarithmic trend in the viability in function of 
time was observed at both temperatures. Viability showed a parallel plot at both temperatures, 
but was higher at –20°C. From 9 months storage, the viability showed no further significant 
decrease. It can be concluded that after storage for 1 year at 8 and –20°C, respectively 6 and 
44% of the initial L. lactis Thy12 count remained viable or about 3.7 x 109 and 2.1 x 1010 
cfu/capsule, respectively.   
0
20
40
60
80
100
120
0 3 6 9 12
Storage time (months)
R
el
at
iv
e 
vi
ab
ili
ty
 (%
) 
 
Figure 5 Relative viability of freeze-dried L. lactis Thy12, filled in ready-to-use enteric-coated HPMC 
capsules (Eudragit L30D-55), packed in Alu-sachets (sealed at 20% RH) and stored for 12 months at 
8 (▲) and –20°C (). 
Table 3 Long-term stability (12 months) of freeze-dried L. lactis Thy12, filled in ready-to-use enteric-
coated HPMC capsules (Eudragit L30D-55), packed in Alu-sachets (sealed at 20% RH). Data are 
presented as relative viability (%) in function of storage time and temperature.   
Relative viability (%) of L. lactis Thy12 stored at different temperatures 
 8°C      n -20°C         n Main Time* n 
1 month 57.4 ± 3.8 3 100.3 ± 1.5 2 74.5 ± 23.7 a 5 
3 months 46.7 ± 0.3 3 77.2 ± 0.5 3 60.4 ± 18.4 b 6 
6 months 24.6 ± 0.3 3 63.7 ± 2.1 3 44.1 ± 21.4 c 6 
9 months 10.4 ± 0.6 3 42.1 ± 3.6 3 26.3 ± 17.5 d 6 
12 months 6.1 ± 0.6 3 44.3 ± 1.9 3 25.2 ± 21.0 d 6 
Main Temperature** 28.4 ± 20.3 a 15 63.0 ± 21.1 b 14 45.1 ± 26.9  29 
a,b,c,d: Groups with the same superscript are not significantly different from each other  (p>0.05) (two-
way ANOVA, post hoc Scheffé), *: global effect of time, irrespective of atmosphere, **: global effect 
of atmosphere, irrespective of time  
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The water content of the powder in the capsules did not significantly change during the 
storage time and, no significant difference in water content was seen between the two storage 
temperatures e.g. for capsules coated with Eudragit FS 30 D: 5.3 ± 0.2% at 8°C and 5.1 ± 
0.0% at –20°C. The Tg of the powder in the Eudragit coated capsules after 1 year storage at 
8°C was 47.7 ± 1.0 °C. Taking into account the Tg – 50°C rule, zero mobility can be expected 
below –2.3°C (T0) (Yu, 2001). This can explain why the viability decreased during storage at 
8°C. However during storage at –20°C, where the storage temperature is far below T0, 
viability also decreased. This might be explained by the strong crystallisation tendency of the 
lactose, present in skim milk matrix as crystallisation of the freeze-dried matrix leads to loss 
of the stabilising power (Franks, 1999). However, X-ray diffraction patterns showed that the 
freeze-dried skim milk matrix remained amorphous for at least 9 months at 8 and –20°C (Fig. 
6). This diffractogram is in clear contrast with this of crystalline skim milk and pure 
crystalline lactose (Fig. 6a). Deleterious metabolic and/or enzymatic reactions which progress 
even at low storage temperatures and water content are probably the cause of the decrease in 
viability (Souzu, 1992). Storage at –20°C assured a better shelf life.  
Figure 6 Diffractogram of freeze-dried skim milk, stored in coated HPMC capsules for 9 months at 8 
and –20°C. Figure 6a Diffractogram of crystalline lactose (a2) and crystalline skim milk (a1).  
a 
a2
a1
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As L. lactis Thy12 was genetically modified for the production of hIL-10, it was extremely 
important to evaluate whether this capacity was maintained during production, passage 
through gastric fluid and storage. In literature, no data are available on the influence of 
processing on recombinant properties. In this study it has been shown that the hIL-10 
producing capacity was maintained after 1 year at both storage temperatures.  
III.4.3.3.2 Viability and hIL-10 production after passage through gastric fluid  
Although the release of marker substance from the enteric-coated capsules was below 1%, 
even after storage for 1 year at 8 and –20°C (Chapter III.4.3.2, Table 2), the viability of L. 
lactis Thy12 decreased significantly in the enteric-coated capsules after subjecting them to 
HCl 0.1N for 2 h. Fig. 7 shows the fraction of L. lactis Thy12 which had maintained viable 
after 2 h HCl 0.1N. No trend is seen in function of time, indicating the maintenance of the 
coating performance during storage. After 2 h in HCl 0.1N, 36.5 ± 8.6% (mean of all the 
values at different time points) L. lactis Thy12 in Eudragit FS 30 D coated capsules 
remained viable. The increased water content of the powder (10.2 ± 0.7%) could explain this 
loss of viability. The viability decreased even more when incorporated in Eudragit L30D-55 
coated capsules (26.9 ± 6.4% remained viable in 0.1N HCl after 2 h) (mean of all the values at 
different time points). This is also in agreement with the higher water content of the powder 
(13.1 ± 2.6%). The powder appeared slightly collapsed, in contrast to the powder in the 
Eudragit FS 30 D coated capsules. This can be supported by the Tg values: -10.1 ± 6.5 and 
11.3 ± 2.2°C after 2 h HCl 0.1N in Eudragit L30D-55 and Eudragit FS 30 D coated 
capsules, respectively. Although viability decreased, the formulation provides some 
protection for L. lactis Thy12 against the detrimental acidic conditions in the stomach as it is 
known that no protection would lead to an extremely poor survival.  
The hIL-10 production capacity was maintained after passage through the gastric fluid stage.  
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Figure 7 Relative viability after 2 h in HCl 0.1N of freeze-dried L. lactis Thy12, filled in ready-to-use 
enteric-coated HPMC capsules (Eudragit L30D-55 () and Eudragit FS 30 D (▲)), packed in Alu-
sachets (sealed at 20% RH) and stored for 1 year at –20°C.  
III.4.3.3.3 In vitro disintegration behaviour of the Eudragit L30D-55 en FS 30 D coated 
HPMC capsules   
The Eudragit L30D-55 en FS 30 D coated capsules have been subjected to the dynamic, 
multi-compartmental in vitro system, simulating the human stomach and small intestine 
(TIM-1) of TNO Pharma (Zeist, the Netherlands) (Fig. 8). The model consists of a number of 
linked glass units with flexible walls inside and is computer-controlled. The intestinal content 
is mixed and moved by peristaltic movements, achieved by pumping water of 37°C around 
the flexible walls. During passage through the gastrointestinal tract, parameters such as 
temperature, pH, gastric and intestinal mixing, peristaltic movements and gastrointestinal 
secretion are continuously monitored and controlled. Several studies have demonstrated the 
predictive value of this model in relation to oral drug delivery systems. 
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Figure 8 Schematic diagram TIM-1: A. Gastric compartment; B. Pyloric sphincter; C. Duodenal 
compartment; D. Peristaltic valve; E. Jejunal compartment; F. Peristaltic valve; G. Ileal compartment; 
H. Ileo-caecal valve; I. pH electrodes; J. Gastric secretion bottles with acid and enzymes; K. Duodenal 
secretion bottles with bile, pancreatin, bicarbonate; L. Secretion of bicarbonate to control the intestinal 
pH; M. Pre-filter system. N. Hollow fibre semi-permeable membrane system; O. Water absorption 
system; P. Closed dialysing system.  
One capsule was mixed with artificial saliva and water, and was introduced into the gastric 
compartment (1 h residence time, pH raised to 4.5-5.0 after the intake of a glass of water, 
decreasing to 1.7 in 30 min). In the duodenal compartment the gastric content is neutralised to 
pH 6.5 ± 0.2, and bile and pancreatin were secreted (1 h residence time). The content of the 
duodenum was delivered into the jejunal compartment (pH 6.8, 1 h residence time) and after 
that into the ileal compartment (pH 7.2, 1 h residence time). The Eudragit L30D-55 coated 
capsules showed no disintegration in the stomach. The capsules passed the duodenum 
compartment intact. The disintegration started immediately in the jejunal compartment (50% 
of the capsule content had disappeared at 90 min after the stomach compartment). The 
capsules showed complete disintegration at 2.9 h after intake (1.9 h after the stomach 
compartment) (n=4).  
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Eudragit FS 30 D capsules passed the stomach and small intestine compartment intact. It 
was observed that the coated capsules became swollen and sticky, and that the pink colour of 
the capsule content (carmin red was included as marker) became more intense, indicating the 
increased permeability towards the distal region. In this model, the ileum pH was 7.2. From 
Chapter III.3 (Table 4) it is shown that the ileum pH ranges from 6.8-8.1. This in vitro study 
confirmed the conclusions of Chapter III.3 i.e. L. lactis Thy12 from the Eudragit FS 30 D 
coated capsule will not be released in the ileum in some of the treated patients. However, in 
these patients, L. lactis Thy12 from the Eudragit L30D-55 coated capsule will be delivered 
in the ileum.  
III.4.3.3.4 Preclinical study in patients suffering from Crohn’s disease   
This formulation i.e. freeze-dried L. lactis Thy12 incorporated in HPMC capsules coated with 
Eudragit L30D-55 and Eudragit FS 30 D has been used in a preclinical study in which hIL-
10 producing L. lactis has been administered to 10 patients suffering from Crohn’s disease 
(Academic Medical Centre of Amsterdam). The results of this study have shown that this new 
therapy is safe, that the biological containment strategy was effective and suggested a clinical 
effectiveness of L. lactis Thy12. 
III.4.4 CONCLUSIONS  
From all these experiments it is clear that our proposed alternative coating method provides a 
simple way to obtain enteric-coated HPMC capsules. This approach results in ready-to-use 
capsules that can be applied to obtain enteric-coated capsules of labile products or new drug 
entities without requiring coating experience or equipment. An important application of these 
ready-to-use enteric-coated capsules in pharmaceutical industry could be the preparation of 
enteric-coated formulations of heat and moisture sensitive materials such as biomaterials 
(peptides, proteins, etc.) for which all handling at elevated temperatures and at high relative 
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humidity must be limited. Also in food industry, this technology could provide a valuable 
tool, e.g. to coat probiotics. From this study, this new concept has been successfully used for 
the development of a pharmaceutical formulation of recombinant L. lactis Thy12. This 
formulation protects L. lactis Thy12 against the detrimental acidic conditions of the stomach 
and after storage for 1 year at -20°C, the enteric properties, an acceptable viability level and 
hIL-10 producing capacity were maintained.     
The ready-to-use enteric-coated capsules are also an efficient tool for R&D departments, 
where some new chemical entities present a challenge in testing for efficacy due to instability 
in gastric fluids or because of irritation of the gastrointestinal tract. The limited amount of 
new chemical entities excludes the development of a coated pellet or tablet formulation. Since 
the coating process of capsules is independent of the capsule content, contrary to pellets and 
tablets, the capsule coating method can be easily applied. 
Besides, the ready-to-use enteric-coated capsules can be used in retail or hospital pharmacy 
where enteric coating of capsules offers for many pharmacists a problem due to lack of 
appropriate equipment and training. In retail or hospital pharmacy the most common method 
used to coat capsules is the dipping method. This procedure is not only time-consuming, but 
often a lot of practical problems are encountered during the dipping procedure that could lead 
to an inhomogeneous coat and doubtful enteric properties.  
ACKNOWLEDGEMENTS 
This work was supported by the Research Fund of the Ghent University. We are grateful to 
Capsugel (Bornem, Belgium) for supplying the HPMC capsules, C.N. Schmidt (Amsterdam, 
the Netherlands) and Röhm (Darmstadt, Germany) for supplying the Eudragit coating 
polymers, Shin-Etsu Chemical Co. (Tokyo, Japan) for supplying the Aqoat AS-HF coating 
polymers and Colorcon (Kent, UK) for supplying the Sureteric coating polymers. 
Appreciation is also expressed to Prof. Dr. Simoens (Veterinary School, Ghent University) for 
Huyghebaert et al., Eur. J. Pharm. Sci., 21 (2004) 617-623 
III.4 Production of ready-to-use enteric-coated HPMC capsules and incorporation of freeze-dried 
Lactococcus lactis Thy12 
123
the use of the scanning electron microscope and to Mr. Bart De Pauw for his technical 
assistance. Besides, we want to acknowledge Inge Bruggeman and Elena Yancheva for their 
technical assistance and Dr. Sci. Els Adriaens for her critical review on the statistical analysis 
of the data. Finally, we want to thank Dr. Marleen Nuenen of TNP Pharma for the 
performance of the in vitro disintegration test in TIM-1.  
REFERENCES 
Cole, E., Scott, R., Connor, A., Wilding, I., Petereit, H., Schminke, C., Beckert, T., Cadé, D., 
2002. Enteric-coated HPMC capsules designed to achieve intestinal targeting. Int. J. Pharm. 
231, 83-95. 
 
Cole, E., Scott, R., Cade, D., Connor, A., Wilding, I., 2004. In vitro and in vivo 
pharmacoscintigraphic evaluation of ibuprofen hypromellose and gelatin capsules. Parm. Res. 
21 (5), 793-798. 
 
Cunningham, C., and Fegely, K., 2001. One-step aqueous enteric-coating systems: scale-up 
evaluation. Pharm. Technol. Eur. 13(10), 48-54. 
 
Felton, L.A., Wiley, C.J., Friar, A.L., 2002. Enteric-coating of gelatin and cellulosic capsules 
using an aqueous-based acrylic polymer. AAPSPharmSci, 4(4), T3320.  
 
Franks, F., 1999. Thermomechanical properties of amorphous saccharides: their role in 
enhancing pharmaceutical product stability, Biotechnol. Genet. Eng. 16, 281-292. 
 
Murthy, K.S., Enders, N.A., Mahjour, M., Fawzi, M.B., 1986. A comparative evaluation of 
aqueous enteric polymers in capsule coating. Pharm. Technol. 10, 36-46.  
 
Ogura, T., Furuya, Y., Matsuura, S., 1998. HPMC capsules: an alternative to gelatin. Pharm. 
Technol. Eur. 10, 32-42.  
 
Scott, R., and Cole, E., 2001. Enteric and colonic delivery using HPMC capsules. US Patent 
9, 836, 627.  
 
Huyghebaert et al., Eur. J. Pharm. Sci., 21 (2004) 617-623 
III.4 Production of ready-to-use enteric-coated HPMC capsules and incorporation of freeze-dried 
Lactococcus lactis Thy12 
124
Souzu, H., 1992. Freeze-drying of microorganisms. In: Encyclopedia of microbiology. 
Lederberg, J. (Ed.), San Diego, pp 231-243.  
 
Steidler, L., Neirynck, S., Huyghebaert, N., Snoeck, V., Vermeire, A., Goddeeris, B., Cox, E., 
Remon, J.P. Remaut, E., 2003. Biological containment of genetically modified Lactococcus 
lactis for intestinal delivery of human interleukin-10. Nature Biotechnology 21, 785-789. 
 
Thoma, K., and Bechtold, K., 1992. Enteric-coated hard gelatin capsules. Capsugel Technical 
Bulletin. 
 
Wheatley, T., and Steuernagel, C., 1997. Latex Emulsions for controlled drug delivery. In: 
Aqueous polymeric coatings for Pharmaceutical Dosage Forms. McGinithy, J.W. (Ed.), New 
York, pp. 1-54.   
 
Yu, L., 2001. Amorphous pharmaceutical solids: preparation, characterisation and 
stabilisation. Adv. Drug. Del. Rev. 48, 27-42. 
 
Huyghebaert et al., Eur. J. Pharm. Biopharm., in press. 
III.5 Development of a multi-particulate, enteric-coated formulation of viable, recombinant L. 
lactis for ileal mucosal delivery of interleukin-10  
125
III.5 DEVELOPMENT OF A MULTI-PARTICULATE, ENTERIC-COATED FORMULATION OF 
VIABLE, RECOMBINANT L. LACTIS FOR ILEAL MUCOSAL DELIVERY OF INTERLEUKIN-10 
III.5.1 INTRODUCTION 
In Chapter III.4 an enteric-coated formulation of L. lactis Thy12 has been developed.  
 Although this formulation is enteric-coated in order to protect L. lactis from the gastric 
fluid that negatively influences its viability (Klijn et al., 1995), passage through the gastric 
fluid stage (HCl 0.1N for 2h) results in loss of viability, depending on the coating polymer 
used. 
 Thereby, this formulation has large dimensions (capsule 00) and is hard to swallow in 
case of large dose administration.  
 Moreover, the interleukin producing L. lactis (pIL-2 and pIL-6) also have a veterinary 
application as mentioned in Chapter I i.e. the stimulation of mucosal immunity in order to 
enhance the efficacy of oral vaccination of piglets against Enterotoxigenic Escherichia 
coli (ETEC) infections, the major cause of economic loss in piglets farming. For easy 
administration to the piglets, the formulation should be mixable with the creep feed. 
In this Chapter, it was the objective to develop a multi-particulate formulation (~1 mm) as this 
offers the following advantages: 
 fast gastric emptying and hence decreased residence time in the presence of the 
detrimental gastric fluids (Krämer and Blume, 1994) 
 ease of swallowing in case of large dose administration 
 ease of administration to piglets as it can be mixed with their creep feed. 
In this Chapter, two main sections can be distinguished  
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- EVALUATION OF COMPACTION, EXTRUSION/SPHERONISATION AND LAYERING FOR THE 
PREPARATION OF AN ORAL, MULTI-PARTICULATE FORMULATION OF VIABLE, HIL-10 PRODUCING 
LACTOCOCCUS LACTIS 
In this section, it was the objective to select a suitable production technique in order to obtain 
a multi-particulate formulation of viable and hIL-10 producing L. lactis for oral 
administration. Moreover, as the formulation has to be enteric-coated, a regular shape of the 
formulation is required. In this study, three formulation techniques were compared. First, 
freeze-dried L. lactis was compacted in order to obtain mini-tablets. Next, liquid L. lactis 
culture was used as granulation fluid for the production of pellets by extrusion/spheronisation. 
Finally, liquid L. lactis culture was layered on inert pellets as an alternative technique for the 
production of pellets. A stability screening was performed after 1 week to make a first 
selection of a suitable production technique. Moreover, the hIL-10 producing capacity was 
evaluated after the production. 
- DEVELOPMENT OF A LAYERED, ENTERIC-COATED MULTI-PARTICULATE FORMULATION OF 
VIABLE, HIL-10 PRODUCING LACTOCOCCUS LACTIS  
Based on the data obtained in the previous part, it was concluded that layering is a promising 
technique for the production of a multi-particulate formulation of viable and hIL-10 
producing L. lactis Thy12. In this section, it was the aim to modify the layering matrix in 
order to increase viability after layering and storage. Next, the layering process time was 
increased in order to determine the influence on layer consistence and viability. Finally, it was 
determined if the dosage form could be effectively coated and if the functionality of the coat 
was maintained after storage at low temperature and low relative humidity. Viability of L. 
lactis Thy12 was determined after coating, after dissolution testing in acid conditions and 
after storage.  
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III.5.2 EVALUATION OF COMPACTION, EXTRUSION/SPHERONISATION AND LAYERING FOR 
THE PREPARATION OF AN ORAL, MULTI-PARTICULATE FORMULATION OF VIABLE, 
HIL-10 PRODUCING LACTOCOCCUS LACTIS 
III.5.2.1 Materials and methods 
III.5.2.1.1 Strains used in this study 
Lactococcus lactis subsp. cremoris MG1363 (Gasson, 1986) and L. lactis Thy 12 (human IL-
10 producing L. lactis MG1363) (Steidler et al., 2003)  
III.5.2.1.2 Preparation of the cell suspensions 
The first experiments were carried out with the non-bioengineered L. lactis subsp. cremoris 
MG1363. For the production of mini-tablets and pellets by extrusion/spheronisation, L. lactis 
culture was prepared by inoculating a stock suspension (stored at –20°C in glycerol/GM17 
(50/50)) 1/1000 in 10% (w/v) skim milk (Difco, Becton Dickinson, Maryland, USA), 
supplemented with 0.5% glucose as a C-source and 0.5% casein hydrolysate (Casiton®, Difco, 
Becton Dickinson) as a N-source. The culture was grown for 16 h at 30°C to obtain a 
saturated culture, which had a viable count of 2 to 3.109 cfu/ml. To prevent further activity or 
growth, the culture was kept on ice until use and in between all handling.  
For the production of pellets by layering, L. lactis Thy12 was inoculated in 10% skim milk 
supplemented with 0.5% glucose, 0.5% Casiton® (Difco, Becton Dickinson) and 50 µg/ml 
thymidine (GCT-milk) (109 cfu/ml) or in M17 supplemented with 0.5% glucose and 50 µg/ml 
thymidine (GM17T) and prepared as cited above. The bacteria grown in GM17T were 
collected by centrifugation at 3000g for 10 min at 4°C. The cell pellet was resuspended in 
skim milk at 1010 cfu/ml (10 times concentrated). 
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III.5.2.1.3 Production of a multi-particulate formulation 
Fig. 1 shows a schematic overview of the processing steps in order to obtain the three 
different multi-particulate formulations.  
L. lactis MG1363 
(2 to 3.109 cfu/ml skim milk) 
           ↓                         ↓ 
L. lactis Thy12 
*109 cfu/ml skim milk 
*1010 cfu/ml skim milk 
↓ Freeze-drying 
↓ 
Grinding of the 
freeze-dried 
powder 
 
↓ 
Compaction 
 
⇓ 
Mini-tablets 
 
↓ 
Granulation with 
Avicel CL 611, 
Explotab 
and L-HPC LH 21 
↓ 
Extrusion-Spheronisation 
↓      ↓ 
Fluid bed drying     Freeze drying 
⇓     ⇓ 
 
Pellets 
 
↓ 
Layering on MCC pellets  
(700-1250 µm),     
30 min,   
30 or 45°C,   
fluid bed (bottom spray,  
Wurster set-up) 
 
⇓ 
 
Pellets 
 
↓ 
 
Storage: 1 week RT, 10 and 60% RH 
Storage:  
1 week RT, 10 % RH 
1 week 8°C, 10% RH 
Figure 1 Schematic overview of the processing steps to obtain the three different multi-particulate 
formulations. 
Production of mini-tablets (n=5) 
Approximately 2 g L. lactis MG1363 culture was filled in vials (glass type 1, Gaash 
Packaging, Mollem, Belgium). The vials were covered with a freeze-drying stopper (V9032 
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FM 257/2 SAF1, bromobutyl with magnesium silicate as filler, kindly donated by Helvoet 
Pharma, Alken, Belgium). Prior to freeze-drying, the vials were kept on ice.  
The vials were loaded on the precooled shelves (- 25°C) of the freeze-dryer (Leybold GT4, 
Finn-aqua, Sohlberg, Germany). The samples were frozen to - 45°C over 105 min at 
1000 mbar. The primary drying (12 h) was performed at - 15°C and 0.8 to 1 mbar and the 
secondary drying (9 h) at 10°C and 0.1 to 0.2 mbar. After freeze-drying, the vials were closed 
under vacuum. Samples were immediately removed from the freeze-drier at the end of the 
cycle and stored on ice until analysis. The freeze-dried cake, containing L. lactis in skim milk 
matrix, was ground to powder by means of pestle and mortar, manually filled in the die and 
subsequently compacted using an eccentric tabletting machine (Korsch EK 0, Frankfurt, 
Germany) equipped with 2 mm flat punches at a compaction pressure of 52 ± 2 MPa, yielding 
1.7 mg mini-tablets. All handling was performed at 20% RH to prevent sticking of the 
hygroscopic powder. Samples were taken immediately after production of the mini-tablets 
and kept on ice until analysis. 
Production of pellets by extrusion/spheronisation (n=5) 
Microcrystalline cellulose containing 11.3 to 18.8 % (w/w) sodium carboxymethyl cellulose 
(Avicel CL611®, FMC Europe, Brussels, Belgium) and low substituted hydroxypropyl 
cellulose (L-HPC LH 21®, kindly donated by ShinEtsu, Tokyo, Japan) were used as 
excipients for the production of pellets. Sodium carboxymethyl starch (Explotab®, kindly 
donated by Penwest Pharmaceuticals, NY, US) was used as a disintegrant.  
L. lactis MG1363 culture was used as the granulation fluid. Avicel CL 611® (60 g), Explotab® 
(20 g) and L-HPC LH 21® (120 g) were pre-blended for 10 min at 60 rpm using a planetary 
mixer with a K-shaped mixing arm (Kenwood Major Classic, Hampshire, UK), subsequently 
wetted by gradual addition of 375 g L. lactis culture and granulated for 15 min. Next the wet 
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mass was extruded in a dome extruder (Type D6-L1, Fuji Paudal Co., Tokyo, Japan) equipped 
with a 1-mm perforated screen and operating at 45 rpm. The extrudates were spheronized for 
3 min on a spheronizer (Caleva model 15, Sturminster Newton, UK) equipped with a cross-
hatched friction plate, operating at 1000 rpm. The pellets were dried either by fluid-bed or by 
freeze-drying. For fluid-bed drying, 160 g wet pellets were dried for 30 min in a fluid-bed 
dryer (Uniglatt D 7852, Glatt, Binzen, Germany) set at 25°C inlet air temperature. For freeze-
drying, 1 g wet pellets were transferred into glass vials and freeze-dried as described above. 
Samples were taken at different stages of the production process (granules, extrudates, wet 
pellets and dried pellets). To avoid any activity of the bacteria, the samples were kept on ice 
until analysis. 
Production of pellets by layering (n=3) 
Microcrystalline cellulose spheres were used as inert carriers. Equal amounts of Cellets® 700 
(700-1000 µm) and Cellets® 1000 (1000-1250 µm), both kindly donated by Pharmatrans 
(Basel, Switzerland) were mixed, to obtain 300g of pellets with an average sphere diameter of 
1000 µm as standard for pellets. The L. lactis Thy12 culture was layered in a fluid-bed 
apparatus (GPCG 1, Glatt, Binzen, Germany) used in the bottom spray mode with the Wurster 
setup (nozzle diameter 0.8 mm; spray rate of 3 g/min for 30 min; atomising pressure 1.5 bar; 
product temperature 30°C or 45°C). The pellets were preheated for 5 min at an inlet air 
temperature of 30°C or 45°C before layering. Throughout the layering process L. lactis Thy12 
culture was stirred using a magnetic stirrer. The experiments were performed in a room with 
low relative humidity (20% RH).  
III.5.2.1.4 Storage  
The pellets made by extrusion/spheronisation and the mini-tablets were stored for 1 week at 
room temperature (RT) (23 ± 2°C) and 10% RH (above silicagel for desiccation (Sigma, 
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Bornem, Belgium)) and at 60% RH (above a saturated sodium bromide solution). The pellets 
produced by layering were stored for 1 week at RT/10% RH and 8°C/10% RH.  
III.5.2.1.5 Evaluation of the multi-particulate formulation 
Determination of viability of L. lactis  
Viability of the bacteria in the mini-tablets and the pellets prepared by 
extrusion/spheronisation was determined using a turbidimetric method as described in 
Chapter III.2. 
For determining the viability of the freeze-dried cake or the mini-tablets, 0.1 g was dissolved 
in 1 ml sterile water. Three dilutions of each sample were loaded in duplicate on a plate for 
analysis in the Bioscreen C (Oy Growth Curves AB Ltd, Helsinki, Finland). For determining 
viability in the pellets prepared by extrusion/spheronisation, 0.1 g was dissolved in 1 ml M17 
and shaked at 1400 rpm for 10 min at 12°C in a Thermomixer comfort (Eppendorf, Hamburg, 
Germany). Three dilutions of each sample were loaded in duplicate onto micro-titer plates for 
analysis in the Bioscreen.  
Viability of the bacteria in the pellets prepared by layering was determined using the standard 
plate count method as the turbidimetric method was not yet optimised for analysing these 
samples. 0.1g of pellets was manually shaken in 1 ml sterile water. Three dilutions of each 
sample were plated in duplicate on agar (1.2%) mixed with M17, supplemented with 0.5% 
glucose and thymidine (50µg/ml). Only the plates with a sufficient and reliable number of 
bacteria were counted to calculate the viability. 
The viability values obtained after layering and after storage were statistically evaluated with 
a one-way ANOVA at a significance level of 0.05. The normality of the data was checked by 
means of a Kolmogorov-Smirnov test and the homogeneity of variances by means of the 
Levene test. A multi comparison among pairs of means was performed using a Scheffé test 
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with p < 0.05 as a significance level. All analyses were performed with SPSS 11.0 for 
Windows. 
Determination of water content 
The water content of the granules, the extrudates and the wet pellets was determined 
gravimetrically by heating 0.5 g sample for 20 min at 100°C in an IR oven (Mettler LP 16M, 
Mettler Toledo, Belgium). The analysis was performed in duplicate. The water content of the 
freeze-dried and fluid-bed dried pellets was determined using a Mettler DL35 Karl Fisher 
titrator (Mettler-Toledo, Beersel, Belgium). The samples were stirred in the reaction medium 
for 80 s. Afterwards the water was titrated with Hydranal® Composite 2 (Riedel-de Haën, 
Seelze, Germany). The analysis was performed in triplicate. 
Determination of hIL-10 production  
The hIL-10 production of the L. lactis Thy12 was determined using a sandwich ELISA as 
described in Chapter III.2. 
III.5.2.2 Results and discussion 
III.5.2.2.1 Viability in mini-tablets, composed of freeze-dried L. lactis 
Previous experiments showed that freeze-drying is an adequate method to dry liquid L. lactis 
suspensions (Chapter III.2). Viability after freeze-drying was 71.05 ± 18.07% (n=5). As a 
powder, containing an acceptable amount of viable L. lactis was available and tablets are the 
most commonly used administration form, the freeze-dried powder was compacted into mini-
tablets. In this study it was evaluated if this technique allows the production of a multi-
particulate formulation containing viable L. lactis. A survival of 15.7 ± 4.9% was obtained in 
the mini-tablets (Fig. 2). This means that 78% of the viability of L. lactis in the freeze-dried 
powder was lost during tabletting indicating the bacteria’s sensitivity to pressure. These 
Huyghebaert et al., Eur. J. Pharm. Biopharm., in press. 
III.5 Development of a multi-particulate, enteric-coated formulation of viable, recombinant L. 
lactis for ileal mucosal delivery of interleukin-10  
133
0
20
40
60
80
100
Mini-tablets Pellets (extr/spher) Pellets (layering)
V
ia
bi
lit
y 
(%
)
 
Figure 2 Absolute viability (% of theoretical, mean ± S.D.) of L. lactis MG1363, incorporated in 
mini-tablets (n=5), pellets produced by extrusion/spheronisation (n=5) and of L. lactis Thy12 in pellets 
produced by layering (30°C) after production (■) and after 1 week storage at RT/10% RH ().  
results are in agreement with Maggi et al. (1994, 2000) who reported that tabletting of freeze-
dried Bifidobacterium adolescentis and Lactobacillus gasseri resulted in a viability loss of 40 
to 99% of initial viability in freeze-dried powder, depending on the strain, the tablet type 
(single- or double-layered) and the tablet composition (effervescent or slow release layer). 
The authors did not mention the compaction force used. In this study, the viability of L. lactis 
MG1363 in the mini-tablets, stored for 1 week at RT and 10% RH was reduced to 3.7 ± 0.8% 
(absolute value) or 25.3 ± 6.1% of its initial viability after production (Fig. 2). Storage for 1 
week at RT and 60% RH resulted in complete loss of viability. Former stability experiments 
performed on freeze-dried powder as such (Chapter III.2) indicated that the viability of L. 
lactis stored at RT and 10% RH continues to decrease gradually. Therefore the formulation 
will definitely not have an acceptable shelf life. Maggi et al. (1994) reported a decrease in 
viability of B. adolescentis and L. gasseri of 50 to 20% after storage for 2 months at RT, 
dependent on tablet type and composition. A dramatic decrease in viability of B. adolescentis 
was reported after storage for 1 year at 4°C as only 1% remained viable. A mixture of three 
selected Lactobacillus species in one tablet resulted in an unchanged viability after 1 year of 
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storage at 4°C. It should however be noticed that no specifications were available on the 
relative humidity conditions during storage. Stadler and Viernstein (2003) reported no 
reduction in viability of freeze-dried Lactobacillus acidophilus (3.109 cells/tablet) formulated 
in tablets after storage for 6 months at 10 and 20°C (2.5.109 cells/tablet), while no data are 
available on the stability of freeze-dried L. lactis. These studies indicated that the stability is 
strain dependent. Moreover, Maggi (1994) and Stadler (2003) prepared standard sized tablets 
(10 mm), whereas in this study we used mini-tablets in which the bacteria are less protected 
from oxygen and moisture as they have a large surface to volume ratio. Furthermore, freeze-
dried L. lactis formulated in tablets has the tendency to be less sensitive to storage than 
freeze-dried L. lactis powder as such; after 1 week at RT and 10% RH, viability dropped to 
25.3 ± 6.1 and 13.6 ± 11.9% of initial viability in the tablets and powder, respectively but no 
significant differences were seen.  
Next to the problem of viability decrease during storage, the production of mini-tablets is very 
expensive, especially as the freeze-drying step is an energy-intensive and time-consuming 
process. In addition, the freeze-dried powder is very hygroscopic and special precautions have 
to be taken during tabletting. Moreover, it has to be investigated if the hygroscopicity will 
allow tablets to be efficiently coated and if L. lactis will survive this coating process.  
III.5.2.2.2 Viability in pellets, produced by extrusion/spheronisation 
A cheaper and faster way to produce a multi-particulate formulation containing viable and 
stable bacteria is the production of pellets by extrusion/spheronisation (Kim et al., 1988). It 
was evaluated whether this technique could be applied to L. lactis MG1363. For this, viability 
of L. lactis MG1363 was determined after the different pelletisation steps (Fig. 3). From Fig. 
3 it is clear that the viability of L. lactis dropped gradually during the production process. A 
rise in temperature during granulation, extrusion and spheronisation might alter the moisture 
content of the product due to evaporation of the granulation fluid during processing (Vervaet 
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et al., 1995). This might thereby dramatically decrease the microorganism’s viability, but Fig. 
3 shows that the loss of viability could not be explained by a decrease of the water content as 
this value remains constant. The shear developed during granulation, and mainly during 
extrusion/spheronisation with an additional rise in temperature (30 to 40°C) might explain the 
drop in viability during pelletisation. However, the most detrimental step is the drying 
process; only 5% of the bacteria in the wet pellets survived the fluid-bed drying. Because 
fluid-bed drying dramatically reduced the viability to 1.0%, freeze-drying was evaluated as an 
alternative drying technique. However, the viability in the freeze-dried pellets dropped to 
0.81%. From these data, it can be concluded that freeze-drying, the most common method for 
preservation of microorganisms, offered no advantage for drying the wet pellets in 
comparison to fluid-bed drying in terms of L. lactis’ viability. After pelletisation, the 
microorganisms are probably damaged to a certain level that no drying method is appropriate 
to maintain the L. lactis viable in the pellets. Moreover, the “low-water” stress applied to the 
bacteria during the two drying techniques brought about cell damage that led to an important 
loss in viability. The viability of the remaining bacteria was determined after a one-week 
storage period (Fig. 2). The viability of L. lactis MG1363 formulated in pellets, stored for 1 
week at RT and 10% RH was reduced to 0.5% of its viability immediately after production. 
Viability of L. lactis MG1363 in pellets stored at RT and 60% RH dropped to zero. Kim et al. 
(1988) prepared viable and stable dry lactic acid bacteria (LAB)-containing particles for food 
and agricultural purposes by mixing liquid culture concentrates of three different LAB strains 
with food grade cellulose. After granulation with a glycerol/water mixture, extrusion and 
spheronisation, the pellets were fluid-bed dried at 20-25°C. This production process was not 
reported as detrimental to the bacteria. Moreover, Kim et al. (1988) reported no loss of 
viability of Streptococcus cremoris and Pediococcus acidilactici (both cocci) in pellets after 1 
week storage at RT but a loss of viability of more than 1 log of Lactobacillus plantarum (rod-
shaped) in the pellets stored at the same conditions. So viability after storage at room 
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temperature showed strain dependency. No indication was given about the relative humidity 
conditions of storage. Viability of L. plantarum, P. acidilactici and S. cremoris remained 
unchanged for 76 days when stored at 4°C. Again, these results emphasised strain 
dependency. Thereby it can be concluded that L. lactis seemed more sensitive to storage. 
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Figure 3 Absolute viability (% of theoretical, mean ± S.D., n=5) of L. lactis MG1363 (■) and the 
water content () during the pellet production process (extrusion/spheronisation) (n=5).  
III.5.2.2.3 Viability in pellets, produced by layering  
As incorporation of L. lactis in pellets by means of extrusion/spheronisation resulted in an 
enormous loss of viability, layering of L. lactis on inert carriers was proposed as an 
alternative production technique for a multi-particulate formulation. While the inert carriers 
were fluidising, the L. lactis culture was atomised and the droplets met the inert carrier and 
consequently dried on the surface. No literature is available on layering of bacteria. Only 
spray drying is reported and showed that this technique allows preservation of 62% 
Lactococcus lactis (Fu and Etzel, 1995). However, this yielded a powder formulation, so 
subsequent compaction would be required to obtain a multi-particulate formulation. This can 
be overcome by layering the culture on inert particles. Maa et al. (1996, 1997) showed the 
possibility to layer lactose powder with recombinant human deoxy-ribonuclease (rhDNAse) 
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by means of a Wurster spray coater at product temperatures ranging from 34 to 43°C and 
yielded granules containing rhDNAse with 65% of its initial activity.  
Preliminary experiments showed that during layering of non-pareil sugar seeds with the L. 
lactis culture, the sugar partially dissolved which resulted in sticking. Decreasing the spray 
rate or increasing the inlet air temperature prevented sticking of the sugar spheres, but resulted 
in a too long process time and increased risk of viability decrease of L. lactis. Inert 
microcrystalline cellulose pellets were used as alternative carriers. The layering was 
conducted in a room with low relative humidity (20%) in order to increase the drying capacity 
of the inlet air in the fluid bed and hence the spray rate without increasing the product 
temperature. L. lactis Thy12 was layered in a 10% (w/w) skim milk solution at a process 
temperature of 30°C on Cellets® 700 and 1000, (1/1, w/w). Skim milk was chosen as matrix 
to layer L. lactis on the inert pellets as freeze-drying experiments (Chapter III.2) revealed the 
stabilising capacity of a skim milk matrix for L. lactis. Preliminary layering tests with a 
reference substance dissolved in skim milk, revealed that the yield of the process was 100%. 
This indicated the absence of spray drying and a good adherence of the skim milk matrix to 
the surface of the Cellets®. The viability of L. lactis Thy12 after layering was 4.9 ± 1.4% (Fig. 
2), remarkably lower as compared to freeze-drying and subsequent tabletting. Shear stress 
generated by atomisation, oxidation and thermal stress may all affect L. lactis viability (Fu 
and Etzel, 1995). Moreover, in contrast to spray drying, L. lactis experienced a longer 
exposure to an elevated temperature during layering. This could explain the more dramatic 
loss of viability than reported by Fu and Etzel (1995) during spray drying.  
The layered pellets were not stored at room temperature and 60% RH as previous data 
showed that storage for 1 week at those conditions resulted in a dramatic loss of viability. 
Comparison of the microorganism’s viability in layered pellets and mini-tablets after storage 
for 1 week at RT and 10% RH, revealed that layered L. lactis Thy12 showed a better stability. 
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68% of L. lactis’ Thy12 initial viability after production in the layered pellets remained viable 
contrary to only 25% in the mini-tablets (Fig. 2). Since L. lactis Thy12 was designed for in 
situ production of therapeutic (hIL-10), accurate dosing is a necessity and requires the 
guarantee of a reproducible viability, especially as a function of time. With their superior 
stability, layered pellets were therefore to be preferred over mini-tablets and pellets prepared 
by extrusion/spheronisation. The results revealed that L. lactis’ viability could be better 
guaranteed by the layering technique.  
Further experiments were performed in order to increase the load of L. lactis Thy12 on the 
Cellets®. In a first approach, the product temperature was increased and so higher drying 
capacity of the inlet air was obtained resulting in the possibility to increase the spray rate. A 
second approach consisted in the increase of the L. lactis Thy12 concentration in the layering 
suspension. Fig. 4 shows the viability after layering and subsequent storage for 1 week at RT 
and 10% RH of L. lactis Thy12 layered at increased product temperature (45°C) and 
increased bacterial cell density (109 to 1010 cfu/ml). A one-way ANOVA revealed no 
significant difference (p>0.05) between the viability after layering of L. lactis Thy12 at 30°C 
and 109 cfu/ml, at 30°C and 1010 cfu/ml and at 45°C and 109 cfu/ml. From these data, it could 
be concluded that viability after layering is independent of process temperature (range from 
30-45°C) and L. lactis concentration in the layering suspension (range from 109 – 1010 
cfu/ml).   
It was also evaluated if the stability of the viability could be improved by decreasing the 
storage temperature to 8°C (Fig. 4). Although viability tends to be higher at 8°C, a one-way 
ANOVA revealed no significant difference (p>0.05) between the viability immediately after 
layering of L. lactis Thy12 and after storage. A long term stability test has to confirm this 
trend. 
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Figure 4 Absolute viability (% of theoretical, mean ± S.D., n=3) of L. lactis Thy12, 109 cfu/ml  
layered at 30°C (■), 109 cfu/ml layered at 45°C () and 1010 cfu/ml layered at 30°C () (n=3).  
As L. lactis Thy12 was bioengineered for in situ production of hIL-10 and hence mucosal 
delivery in patients with Crohn’s disease, the success of the new delivery system depends on 
the hIL-10 producing capacity. In this study, it was confirmed that the hIL-10 producing 
capacity was maintained after layering.  
III.5.2.3 Conclusions 
Form this study it can be concluded that layering of L. lactis culture on inert microcrystalline 
cellulose pellets is an economical, single-step production process of a multi-particulate 
formulation of viable, interleukin-10 producing Lactococcus lactis Thy 12. Moreover, the 
layered batch can be subsequently coated in the same apparatus. Although viability dropped 
to 4.9% after production, 68% of this initial viability was maintained after 1 week storage at 
RT and 10% RH. The load of L. lactis Thy12 on the pellets can be increased by increasing 
product temperature (and hence spray rate) and cell density of L. lactis in the layering 
suspension. This formulation contains 3.8 x 108 cfu/g pellets. In the clinical trial, a dose of 3 x 
1011 cfu’s (10 enteric-coated capsules 00) was administered twice a day. This implies the 
administration of 800 g of layered pellets. Further experiments have to be performed to 
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increase viability after layering and storage, to increase the load and to optimise enteric-
coating of this formulation. 
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III.5.3 DEVELOPMENT OF A LAYERED, ENTERIC-COATED MULTI-PARTICULATE 
FORMULATION OF VIABLE, HIL-10 PRODUCING LACTOCOCCUS LACTIS  
III.5.3.1 Materials and methods 
III.5.3.1.1 Strains used in this study 
L. lactis Thy12 (human IL-10 producing L. lactis MG1363) (Steidler et al., 2003)  
III.5.3.1.2 Preparation of the layering solutions  
An L. lactis Thy12 culture was prepared by inoculating a stock suspension, stored at –20°C 
in glycerol/GM17 (50/50)/thymidine, 1/1000 in M17 supplemented with 0.5% glucose and 
50 µg/ml thymidine (GM17T). The culture was grown for 16 h at 30°C to reach the 
stationary phase at 2 to 3 x 109 cfu/ml. The bacteria were collected by centrifugation at 
3000g for 10 min at 4°C. The cell pellet was resuspended at 1010 cfu/ml in different 
layering solutions (10% (w/v) skim milk (Difco, Becton Dickinson, Maryland, USA), 10% 
(w/v) skim milk + 5% (w/v) inulin (EXL 608, kindly donated by Sensus, Roosendaal, 
The Netherlands), 10% (w/v) inulin, 5% (w/v) inulin or 2.5% (w/v) inulin), prepared by 
dissolving inulin in boiling water and skim milk in cold water. To prevent further activity 
or growth, the cultures were kept on ice in between all handling steps. 
For the determination of the yield, thymidine (Alkemi, Lokeren, Belgium) was added to 
the layering solutions as a marker substance, instead of the bacteria. 
III.5.3.1.3 Layering process (n=3) 
Microcrystalline cellulose spheres were used as inert carriers. Equal amounts of Cellets® 
700 (700-1000 µm) and Cellets® 1000 (1000-1250 µm), both kindly donated by 
Pharmatrans (Basel, Switzerland) were mixed, to obtain 300 g of pellets with an average 
diameter of 1000 µm as standard for pellets. Layering was performed in a fluid-bed 
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apparatus (GPCG 1, Glatt, Binzen, Germany) used in the bottom spray mode with the 
Wurster setup (nozzle diameter 0.8 mm; spray rate of 3 g/min for 30 min or 3 h; atomising 
pressure 1.5 bar; product temperature 45°C). Before layering, the pellets were preheated 
until a product temperature of 45°C was reached. Throughout the layering process the 
layering solution was kept on ice and manually homogenised from time to time. The 
experiments were performed in a production room at 20% RH.  
After layering, the pellets were immediately analysed (yield, viability) or packed in Alu 
sachets (LPS, Vapor flex barrier bag, New Jersey, US) and sealed at 20% RH. To study the 
influence of the layering matrix composition on storage stability of L. lactis Thy12, the 
sachets were stored for 12 months at room temperature (RT) (23 ± 2°C), 8°C and –20°C. 
Before further coating, the sachets were stored at –20°C.  
III.5.3.1.4 Evaluation of the layered pellets  
Determination of viability of L. lactis Thy12  
Viability was determined immediately after layering. To determine the influence of the 
layering matrix composition on storage stability, the pellets, layered with five different 
matrices, were analysed after 1 month storage at all conditions. To determine long term 
storage stability, only the pellets layered with the 10% skim milk matrix, stored at -20°C 
were analysed. Viability of the bacteria was determined using a turbidimetric method as 
described in Chapter III.2. 0.1 g of pellets were manually shaken in 1 ml sterile water. 
Three dilutions of each sample were loaded in duplicate onto micro-titer plates for analysis 
in the Bioscreen. The viability values were statistically evaluated with a one-way ANOVA 
at a significance level of 0.05. The normality of the data was checked by means of a 
Kolmogorov-Smirnov test and the homogeneity of variances by means of the Levene test. 
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A multi comparison among pairs of means was performed using a Scheffé test with p < 
0.05 as a significance level. All analyses were performed with SPSS 11.0 for Windows. 
Determination of the amorphous properties of the layered matrix 
The 10% inulin matrix, layered on the pellets was focused with a Kaiser Optical Systems 
Raman Rxn1 Microprobe (microscope objective – 10x) coupled to a Raman Rxn1 
Analyser (air-cooled CCD detector) via a proprietary holographic optical module. The 
Raman Rxn1 Analyser is an axial transmissive spectrograph that employs holographic 
technology. A 785 nm InvictusTM laser with 400 mW of power was employed for 
excitation. 10 s exposures were used for measurements. The obtained spectrum was 
compared with that of crystalline and amorphous inulin in order to characterise the 
molecular arrangement of inulin in the matrix. 
Determination of the yield of the layering process 
Three batches of pellets were layered during 30 min with the marker substance in the 10% 
skim milk + 5% inulin matrix. After sonication of the pellets in demineralised water for 10 
min and subsequent filtration (Celtron 30/0.2 CA, Schleicher & Schuell, Dassel, 
Germany), the concentration of thymidine was measured spectrophotometrically (Perkin 
Elmer, Zaventem, Belgium) at 267 nm. 
Determination of the influence of process time on yield and viability 
Two batches of pellets were layered for 168 and 180 min, respectively with the marker 
substance in the 10% skim milk + 5% inulin matrix. Samples were taken at 30 min interval 
and yield was determined as described above. Thereby, two batches of pellets were layered 
for 180 min with L. lactis Thy12 incorporated in the 10% skim milk + 5% inulin matrix. 
Samples were taken at 30 min interval and viability was determined as described above. 
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Scanning electron microscopy 
The morphology of the layer surface and the layer thickness of pellets layered for 30, 60, 
90, 120, 150 and 180 min were examined by scanning electron microscopy (SEM) (Jeol 
JSM 5600 LV, Jeol, Tokyo, Japan). Pellets were radially sheared and platina coated using a 
sputter coater (Auto Fine Coater, JFC-1300, Jeol, Tokyo, Japan). The layer thickness of five 
pellets was measured at minimum four sites per pellet. 
III.5.3.1.5 Coating 
Preparation of the coating dispersions 
The composition of the coating dispersions containing Eudragit FS 30 D and Eudragit 
L30D-55 is shown in Table 1. For the preparation of the Eudragit FS 30 D coating 
dispersion, a 30 % (w/w) aqueous Eudragit FS 30 D dispersion was used (Röhm, 
Darmstadt, Germany). Polysorbate 80 (wetting agent) (Tween® 80, Alpha pharma, 
Nazareth, Belgium) and glyceryl monostearate (glidant) (Federa, Braine-l’Alleud, 
Belgium) were added to water and stirred for 10 min with a high-speed mixer until a fine, 
homogenous dispersion was obtained. This dispersion was gently added to the Eudragit 
FS 30 D dispersion and mixed by magnetic stirring. For the Eudragit L30D-55 coating 
dispersions (A and B), the preparation was identical, except that triethyl citrate (Sigma-
Aldrich, Bornem, Belgium) (20% on the dry polymer) was used as plasticiser. For the 
Eudragit FS 30 D coating dispersions no plasticiser was needed since Eudragit FS 30 D 
exhibits a minimum film-forming temperature (MFT) of 14°C (contrary to Eudragit 
L30D-55 (27°C)). The difference between the two Eudragit L30D-55 coating dispersions 
A and B is the polymer content: 15.3 and 22.8 % (w/w), respectively. In order to avoid 
influence of process time, the polymer content in dispersion B was increased to reach a 
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polymer weight increase on the layered pellets of 30 % (w/w) in a process time comparable 
as to reach a polymer weight increase of 15% (w/w) (dispersion A).  
Table 1 Composition of coating dispersions containing Eudragit FS 30 D, Eudragit L30D-55 (A 
and B) 
 Eudragit FS 30 D Eudragit L30D-55 
(A) 
 Eudragit L30D-55 
(B)  
 Total (g) Dry (g)  Total (g) Dry (g)  Total (g) Dry (g) 
Eudragit FS 30 D (30% aq disp) 55 16.5  - -  - - 
Eudragit L30D-55 (30% aq disp) - -  51 15.3  51 15.3 
Glyceryl monostearate 1.3 1.3  1.3 1.3  1.3 1.3 
Tween 80 (33% aq. sol.)  1.6 0.5  1.6 0.5  1.6 0.5 
Triethyl citrate - -  3.2 3.2  3.2 3.2 
Water 41.7 -  43 -  10 - 
Polymer content (%, w/w)               16.4           15.3   22.8  
Solid content (%, w/w)                    18.4           20.2   30.3  
 
Coating process 
The coating dispersions were passed through a 0.3 mm sieve before use. Throughout the 
coating process the coating dispersions were stirred using a magnetic stirrer. 300 g of 
pellets were coated in a fluid bed coating apparatus (GPCG 1, Glatt, Binzen, Germany), 
used in the bottom spray mode with the Wurster setup (nozzle diameter 0.8 mm; atomising 
pressure 1.5 bar). The spray rate was 4 g/min for the Eudragit FS 30 D and Eudragit 
L30D-55 (A) dispersion and 5.3 g/min for the Eudragit L30D-55 (B) dispersion. For all 
coating experiments, the product temperature was 23-25°C. Before coating, the pellets 
were preheated to the desired product temperature during coating. After coating, the pellets 
were standard cured in the apparatus for 15 min at the same conditions as the coating 
process. Then the pellets were packed in Alu sachets (LPS, Vapor flex barrier bag, New 
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Jersey, US) sealed at 20% RH, cured for 2 or 5 days and subsequently stored at room 
temperature (RT) (23 ± 2°C), 8°C or –20°C. The pellets, layered for 30 min with the 
marker substance in the 10% skim milk + 5% inulin matrix were coated with 15 % (w/w) 
Eudragit FS 30 D and 15 and 30 % (w/w) Eudragit L30D-55. The pellets, layered for 
180 min with L. lactis Thy12 in the 10% skim milk + 5% inulin matrix were coated with 
15 % (w/w) Eudragit FS 30 D and 30 % (w/w) Eudragit L30D-55.  
Evaluation of the coated pellets 
Evaluation of the enteric properties after coating and storage 
Dissolution testing (n=3) was performed using the reciprocating cylinder method (USP 
apparatus 3) (Bio-Dis, Vankel, NJ, USA) at a dip rate of 21 dpm using 1,3 g pellets per 
vessel (250 ml) with HCl 0.1N for 2 h. The concentration of thymidine was measured 
spectrophotometrically (Perkin Elmer, Zaventem, Belgium) at 267 nm.  
Determination of viability of L. lactis Thy12 after coating and after passage through the 
gastric fluid stage 
For the determination of the viability after coating, a dissolution test (n=3) was performed 
using the reciprocating cylinder method (USP apparatus 3) (Bio-Dis, Vankel, NJ, USA) at a 
dip rate of 21 dpm using 1,3 g coated pellets per vessel (250 ml) with phosphate buffer 
(0.0125M) pH 7.4 for 40 min. For the determination of the viability after passage through 
the gastric stage, first a dissolution test (n=3) was performed using 1,3 g coated pellets per 
vessel (250 ml) with consequently HCl 0.1N for 2 h and phosphate buffer (0.05M) pH 7.4 
for 40 min. Next, dissolution testing was performed in phosphate buffer (0.05M) pH 7.4 for 
40 min, without the previous gastric fluid stage. Then viability after gastric fluid stage was 
calculated as follows: (viability after HCl 0.1N (2h) + phosphate buffer 0.05M (40 
min))/(viability after phosphate buffer 0.05M (40 min))*100.  
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III.5.3.2 Results and Discussion 
III.5.3.2.1 Optimisation of the layering matrix to increase viability after layering and 
storage 
In Chapter III.2, it has been shown that addition of 5% inulin to the 10% skim milk matrix 
resulted in a significant increase of the stabilising capacity of the 10% skim milk matrix 
during storage of freeze-dried L. lactis Thy12 at 8°C/10% RH. Next, in the previous 
section of this Chapter (5.2), it has been shown that, in order to increase the load of L. 
lactis Thy12 on an inert carrier, increasing the product temperature to 45°C and the 
bacterial concentration in the layering solution from 109 to 1010 CFU/ml did not lead to a 
significant change in viability after layering and storage. Therefore, further experiments 
were performed at 45°C with a cell concentration in the layering solution of 1010 CFU/ml 
and a modified layering matrix in an attempt to increase viability after layering and 
storage. As a reference, 10% skim milk was used. Analogous to the freeze-drying 
experiments (Chapter III.2), the 10% milk + 5% inulin and 10% inulin matrix were 
evaluated. Besides two other inulin concentrations (5 and 2.5%) were evaluated.  
Comparison of the viability values in the different matrices revealed that the viability after 
layering in the 10% milk + 5% inulin matrix was significantly higher than in the other 
matrices (Fig. 5). However, there was no significant difference with the 10% inulin matrix. 
After storage for 1 month at RT, viability dropped to zero in all matrices, except in the 
10% milk matrix (3.3 ± 2.5%) (Fig. 5). After storage for 1 month at 8°C, no significant 
differences were observed between the matrices. However, 10% milk matrix tends to be 
the best performing matrix as viability remained quasi unchanged after 1 month. In the 
other matrices, the relative viability dropped below 45%. The lowest viability was seen in 
the pure inulin matrices.   
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Figure 5 Relative viability of L. lactis Thy12 after layering in different matrices and storage in Alu 
sachet (sealed at 20% RH) for 1 month at different conditions (RT, 8 and –20°C). Insert: Absolute 
viability after layering.(10% skim milk,  10% inulin,  10% milk + 5% inulin,  5% inulin, 
■ 2.5% inulin) (n=3)   a,b: Groups within the same condition with the same superscript are not 
significantly different from each other  (p>0.05) (one-way ANOVA, post hoc Scheffé) 
From these data it can be concluded that skim milk is an essential compound for the 
stabilisation of bacteria during storage and that the addition of inulin results in a 
destabilising effect. As it is generally known that crystalline structures present in the 
amorphous matrix lead to destabilisation of the biomaterials included (Crowe et al., 1996), 
the molecular arrangement of the inulin molecules was determined. However, no 
crystalline inulin could be identified in the layered matrix using Raman technology.  
Independent of the matrix used, no significant differences were seen between the viability 
values after storage for 1 month at –20°C. Remarkably, the average relative viability 
values observed after 1 month storage exceeded those determined immediately after the 
layering process. This apparent discrepancy could be related to our method of assessing 
viability (Bioscreen) which in essence measures turbidity of the culture and hence its 
capacity to multiply. It is conceivable that, although still viable during the layering process, 
Huyghebaert et al., Eur. J. Pharm. Biopharm., submitted. 
III.5 Development of a multi-particulate, enteric-coated formulation of viable, recombinant L. 
lactis for ileal mucosal delivery of interleukin-10  
149
the bacteria have temporarily lost their capacity to resume multiplication. Storage at –20°C 
could then lead to restoration of the multiplying capacity.  
Relying on the previous results, the viability of the three batches of L. lactis Thy12 layered 
in 10% skim milk matrix was evaluated in function of storage time in Alu sachets (filled 
and closed at 20% RH) at –20°C (Fig. 6). For batch 1 and 2, viability did not significantly 
change after 8 and 9 months storage, respectively. For batch 3, viability decreased 
significantly after 12 months storage (60%). So, the viability profile as a function of time is 
variable form batch to batch.  
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Figure 6 Absolute viability of L. lactis Thy12 after layering in 10% skim milk matrices and storage 
in Alu sachet (sealed at 20% RH) in function of storage time at –20°C. ( Batch 1, ■ Batch 2,  
Batch 3)  a,b,c,d,e,f,g,h: Groups within the same series with the same superscript are not significantly 
different from each other  (p>0.05) (one-way ANOVA, post hoc Scheffé) 
However, the viability is adequately maintained in function of storage time. It can be 
concluded that layering of L. lactis Thy12 in the 10% skim milk matrix on inert pellets 
results in a valuable multi-particulate formulation of L. lactis Thy12 since it was designed 
for in situ production of a therapeutic (hIL-10). Hence, accurate dosing is a necessity and 
requires the guarantee of a reproducible viability, especially as a function of time. In 
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comparison with the stability of freeze-dried L. lactis Thy12 in the same matrix (42% 
remained viable after 9 months storage in Alu sachets at –20°), it can be concluded that the 
layered L. lactis Thy12 showed a superior stability.  
III.5.3.2.2 Determination of the yield and reproducibility of the layering process  
As the 10% milk + 5% inulin matrix resulted in the best viability immediately after 
layering, the process yield and the reproducibility (inter- and intra-batch variability) was 
determined using a marker substance (thymidine). Layering of the 10% milk + 5% inulin 
matrix is a reproducible process as the inter- and intra batch variability was below 4.74 and 
2.80%, respectively. Moreover, the process yield was high (91.99 ± 4.74%, n=3). The loss 
of yield (~8%) can be explained by spray drying, as the fluid bed container was not 
optimally filled.  
III.5.3.2.3 Viability as function of process time  
It was confirmed that the layering process could be run for at least 3 h without any 
technical problems e.g. sticking of the pellets and blocking of the nozzle. In order to detect 
any damage and subsequent peeling off of the matrix layer, the yield was determined after 
different process times 30, 60, 90, 120, 150 and 180 min for two batches. Fig. 7 indicates 
that the yield remained constant during the entire layering process. The layer thickness of 
the layered pellets was measured in function of process time (SEM). There was a linear 
increase of the layer thickness as a function of process time (y = 0.299x + 0.116, r2= 
0.998). The surface appeared smooth and showed very few superficial cracks (Fig. 8). This 
is in contrast to the surface of pellets layered at 30°C looking rough and showing deep 
cracks, probably due to the high Tg of inulin. This can lead to problems of coating 
performance after enteric-coating of these pellets. 
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Figure 7 Layering yield (%) of 2 batches in function of the process time using 10% milk + 5% 
inulin matrix and thymidine as marker substance. The horizontal lines indicate the mean yield for 
the total process time ( Batch 1,  Batch 2). 
Figure 8 Cross section of a Cellet® layered for 150 min with a 10% milk + 5% inulin matrix: layer 
thickness. Insert (a): surface of the layer. 
The viability of L. lactis was also followed as a function of the process time. Fig. 9 shows 
the viability obtained in two batches after 30 min layering (29% and 27%). The viability 
slightly decreased after 60 min, but proceeding the process for another 2 h did not 
significantly affect the viability. Probably, an equilibrium was reached around 60 min 
process time: the death rate of newly layered bacteria is constant and once the bacteria are 
dried on the surface of the inert carriers, they maintain viable.  
a 
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Figure 9 Viability (%) of L. lactis Thy12, layered in 10%milk + 5%inulin matrix in function of 
process time. a,b,c,d: Groups within the same serie with the same superscript are not significantly 
different from each other  (p>0.05) (one-way ANOVA) ( Batch 1,  Batch 2). 
III.5.3.2.4 Enteric properties of a coated, layered pellet formulation and influence of curing 
and storage conditions on enteric properties 
It is generally accepted (European Pharmacopoeia) that release from an enteric-coated 
formulation in HCl 0.1N after 2 h may not exceed 10%. In this study, a lower limit of 3.5% 
was set forward, as a minimum of acid penetration through the coat is prerequisite for 
maintaining the viability of the acid-sensitive L. lactis. The pellets were coated with two 
different coating polymers i.e. Eudragit L30D-55 and Eudragit FS 30 D. Next to 
protection against the detrimental gastric fluid and bile salts, this coating polymers are 
chosen for their ileum targeting properties in relation to Crohn’s disease treatment. Chapter 
III.3 indicated that none of the available coated polymers ensured ileal targeting. This 
could be circumvented by administration of the combination of one pellet fraction coated 
with Eudragit L30D-55 while another was coated with Eudragit FS 30 D ensuring ileum 
release in patients with low and high ileum pH profiles, respectively.    
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Fig. 10 reveals that from pellets, coated with 15% (w/w) Eudragit L30D-55, release was 
above the limit of 3.5%, even after curing for longer periods (5 days) and at higher 
temperature (60°C). Increasing the amount of polymer applied to the layered pellet (30%, 
w/w) resulted in a release in HCl 0.1N after 2 h below 3.5%, already after curing for 2 days 
at –20°C. For the Eudragit FS 30 D polymer, 15% (w/w) weight increase on the pellets 
was sufficient to result in a release in HCl 0.1N after 2 h below 2%. Generally, it can be 
concluded that Eudragit FS 30 D is a less permeable polymer than Eudragit L30D-55 as 
only 15% weight increase is required to obtain the desired enteric properties, contrary to 
30% of Eudragit L30D-55.  
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Figure 10 Release in HCl 0.1N after 2 h from pellets, layered with 10% milk + 5% inulin matrix 
and coated with 15% (w/w) Eudragit® FS 30 D (), 15 (■) and 30% () (w/w) Eudragit® L30D-
55, cured and stored for different periods and conditions. 
Fig. 10 also shows that after storage for 6 months, the release remained low at all 
conditions for both Eudragit FS 30 D (15%) and Eudragit L30D-55 (30%) coated 
pellets, indicating their maintenance of the enteric properties. It can be concluded that the 
coating compositions used are convenient for storage at low temperature (-20°C) and low 
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relative humidity (20% RH), the best storage conditions in terms of L. lactis’ Thy12 
viability.    
III.5.3.2.5 Viability of L. lactis Thy12 after coating and after passage through the gastric 
stage 
The two batches, layered for 180 min with L. lactis Thy12 (1010 cfu/ml) in 10% milk + 5% 
inulin matrix were coated with 30% (w/w) Eudragit L30D-55 and 15% (w/w) Eudragit 
FS 30 D, respectively. Comparison of the viability data after coating with 30% (w/w) 
Eudragit L30D-55 and 15% (w/w) Eudragit FS 30 D, respectively revealed a serious 
drop in viability after Eudragit L30D-55 coating (from 11.4% in the uncoated pellets to 
3.8% after coating), contrary to Eudragit FS 30 D (17.33 ± 1.13% in the uncoated pellets 
to 18.36 ± 0.13% after coating). As the pH of the coating solutions (2.5) and the coating 
conditions (process time and coating temperature) were similar for both polymers, it can be 
concluded that these factors have no detrimental effect on the viability of L. lactis Thy12. 
Probably, the coating compounds, released during the dissolution test have a detrimental 
effect on the L. lactis’ Thy12 viability. In comparison to the Eudragit FS 30 D coated 
pellets, a same quantity of Eudragit L30D-55 coated pellets contains twice as much 
polymer and Tween 80. From previous experiments it is known that Tween 80 
influences the growth of L. lactis at a concentration of 50 mg/ml. In this dissolution test, 
Tween 80 is only present in a concentration of 0.052 mg/ml. However, a local exposure 
to higher concentrations immediately after dissolution could have a detrimental effect.  
After simulation of the gastric transit (HCl 0.1N for 2h) of the Eudragit FS 30 D coated 
pellets, about 85% of the bacteria remained intact, indicating the good protective capacity 
of the polymer against the detrimental gastric fluid. However, after passage through the 
gastric stage of the Eudragit L30D-55 coated pellets, only 5% of the bacteria remained 
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viable. It might be concluded that this polymer is much more permeable (cf. above), in spite 
of the higher coat thickness used (30% weight increase) and that it is therefore less 
appropriate for protection of L. lactis against the detrimental gastric fluid. However, it has 
to be further investigated if, as described above, some coating compounds released during 
dissolution testing have a detrimental effect on L. lactis’ Thy12 viability.  
The pellets coated with 15% (w/w) Eudragit FS 30 D, packed in Alu sachets and sealed at 
20% RH, were stored for 8 months at –20°C. The viability decreased significantly from 
18.5 ± 1.1% after layering to 14.8 ± 0.2% after 8 months storage. However, still 80% of L. 
lactis Thy12 remained viable in the enteric-coated pellets during this storage period. 
III.5.3.3 Conclusions 
In this study, some new aspects of the layering technique, in order to produce a multi-
particulate formulation of L. lactis Thy12 were shown. First, it can be concluded that the 
technique could be performed for long times without encountering technical problems, 
with good layer consistence and with maintenance of viability. This broadens the 
applicability of the technique as the load of the bacteria can be remarkably increased. Next, 
the superior stability of layered L. lactis Thy12 in comparison with freeze-dried L. lactis 
Thy12 has been shown, based on long term stability data. Besides, coating of the layered 
multi-particulate formulation with 15% Eudragit FS 30 D resulted in good enteric 
properties: 85% of the bacteria remained viable in Eudragit FS 30 D coated pellets after 
passage through the gastric stage. Moreover, after an 8 months storage period (–20°C), 
80% of L. lactis Thy12 remained viable in the Eudragit FS 30 D coated pellets. However, 
the load of L. lactis Thy12 on the inert pellets should be further increased in order to reach 
acceptable dose quantities. Besides, since it appears that the Eudragit L30D-55 polymer, 
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contrary to Eudragit FS 30 D, is not acceptable to provide protection against the 
detrimental fluid, this coating has to be further investigated and optimised.  
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IV.1 INTRODUCTION 
Enterotoxigenic Escherichia coli (ETEC) cause diarrhoea and mortality in neonatal 
(Alexander, 1994) and recently weaned (Hampson, 1994) piglets and hence leads to 
economic losses in pig farming. Passive colostral and lactogenic immunity can effectively 
prevent neonatal infections (Rutter and Jones, 1973; Deprez et al., 1986) but active 
intestinal mucosal immunisation is needed for protection of newly weaned piglets since 
they are deprived of passive lactogenic immunity. This can occur following oral infection 
but is not obtained by parenteral immunisation, which tends to stimulate the systemic 
rather than the mucosal immune system (Moon and Bunn, 1993). As vaccination of piglets 
against postweaning infections is still an important challenge, there is clearly a need for 
competent oral vaccines for induction of mucosal protection.  
Some of the ETEC strains bear F4 fimbriae, allowing adherence of the bacteria to F4-
specific receptors (F4R), present on brush borders of villous enterocytes and subsequent 
colonisation of the small intestine. Newly weaned piglets can be orally immunised with 
isolated F4 fimbriae in solution against F4+E. coli infection (Van de Broeck et al., 1999a). 
However, to protect the piglets against postweaning F4+ETEC infection, the piglets have to 
be immunised during the suckling period. As oral solutions are unpractical for 
administration to suckling animals, a multi-particulate formulation of F4 fimbriae would 
have a considerable advantage as it could be mixed with their creep feed. Moreover, from 
an economical point of view, in order to reduce dose and dosing frequency, the F4 
administered should be delivered efficiently to the mucosal surfaces to induce 
immunisation. Therefore, the formulation has to be enteric-coated to protect the F4 
fimbriae against detrimental effects of gastric acids, pepsin, bile and of neutralising 
antibodies present in the mother’s milk, the most important feed of suckling piglets, 
present along the gastrointestinal (GI) tract (Snoeck et al., 2003; 2004a). Furthermore, the 
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F4 fimbriae have to be targeted to the major inductive sites of the F4-specific intestinal 
immune response, namely the jejunal Peyer’s patches (Snoeck et al., submitted). In order 
to select an appropriate coating thickness and coating material for protecting and targeting 
of the F4 fimbriae, the transit time as well as pH along the GI tract of suckling piglets was 
studied (Snoeck et al., 2004a; 2004b). It has been shown that the pH at the beginning of the 
jejunum is 6.3 and that 1.5 to 3.5 h after oral administration of non-disintegrating radio-
opaque pellets, more than 75% were removed from the stomach.  
The use of enteric-coating polymers for mucosal delivery of vaccines has been reviewed 
(O’Hagan, 1998). Klipstein et al. (1983) formulated the B subunit of Escherichia coli heat-
labile enterotoxin by tabletting the freeze-dried toxin and subsequent enteric-coating. 
Subsequent oral administration to rat resulted in a strong degree of serum and mucosal 
antitoxin response. Jain et al. (1996), Wong et al. (1992) and Flanagan et al. (1996) 
described the coating of ovalbumin, Vibrio anguillarum, and heat-killed E. coli, 
respectively on non-pareil seeds and subsequent coating with aqueous Eudragit L30D-55. 
Oral administration to mice, salmonid fish and mice, respectively induced an immune 
response.  
The aim of this study was to develop an enteric-coated multi-particulate formulation, 
which ensures protection of the F4 fimbriae against the detrimental gastro-intestinal 
influences (acids, pepsin, bile, neutralising antibodies) and subsequent release of the 
protein at the target site (major inductive sites; jejunal Peyer’s patches) in an immunising 
conformation. Since binding of F4 to the F4R present on the villous enterocytes in the 
small intestine is a prerequisite for the induction of a protective intestinal immune response 
(Van den Broeck et al., 1999a), maintenance of the correct F4 confirmation to ensure this 
binding is of crucial importance. First, a feasibility study was performed to evaluate the 
sensitivity of F4 towards different formulation techniques (freeze-drying, 
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extrusion/spheronisation). Then, a pellet formulation was optimised in order to meet the 
requirements of F4 release and enteric properties. In a last part, the F4 stability in and 
release from the optimised pellet formulation was determined.  
IV.2 MATERIALS AND METHODS 
IV.2.1 PREPARATION OF F4 STOCK SOLUTION 
The F4ac fimbriae of the enterotoxigenic E. coli bacteria were isolated as previously 
described (Van den Broeck et al., 1999a). The protein concentration of the isolated solution 
was determined using the Bicinchoninic Acid Protein Assay Kit (Sigma-Aldrich, Bornem, 
Belgium). The purity was assessed by electrophoresis on a SDS-12% polyacrylamide slab 
gel, followed by analysis of the Coomassie stained gel using the gel analysis software, 
Image Master 1D (Amersham Pharmasia biotech, Newcastle upon Tyne, England), so 
that the concentration of the F4 fimbriae in the solution could be determined. 
IV.2.2 FREEZE-DRYING OF THE F4 SOLUTION 
A PBS solution of F4 (3.1 mg/ml) was filled in vials (glass type 1, Gaash Packaging, 
Mollem, Belgium). The vials were covered with a freeze-drying stopper (V9032 FM 257/2 
SAF1, bromobutyl with magnesium silicate as filler, kindly donated by Helvoet Pharma, 
Alken, Belgium). Prior to freeze-drying, the vials were kept on ice. The vials were loaded 
on the precooled shelves (-25°C) of the freeze-dryer (Leybold GT4, Finn-aqua, Sohlberg, 
Germany). The samples were frozen to - 45°C over 105 min at 1000 mbar. The primary 
drying (12 h) was performed at –15°C and 0.8 to 1 mbar and the secondary drying (9 h) at 
10°C and 0.1 to 0.2 mbar. After freeze-drying, the vials were closed under vacuum. 
Samples were kept on ice until analysis. 
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IV.2.3 PRODUCTION OF THE PELLETS  
IV.2.3.1 Feasibility study  
As the isolation of F4 fimbriae from the E. coli is a very time-consuming and expensive 
process, a small-scale production method (batch size: 10g) was used for the feasibility 
study on the incorporation of F4 in pellets (three batches). Microcrystalline cellulose 
containing 11.3 to 18.8% (w/w) sodium carboxymethyl cellulose (Avicel CL 611, FMC 
Europe, Brussels, Belgium) and α-lactose monohydrate 200 Mesh (Pharmatose 200M, 
kindly donated by De Melkindustrie, Veghel, the Netherlands) were used as excipients. 
Sodium carboxymethyl starch (Explotab®, received from Penwest Pharmaceuticals, NY, 
US) was used as a disintegrant. The powders were pre-blended in a ratio of 2.5% (w/w) 
Avicel® CL 611, 87.5% (w/w) α-lactose monohydrate 200 Mesh and 10% (w/w) 
Explotab® in a mortar and a pestle. Exactly 6.36 ml F4 solution (3.1 mg/ml PBS) was 
added as the granulation fluid in order to obtain a concentration of 0.2% (w/w) of fimbriae 
in the pellets. Extrusion was performed using a single screw extruder (Dome extruder lab 
model DG-L1, Fuji Paudal, Tokyo, Japan) at 45 rpm, through a 1 mm perforated screen. 
The extrudate (8 g) was spheronised on a mini-spheroniser (Caleva model 120, Sturminster 
Newton, UK), using a cross-hatched friction plate, operating at 1680 rpm with a residence 
time of 2 min. The pellets were dried either by fluid-bed or freeze-drying. During fluid-bed 
drying, the wet spheres were dried in a fluid bed dryer (Uniglatt D7852, Glatt, Binzen, 
Germany) for 8 min at an inlet air temperature of 25°C. For freeze-drying, the pellets were 
transferred into glass vials and freeze-dried as described above. Samples were taken of the 
wet and the dry pellets.  
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IV.2.3.2 Optimisation of a disintegrating pellet formulation, downscaling and 
incorporation of F4 fimbriae 
Different pellet formulations were prepared and evaluated for their disintegration 
properties (Table 1). The composition of the pellets was changed either by varying the type 
and ratio of lactose (α-lactose monohydrate 200 Mesh (Pharmatose® 200M) and 90 Mesh 
(Pharmatose® 90M) and β-lactose (Pharmatose® DCL21) (De Melkindustrie)), by adding 5 
and 10% (w/w) sodium carboxymethyl starch (Explotab®) or by varying the ratio 
lactose/microcrystalline cellulose (Avicel PH 101, FMC, Brussels, Belgium) from 80/20 
to 90/10 and 95/5 (w/w).  
The pellet excipients were weighted (700 g in total), preblended and granulated with 
demineralised water in a planetary mixer (Kenwood Major Classic, Hampshire, UK) at 60 
rpm for 2 min. Extrusion was performed in a single screw extruder (Dome extruder labo 
model DG-L1, Fuji Paudal Co., Tokyo, Japan) at 45 rpm, through a 1 mm perforated 
screen. The extrudates (600 g) were spheronised on a spheroniser (Caleva model 15, 
Sturminster Newton, UK), using a cross-hatched friction plate, operating at 1000 rpm with 
a residence time of 4 min. The wet spheres were dried in a fluid bed dryer (Uniglatt 
D7852, Glatt, Binzen, Germany) for 20 min at an inlet air temperature of 25 °C. The 700 to 
1250 µm fraction was separated using a sieve shaker (VE 1000, Retsch, Haan, Germany) 
for 20 min at an amplitude of 2. 
For the coating experiments, 1% (w/w) thymidine was incorporated in the pellets as marker 
substance by means of preblending with the other excipients. To evaluate the F4 release 
from the optimised pellets, 0.04% (w/w) F4 was incorporated during the granulation step 
as an F4 solution in PBS.  
For the downscaling experiments, the pellet production was performed as described above 
except that 40, 100 and 300 g of excipients was used instead of 700 g.  
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Table 1 Composition of the pellet formulations 
 I II III IV V VI VII VIII IX X 
Excipient (%, w/w)           
Microcrystalline cellulose 20 20 20 20 20 20 19 18 10 5 
α-lactose monohydrate 200 Mesh 80 / / / / / / / / / 
α-lactose monohydrate 90 Mesh / 80 / 20 40 60 57 54 67.5 71.3
β-lactose / / 80 60 40 20 19 18 22.5 23.7
Sodium carboxymethyl starch / / / / / / 5 10 / / 
 
IV.2.3.3 Coating of the pellets with Eudragit L30D-55  
The pellets were coated with Eudragit L30D-55, an anionic copolymer of methacrylic acid 
and ethylacrylate (1:1). Previous experiments showed that Eudragit L30D-55 dissolves 
from pH 6.0 (Chapter III.3). The preparation of the Eudragit L30D-55 coating dispersion 
and the coating process parameters are described in Chapter III.3. If only a small amount of 
pellets was available, coating was performed together with microcrystalline cellulose pellets, 
containing 0.3% carmin red. After coating, the pellets of interest were selected based on 
colour. The pellets were coated with 15 or 30% (w/w) Eudragit L30D-55. As no spray 
drying occurred during the process, the amount of polymer applied to the pellets was 
calculated based on the amount of polymer remaining after the process. After coating, the 
pellets were cured for 24 h or 4 days at 4°C and 10% RH.  
IV.2.3.4 Storage of the pellets  
For the feasibility test, pellets were stored for 1 month at 8°C and 10% RH (above silica 
gel for desiccation (Sigma, Bornem, Belgium) and at room temperature (RT) (23 ± 2 °C) 
and 10 or 60% RH (above a saturated sodium bromide solution). 
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IV.2.3.5 Evaluation of the pellets 
IV.2.3.5.1 F4 biological activity  
To test the biological activity of F4 fimbriae, 10 ml PBS (pH 7.4) was added to 1 g of 
pellets for the feasibility test, whereas 1.2 g of the coated pellets of the optimised 
formulation was first pulverised in a mortar using a pestle after which 10 ml PBS was 
added. Subsequently, the pellets were homogenised on a rotating wheel for 1 h at RT and 
centrifugated at 3000 rpm and 18°C. The supernatant was filtered using a Whatman filter 
50 and stored at -20° C until analysis. The extraction control was performed by 
redissolving the centrifuged pellet in 10 ml PBS (pH 7.4). It was homogenised on a 
rotating wheel at 4°C, overnight and subsequently centrifugated at 3000 rpm and 18°C. 
The supernatant was filtered and stored at -20°C until analysis. 
The amount of biological active F4 in the samples was determined by ELISA using an F4-
specific Mab recognising the c epitope of the F4ac which is involved in the interaction with 
the F4R. Moreover, analysis of the F4R binding capacity of the F4 in the samples using an 
in vitro competitive inhibition villous adhesion assay (bioassay) demonstrated that the 
ELISA results correlated very well with the F4R binding capacity. Consequently, this 
ELISA can be used to determine the biological activity of the samples and because of its 
high sensitivity was preferred above the competitive inhibition villous adhesion assay. 
Furthermore, the samples, with and without previously boiling, were assessed by 12%-
SDS-PAGE followed by immunoblotting as described by Snoeck et al. (2004b) to evaluate 
the degradation of the multimeric F4 fimbriae and of its major subunit. 
The ELISA used has been described by Van der Stede et al. (2003). Briefly, the wells of a 
96-well microtiter plate were coated with F4-specific monoclonal antibodies (Mab) (clone 
CVI F4ac-5, ID-DLO, Lelystad, The Netherlands) (Van Zijderveld et al., 1990) followed 
by blocking of the remaining binding sites. Subsequently, the F4 stock solution and the 
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samples were added in series of twofold dilutions in ELISA dilution buffer (PBS, pH 7.4 
with 0.05% (v/v) Tween 20 and 3% (w/v) BSA). The dilution of the stock solution was 
started at a concentration of 25 µg/ml. Thereafter, an optimal dilution of an F4-positive 
serum from a pig repeatedly immunised intramuscularly with purified F4, and an optimal 
dilution of biotinylated-swine-specific IgG Mab and peroxidase-conjugated streptavidin 
were added. Finally, an ABTS solution containing H2O2 was added after which the optical 
density was spectrophotometrically measured at 405 nm.  
The in vitro competitive inhibition villous adhesion assay was based on the in vitro 
inhibition villous adhesion assay of Van den Broeck et al. (1999b). Briefly, 50 villi with F4-
receptors were incubated with different dilutions of the F4 stock solution (concentration of 
F4: 0, 25, 50, 100, 200, 300, 400 µg/ml) or the samples, and with 4.108 F4ac+ E. coli in 0.5 
ml PBS supplemented with 1 % D-mannose during 1 h at RT while being gently shaken. 
Subsequently, the number of bacteria adhering per 250 µm villous brush border length was 
calculated using phase-contrast microscopy at a magnification of 600. As standard for the 
concentration determination of the biologically active F4 in the samples, the F4 stock 
solution was used in both tests. The F4 biological activity was expressed as % of theoretical 
activity.  
The biological activity values obtained after storage for 1 month at different temperature 
and relative humidity were statistically evaluated with a two-way ANOVA at a significance 
level of 0.05. The normality of the data was checked by means of a Kolmogorov-Smirnov 
test and the homogeneity of variances by means of the Levene test. A multi comparison 
among pairs of means was performed using a Scheffé test with p < 0.05 as a significance 
level. All analyses were performed with SPSS 11.0 for Windows. 
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IV.2.3.5.2 Disintegration test 
A disintegration test was performed for 30 min using the reciprocating cylinder method 
(USP apparatus 3) (Bio-Dis, Vankel, NJ, USA) at a dip rate of 21 dpm using 0.5 g pellets 
per vessel (250 ml) with phosphate buffer (PB) (0.05 M) at pH 6.3. After the test, the 
pellets were dried and evaluated by optical microscopy (Olympus SZX9 stereomicroscope) 
or by scanning electron microscopy (SEM) (Jeol JSM 5600 LV, Jeol, Tokyo, Japan). 
Pellets were radially sheared and platinum coated using a sputter coater (Auto Fine Coater, 
JFC-1300, Jeol, Tokyo, Japan) before scanning electron microscopy was performed.   
IV.2.3.5.3 Dissolution testing 
Dissolution testing (n=3) was performed using the reciprocating cylinder method using 1.2 
g of coated pellets per vessel with two consecutive media: HCl 0.1 N (250 ml) (2 h) and 
consequently a phophate buffer (250 ml) (BP) 0.05 M at pH 6.3. The thymidine 
concentration was measured spectrophotometrically (Perkin Elmer, Zaventem, Belgium) at 
267 nm.  
IV.2.3.5.4  F4 release test 
A dissolution test was performed as described above (n=2). F4 was concentrated from the 
dissolution samples by filtrating 80 ml of the sample using a Centricon Plus-80 Filter Unit 
with Ultracel-PL membrane (Millipore, Brussels, Belgium) (MW cut-off 10.000) and a 
swinging bucket centrifuge for 20 min at 4500 rpm and 4°C. Retention of recovered F4 
was performed using the swinging bucket centrifuge for 2 min at 2000 rpm at 4°C. The 
remaining solution was heated to 100°C for denaturation. SDS electrophoresis and 
subsequent immunoblotting of the samples (undiluted and diluted ½) was performed using 
an F4ac specific Mab for F4 specific red staining.  
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IV.3 RESULTS AND DISCUSSION 
IV.3.1 FEASIBILITY STUDY 
Preliminary studies have shown that incorporation of F4 fimbriae in a non-disintegrating 
pellet formulation consisting of pure microcrystalline cellulose (Avicel PH101) results in 
a very low release (< 5%) of biologically active F4 in phosphate buffer pH 6.3. This could 
be attributed to the denaturation of F4 during the pellet production process or to a 
hampered release of the protein from the microcrystalline cellulose pellets especially as F4 
fimbriae (consisting of hundreds of identical protein subunits of 27.5 kDa) (0.1 to 1 µm 
length and 2.1 nm ∅) have much larger dimensions than conventional drugs (Angstrom-
range (0.1 nm)). Besides, these pellets did not disintegrate while Fig. 1a shows that no 
pores were formed after a 30 min disintegration test in phosphate buffer pH 6.3. These data 
clearly indicated the need for a disintegrating pellet formulation or at least a porous pellet, 
which ensures the release of F4 fimbriae. Preliminary studies have demonstrated that a fast 
disintegrating pellet formulation consisting of 87.5% α-lactose monohydrate 200 Mesh, 
2.5% Avicel CL 611 and 10% Explotab disintegrated within 10 min in PB pH 6.3.  
a
 
Figure 1 SEM picture of the surface and cross section of pellets consisting of microcrystalline 
cellulose after disintegration test (30 min, PB pH 6.3). 
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Based on the biological activity of F4 incorporated in this pellet formulation by 
extrusion/spheronisation, this technique looked very promising for the production of a 
multi-particulate formulation of F4 (Fig. 2). Immediately after production, the wet pellets 
contained 86 ± 7% biologically active F4. No significant decrease in F4 biological activity 
was seen during drying. Both drying techniques, freeze-drying (77 ± 25%) and fluid bed 
drying (69 ± 12%) resulted in comparable activity. Freeze-drying of the F4 solution as 
such resulted in a similar activity (Fig. 2). After freeze-drying in PBS, without any 
lyoprotectant added, 64% remained active. However, as freeze-drying resulted in a 
powder, a subsequent compaction step was required to obtain a multi-particulate 
formulation (mini-tablets). This could lead to a further decrease in biological activity. The 
compaction of a hygroscopic freeze-dried powder has also to be performed at low relative 
humidity and the production of mini-tablets and the subsequent coating has technical and 
economical inconveniences.  
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Figure 2 Biological activity (% of theoretical, mean ± S.D.) of freeze-dried F4 solution (n=1) ( 
after freeze-drying), of F4 incorporated in wet pellets by extrusion/spheronisation (n=1), in fluid 
bed dried pellets (mean ± S.D., n=3) (after production , after 1 month storage 8°C/10% RH ■, 
RT/10% RH and RT/60% RH ) and in freeze-dried pellets (n=1) (after production) (*: Groups 
with the same superscript are not significantly different from each other (p>0.05) (one-way 
ANOVA, post hoc Scheffé) 
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Statistical analysis of the F4 biological activity values after storage for 1 month of the fluid 
bed dried pellets revealed that its stability decreased significantly at all storage conditions 
(p<0.05). Although no significant differences were seen between the different storage 
conditions, the F4 activity tended to be negatively influenced by storage at high 
temperature and high relative humidity (Fig. 2). From these results, it can be concluded 
that F4 fimbriae can be incorporated in a pellet formulation by extrusion/spheronisation 
and subsequent fluid bed drying with maintenance of the F4 biological activity.  
The F4 pellets were coated with 15% (w/w) Eudragit L30D-55. Although a dissolution 
test showed that these pellets had poor enteric properties (24% release of marker substance 
in HCl 0.1N after 2 h), good immunisation results were obtained after administration of the 
F4 pellets to the piglets (Snoeck et al., 2003). The enteric properties of the pellets could not 
be improved by increasing the coat thickness to 30% (w/w) Eudragit L30D-55 (19.4% 
release of marker substance). SEM revealed that the pellets had no spherical shape and 
their surface was not smooth at all. However, the coating layer nicely covered the irregular 
surface (Fig. 3). SEM of a cross section of a pellet showed that because of the irregular 
shape of the pellets, the coating thickness was not homogenous (Fig. 3a). The maximum 
thickness was 58 µm, comparable with values obtained in previous experiments (61.3 ± 8.6 
µm) (Chapter II.2). Nevertheless, on some spots, the thickness was reduced to 16.3 µm. To 
reach good enteric properties, a weight gain of 15% (w/w) of Eudragit L30D-55 is 
recommended. This corresponds to a layer thickness of approximately 30 µm and might 
explain the high release of marker substance in HCl 0.1N after 2 h.  
Huyghebaert et al., Eur. J. Pharm. Biopharm,in press.  
IV. Development of an enteric-coated pellet formulation of F4 fimbriae for oral vaccination of 
suckling piglets against enterotoxigenic Escherichia coli   
171
58.0µm
16.3µm
a
 
Figure 3 SEM picture of pellets consisting of 87.5% α-lactose monohydrate 200 Mesh, 2.5% 
Avicel CL 611 and 10% Explotab, coated with 30% (w/w) Eudragit L30D-55 with inserted 
SEM picture of a cross section showing coating thickness (Fig. 3a).  
Another possible explanation is the presence of disintegrants in the pellets. Swelling, as a 
result of the influx of dissolution medium could cause rupture of the coating and hence 
drug release. The production of pellets on a small scale, missing adequate pressure build up 
during pelletisation can not explain the poor enteric properties, as production on a large 
scale and subsequent coating also resulted in poor enteric properties (47.8 ± 0.9% marker 
substance released in HCl 0.1N after 2 h). 
IV.3.2 OPTIMISATION OF THE PELLET FORMULATION 
The pellet formulation was optimised to improve the enteric properties of the coated pellets 
as this could lead to a dose reduction of enteric-coated F4 pellets needed for oral 
vaccination. Therefore, a disintegrating pellet formulation had to be developed with 
spherical appearance and without incorporation of disintegrants, resulting in good enteric 
properties after coating and the subsequent release of F4 in buffer solution. α-Lactose 
monohydrate was chosen as main excipient of the disintegrating pellets as α-lactose 
monohydrate is water soluble (1 g / 5 ml). As pelletisation of lactose alone is impossible 
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(Villar-López et al., 1999), microcrystalline cellulose was chosen as an additional excipient 
because of its excellent pellet-forming capacity (Newton et al., 1992). It was used in a 
concentration of 20% (w/w) (Formulation I, Table 1) (Dyer et al., 1994). In order to 
evaluate the influence of lactose solubility and particle size on disintegration properties, 
pellets were prepared with either α-lactose monohydrate 200 Mesh (I), 90 Mesh (II) or β-
lactose (III). Although the large lactose fraction in the pellets, none of the pellets were 
completely dissolved after testing for 30 min in PB pH 6.3. Probably, compaction forces 
applied on the pellets during extrusion and subsequent spheronisation lead to dense pellets 
and hence poor disintegration properties. Optical microscopy revealed that after the 
disintegration testing, the size of the pellets consisting of β-lactose decreased significantly, 
in contrast to pellets consisting of α-lactose monohydrate 90 Mesh. This could be 
explained by the higher solubility of β-lactose (1 g/ 2.2 ml). SEM revealed that although 
some ruptures appeared after the disintegration test, the remaining pellets consisting of β-
lactose were still dense. Comparison of Figs. 4 and 5 clearly shows that the remaining α-
lactose monohydrate 90 Mesh pellets were more porous than the remaining α-lactose 
monohydrate 200 Mesh pellets.   
The advantageous properties of β-lactose and α-lactose monohydrate 90 Mesh were 
combined in one pellet formulation at 3 different α-lactose monohydrate 90 Mesh/β-
lactose ratio’s: 25/75 (IV), 50/50 (V) and 75/25 (VI). After the dissolution test, none of the 
pellets completely disintegrated but the pellets with α-lactose monohydrate 90 Mesh/β-
lactose ratio of 75/25 (VI) had a very porous surface, a sponge-like inner structure and 
some ruptures (Fig. 6). During this test, the pellet’s density clearly decreased and after the 
test, the pellets appeared totally wet and soft, and disintegrated by simple touching. This 
might indicate that during in vivo passage, the pellets will easily disintegrate under the 
influence of gastro-intestinal motility. Following production, the pellets appeared spherical 
Huyghebaert et al., Eur. J. Pharm. Biopharm,in press.  
IV. Development of an enteric-coated pellet formulation of F4 fimbriae for oral vaccination of 
suckling piglets against enterotoxigenic Escherichia coli   
173
and had a smooth surface. The pellets were coated and subsequently cured at 8°C/10% RH 
(4 days) as previous results showed that F4 stability was best maintained after storage at 
low temperature and low relative humidity. This resulted in good enteric properties (7.3 ± 
0.2% marker substance released in HCl 0.1N after 2 h) (Fig. 7). Four days of curing were 
necessary as curing for 2 days at these conditions resulted in poor enteric properties of the 
coated pellets (17.8 ± 1.5% released in HCl 0.1N after 2 h). 
Figure 4 SEM picture of the surface and cross 
section (a) of pellets consisting of 80% (w/w) α-
lactose monohydrate 200 Mesh and 20% (w/w) 
microcrystalline cellulose (Formulation I) after 
disintegration test (30 min, PB pH 6.3). 
Figure 5 SEM picture of the surface and cross 
section (a) of pellets consisting of 80% (w/w) 
α-lactose monohydrate 90 Mesh and 20% 
(w/w) microcrystalline cellulose (Formulation 
II) after disintegration test (30 min, PB pH 6.3). 
Further attempts were made to improve the disintegration of the pellets as Debunne et al. 
(2002) showed that addition of 11% of Explotab doubled the amount released of a poorly 
water-soluble drug within 45 min in PB pH 6.8. Nevertheless, Fig. 7 shows that addition of 
5 and 10% (w/w) sodium carboxymethyl starch (formulation VII and VIII, respectively) 
resulted in coated pellets with poor enteric properties (23.9 ± 0.5 and 44.7 ± 4.0 % marker 
substance released in HCl 0.1N after 2 h, respectively). This confirmed the previous 
hypothesis that incorporation of Explotab could result in swelling of the pellets during 
coating and/or dissolution testing in HCl with subsequent rupture of the coating. Increasing 
a
a
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the ratio lactose/microcrystalline cellulose from 80/20 (I) to 90/10 (IX) and 95/5 (X) could 
improve the disintegration but resulted in poor enteric properties (17.7 ± 1.4 and 16.5 ± 1.7 
% marker substance released in HCl 0.1N after 2 h, respectively). 
 
 
Figure 6 SEM picture of pellets consisting of 20% (w/w) microcrystalline cellulose and 80% 
lactose (α-lactose monohydrate 90 Mesh/ β-lactose ratio 75/25 (w/w)) (Formulation VI) after 
disintegration test (30 min, PB pH 6.3). 
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Figure 7 Release of marker substance (mean ± S.D., n=3) after 2 h dissolution in HCl 0.1 N of 
pellets of different composition (cfr Table 1). The horizontal line marks the limit indicated by the 
European Pharmacopoeia for enteric-coated formulations (max. 10% release after 2h 0.1N HCl).                               
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IV.3.3 DOWNSCALING OF THE PRODUCTION PROCESS 
As the F4 solution is only available in low quantities, down scaling experiments were 
performed in an attempt to produce pellets on a smaller scale. Decreasing the excipient 
load for production of the pellets from 700, 300, 100 to 40 g resulted in poor enteric 
properties i.e. from 7.3, 16.5, 17.2 to 50.3 % marker substance released in HCl 0.1 N after 
2 h. This shows that a minimum of excipient was required to produce pellets by 
extrusion/spheronisation to result in good enteric properties after coating. Probably, a 
certain compaction force is necessary to produce compact pellets.  
IV.3.4 F4 STABILITY IN AND RELEASE FROM THE OPTIMISED PELLET FORMULATION 
Determination of the biological activity of F4 incorporated in the optimised coated pellet 
formulation (formulation VI) by ELISA showed the presence of interfering compounds as 
a biological activity of more than 100% was found (values around 150%). F4 biological 
activity from pure F4 solution, incubated with placebo coated pellets even reached values 
around 200%. However, coated placebo pellets showed no background signal, 
demonstrating that the pellet excipients and coating polymer alone were not responsible for 
the interference. This suggests that an interaction between F4 and the pellet excipients 
and/or coating polymer might take place causing the interference in ELISA.  
The molecular weight of the F4 in the dissolution sample was compared to that of the 
native F4 in the F4-stock solution by 12%-SDS-PAGE with previously boiling the samples 
followed by silver staining or immunoblotting (Fig. 8). The 27.5 kDa band of the major 
subunit of the F4 was absent in the dissolution sample and instead, a smear of high 
molecular weight proteins reacting with the F4-specific Mab was seen. This demonstrated 
that the F4 had probably interacted with other compounds, such as the coating polymer 
(polymer: 135 kDa). The deprotonated carboxylic functions of the coating polymer 
probably interact with the cationic regions in the F4 protein.  
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From the present studies, it can be concluded that F4 is released from the optimised and 
coated pellet formulation but there seems to be an incompatibility between the protein and 
the coating polymer.  
Incompatibility between the protein and the enteric-coating polymer resulted in an 
unpredictable quantification of in vitro biological activity, resulting in lack of quality 
control of this dosage form and accurate dosing. Consequently, careful pre-formulation 
studies are required before an oral enteric-coated protein formulation can be developed in 
order to exclude incompatibility between the protein and Eudragit L30D-55. In vivo 
experiments have to reveal if this interaction will lead to altered immunisation capacity of 
the F4-fimbriae. 
F4 stock              Dissolution samples
solution
F4 major subunit
 
Figure 8 12%-SDS-PAGE (with previously boiling of the samples) followed by immunoblotting of 
native F4 in the F4-stock solution and of F4 in the dissolution samples (n=2, undiluted (lane 1 and 
3) and diluted ½ (lane 2 and 4)).  
IV.4 CONCLUSIONS  
From this study, it can be concluded that incorporation of an F4 solution by granulation of 
a dry powder mass, followed by extrusion/spheronisation and fluid bed drying is a suitable 
technique for the production of a multi-particulate formulation of biologically active F4. 
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This opens interesting perspectives for the large-scale production of oral mucosal vaccines. 
A pellet formulation consisting of lactose (α-lactose monohydrate 90 Mesh/β-lactose 
75/25 (w/w)) and microcrystalline cellulose in a ratio of 80/20 (w/w) showed good release 
properties of F4 and coating with 15% (w/w) Eudragit L30D-55 resulted in good enteric 
properties of the pellets. For practical application, oral vaccination of piglets requires the 
daily administration of 2 mg of F4 fimbriae. This corresponds with 2.1 g of the enteric-
coated pellet formulation, which is an acceptable dose quantity as the daily uptake of creep 
feed by suckling piglets is 50 g. Although from this study it is known that the biological 
activity in the pellets decreased significantly after storage at 8° C and RT. This involves 
further optimisation (stabilising additives or lowering the storage temperature) in order to 
obtain a practically applicable formulation.    
However, an interaction between F4 fimbriae and the coating polymers was noticed after 
dissolution testing, resulting in an unpredictable quantification of in vitro F4 biological 
activity and in lack of quality control of this dosage form and accurate dosing. 
Consequently, careful pre-formulation studies are required before an oral enteric-coated 
protein formulation can be developed in order to exclude incompatibility between the 
protein and Eudragit L30D-55. In vivo experiments have to reveal if this interaction will 
alter the immunisation capacity of the F4-fimbriae.  
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Chapter V 
GENERAL CONCLUSIONS AND FUTURE PERSPECTIVES 
 
It can be concluded that the first objective of this research i.e. the development of an enteric-
coated formulation of viable and hIL-10 producing recombinant L. lactis was successfully 
achieved. A freeze-dried powder formulation of L. lactis Thy12 was filled in ready-to-use 
enteric-coated HPMC capsules. In order to meet both requirements of gastric protection and 
ileum targeting and since none of the tested polymers or polymer mixtures can guarantee these 
requirements on their own, the issue of the high gastrointestinal pH variability among individuals 
was circumvented by the use of a combination of doses i.e. one dose coated with Eudragit 
L30D-55 (ensuring ileum release in patients with a low GI-pH profile) while another dose was 
coated with Eudragit FS 30 D (ensuring ileum release in patients with a high GI-pH profile). 
These formulations both protect L. lactis Thy12 against the detrimental acidic conditions. A first 
stability study showed that in order to maintain an acceptable stability, the freeze-dried powder 
should be stored at low temperature (8°C) and N2 atmosphere. However, this storage condition 
was not applicable once the powder has been filled in capsules at 20% RH. Since storage at 20% 
RH resulted in an unacceptable loss of viability, storage temperature was decreased to -20°C. 
After storage of the enteric-coated formulation for 1 year at –20°C the enteric properties, an 
acceptable viability and hIL-10 producing capacity were maintained. This formulation has been 
used successfully in a preclinical study in patients suffering from Crohn’s disease. The results of 
this study have shown that this new therapy is safe, the biological containment strategy was 
effective and suggested a clinical effectiveness of L. lactis Thy12. 
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In order to meet the requirements of a multi-particulate formulation of L. lactis Thy12, it has 
been shown that layering of L. lactis Thy12 on inert carriers is a promising technique for the 
preparation of a multi-particulate formulation of viable, hIL-10 producing bacteria. It is a fast and 
more economical formulation technique in comparison to the one of the previously developed 
formulation as only one apparatus is required for both layering and coating. Moreover, this 
formulation is easier to swallow. In the clinical study, the large size of the enteric-coated capsules 
in combination with the high dose (10 capsules, twice a day) caused problems of swallowing in 
some patients. Next, in comparison with freeze-dried L. lactis Thy12, layered L. lactis Thy12 
have a superior storage stability, in comparison to the freeze-dried L. lactis Thy12. Coating of the 
layered multi-particulate formulation with 15% Eudragit FS 30 D resulted in good protecting 
properties against the detrimental gastric fluid. However, the load of L. lactis Thy12 on the inert 
pellets should be further increased in order to reach acceptable dose quantities to enhance patient 
compliance. Besides, since it appears that the Eudragit L30D-55 polymer, contrary to Eudragit 
FS 30 D, is not acceptable to provide protection against the detrimental gastric fluid, this coating 
has to be further investigated and optimised.  
Next, it can be concluded that for the second objective of this research i.e. the development of an 
enteric-coated formulation of F4 fimbriae, some unsolved problems are left. From this study, it 
was concluded that incorporation of an F4 solution by granulation of a dry powder mass, 
followed by extrusion/spheronisation and fluid bed drying is a suitable technique for the 
production of a multi-particulate formulation of biologically active F4. This opens interesting 
perspectives for the large-scale production of oral vaccines. A pellet formulation consisting of 
lactose (α-lactose monohydrate 90 Mesh/β-lactose 75/25 (w/w)) and microcrystalline cellulose in 
a ratio of 80/20 (w/w) showed good release properties of F4 and coating with 15% (w/w) 
Eudragit L30D-55 resulted in good enteric properties of the pellets. However, further 
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optimisation (stabilising additives or lowering the storage temperature) in order to obtain a 
practically applicable formulation is required as this research indicated that the biological activity 
in the pellets decreased significantly after 1 month storage at 8°C and RT.  Next, an interaction 
between F4 fimbriae and the coating polymer was noticed after dissolution testing, resulting in an 
unpredictable quantification of in vitro F4 biological activity and in lack of quality control of this 
dosage form and accurate dosing. Consequently, careful pre-formulation studies are required 
before an oral enteric-coated protein formulation can be developed in order to exclude 
incompatibility between the protein and Eudragit L30D-55. In vivo experiments have to reveal if 
this interaction will alter immunisation capacity of the F4 fimbriae.  
 
The first objective of this research i.e. the development of an enteric-coated formulation of viable 
and hIL-10 producing recombinant L. lactis was successfully achieved. Although this formulation 
was successfully used in a preclinical trial, there are some drawbacks remaining. The major one is 
the complicated and hence time consuming production process (culture preparation, freeze-
drying, capsule coating, capsule filling) (1). As plans are made to perform a multi-centre study in 
which hundreds of patients will be included, the production of this formulation is no longer 
feasible on lab scale. Therefore, as well as for GMP requirements, the need for a specialised 
production site raises. This would involve high investment cost as the production of this 
formulation includes expensive apparatus (freeze-dryer, fluid bed coater) (2). Moreover, 
monolithic enteric-coated formulations should be avoided because of risk of too long gastric 
residence time (up to 8h) and hence risk of accumulation and dose-dumping. Therefore, a multi-
particulate formulation should be preferred (3). Especially in this study, in which the incorporated 
L. lactis is extremely acid sensitive, a multi-particulate formulation is to be preferred. For those 
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three reasons, future research will focus on the optimisation of a multi-particulate formulation. As 
from this study it was concluded that layering is a promising technique for the production of a 
viable, hIL-10 producing L. lactis, this technique will be the basis for further research. The main 
obstacle remaining is the load of L. lactis on the inert carriers. Therefore, apparatus design, 
layering matrix (L. lactis density and composition), inert carrier design and process parameters 
have to be further optimised in order to increase the load of viable L. lactis in the multi-particulate 
formulation. Next, in order to protect the L. lactis from the gastric fuid and bile salts, the coating 
polymers have to be further investigated and modified.   
Concerning the second objective of this research, it has been shown that the use of an enteric-
coated formulation containing an antigen as oral vaccine offers benefit in terms of protective 
effects. However, the interaction between the F4 protein and the coating polymer has to be 
further investigated as this can be a bottle-neck in further development of any oral antigen 
formulation. To improve oral vaccine efficiency, micro- or nano-particles can be developed in 
order to reach selective M-cell uptake. However, since the production of micor/nano-particles 
often involves the use of organic solvents, high shear forces or higher temperature, other 
production techniques have to be developed, which have no impact on the biological activity of 
the incorporated antigen.  
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SUMMARY 
 
The first objective (Chapter I) of this research was the development of an oral, enteric-coated 
formulation of viable, interleukin producing Lactococcus lactis for the treatment of Crohn’s 
disease (Chapter II) and for the stimulation of mucosal immunity (Chapter II) in suckling 
piglets in order to improve oral vaccination efficiency against enterotoxigenic Escherichia 
coli (ETEC). This veterinary application brings about the second objective of this work i.e. 
the development of an oral, enteric-coated formulation of F4 fimbriae, borne by ETEC strains, 
for oral vaccination of suckling piglets against ETEC.  
In Chapter III, an oral, enteric-coated formulation of viable, interleukin-10 producing L. lactis 
Thy12 has been developed (Chapter III.1). As bacteria are available as a liquid suspension 
after cultivation, the first step in the development was the solidification of this liquid 
suspension. In Chapter III.2 a freeze-dried L. lactis Thy12 formulation was developed with 
preservation of its viability and hIL-10 producing capacity. It was concluded that freeze-
drying of L. lactis MG1363, grown until the stationary phase in skim milk, without any 
previous freezing step resulted in an acceptable survival (60%). In order to determine the best 
storage condition of the freeze-dried powder, short- and long-term stability tests were 
performed and showed a significant influence of storage temperature and atmosphere on 
viability. Storage at 8°C/N2 resulted in the best survival. It was also shown that the hIL-10 
producing capacity of L. lactis Thy12 was maintained after freeze-drying and storage. To 
increase the concentration of the bacteria in the freeze-dried powder, they were concentrated 
by centrifugation. Although L. lactis Thy12 tolerated this procedure, the concentration factor 
was limited to 10. Further experiments were performed to optimise the freeze-drying matrix. 
It was shown that incorporation of the nutrients i.e. glucose and casein hydrolysate in the 
matrix tended to have a negative influence on the viability of L. lactis Thy12. The 
incorporation of 1.25% vitamine C, 10% trehalose or 5% inulin in the skim milk matrix 
resulted in a significant better viability after storage.  
In Chapter III.3, the suitability of polymers for enteric-coating and ileal targeting of 
recombinant L. lactis Thy12 was evaluated in vitro based on the release of thymidine, the 
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essential nutrient of recombinant L. lactis Thy12. Only thymidine pellets coated with 
Eudragit FS 30 D and L30D-55 met the specifications of the European Pharmacopoeia 
concerning enteric-coated formulations (< 10% release after 2 h in HCl 0.1N) without 
requiring a high curing temperature, while pellets coated with Aqoat, Eudragit S, or a 
mixture of Eudragit FS 30 D/L30D-55 (8/2) failed the dissolution test in acidic medium. 
Aqoat AS-HF, Eudragit L30D-55 and a mixture of Eudragit FS 30 D/L30D-55 (8/2) 
dissolved at a pH lower than 6.8, the pH at the target site. Consequently thymidine will be 
released and absorbed in the proximal small intestine and the co-formulated L. lactis will be 
subjected to the detrimental bile salts present in the jejunum. Eudragit FS 30 D and S 
dissolved at a pH above the pH at the target site. Consequently, thymidine and the co-
formulated L. lactis will only be released in the most distal parts of the ileum. This implies 
that the hIL-10 production will not occur in the ileum but only in the colon.  
Chapter III.4 deals with the development of an alternative method for the enteric-coating of 
HPMC capsules, eliminating the sealing step and providing enteric-coated capsules for 
incorporation of freeze-dried L. lactis Thy12. The separate coating of the caps and the bodies 
resulted, after manual assembly, in enteric-coated HPMC capsules that comply with the 
requirements of the European Pharmacopoeia for enteric-coated formulations. The coating 
composition was optimised to allow storage at low temperature and low relative humidity and 
to allow passage through the stomach. The method was reproducible and the coated capsules 
can be stored (either prior to filling or already filled) without affecting the enteric properties. 
Besides, the method is applicable for a broad range of enteric-coating polymers (Eudragit® 
L30D-55 and FS 30 D, Aqoat® AS-HF and Sureteric®) and capsule sizes (number 4 to 00). 
Freeze-dried L. lactis Thy12 was incorporated in the ready-to-use enteric-coated capsules 
coated either with Eudragit® L30D-55 or Eudragit® FS 30 D (7 mg/cm2). This formulation 
protected L. lactis Thy12 against the detrimental acidic conditions of the stomach and after 
storage for 1 year at 8 and –20°C, the enteric properties, an acceptable viability and the hIL-
10 producing capacity were maintained.  
In Chapter III.5 an enteric-coated, multi-particulate formulation (~1 mm) of viable and hIL-
10 producing L. lactis has been developed. This dosage form shows an accelerated gastric 
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emptying and hence decreased residence time in the presence of detrimental gastric fluids and 
an easy administration to piglets as it can be mixed with their creep feed. In a first section, a 
suitable production technique was selected. Three formulation techniques were compared. 
First, freeze-dried L. lactis was compacted into mini-tablets. Next, liquid L. lactis culture was 
used as the granulation fluid for the production of pellets by extrusion/spheronisation. Finally, 
liquid L. lactis culture was layered on inert pellets as an alternative technique for the 
production of pellets. Viability dropped to 15.7% after compaction of freeze-dried L. lactis 
and to 1.0% after pelletisation of liquid L. lactis by extrusion/spheronisation. The viability in 
the mini-tablets and pellets, stored for 1 week at RT and 10% RH was reduced to 23 and 0.5% 
of initial viability, respectively. Storage for 1 week at RT and 60% RH resulted in complete 
loss of viability. Layering of L. lactis on inert pellets resulted in a low viability (4.9%), but 1 
week after storage at RT and 10% RH, 68% of initial viability was maintained. Increasing 
product temperature and cell density of L. lactis in the layering suspension did not 
significantly change viability after layering and storage. hIL-10 production capacity of L. 
lactis Thy12 was maintained after layering. In a next section, the layering matrix was 
modified in order to increase viability after layering and storage. L. lactis Thy12 was layered 
in different matrices (10% skim milk and/or 2.5, 5, 10% inulin). After layering, the highest 
viability was obtained in the 10% skim milk matrix supplemented with 5% inulin (8.7%). 
However, upon storage, 10% skim milk alone yielded the highest viability. Moreover, L. 
lactis Thy12 layered in 10% skim milk showed superior long term stability in comparison 
with L. lactis Thy12 freeze-dried in 10% skim milk. The layering process could be performed 
for 3 h without encountering technical problems and viability remaining constant during the 
entire process. Enteric properties of the layered pellets were obtained with a 30% Eudragit 
L30D-55 or 15% Eudragit FS 30 D coating and were maintained during an initial six months 
storage period (-20°C/20% RH). After in vitro simulation of the gastric stage, only 5% of the 
bacteria remained viable in Eudragit L30D-55 coated pellets, contrary to 85% in Eudragit 
FS 30 D coated pellets. After a 8 month storage period at –20°C, 80% of the initial L. lactis 
Thy12 remained viable in the Eudragit FS 30 D coated pellets. 
Chapter IV described the development of an enteric-coated multi-particulate formulation of 
F4 fimbriae. A feasibility test showed that incorporation of F4 fimbriae in a disintegrating 
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pellet formulation consisting of 87.5% Pharmatose 200M, 2.5% Avicel CL 611 and 10% 
Explotab by extrusion/spheronisation and subsequent fluid-bed drying resulted in 69 ± 12% 
of the biological activity remaining. But subsequent coating resulted in pellets with poor 
enteric properties, although good in vivo immunising results were obtained after 
administration to piglets. From an economical point of view, a pellet formulation was 
optimised to decrease vaccine dose and dosing frequency. After disintegration testing, pellets 
consisting of lactose (α-lactose monohydrate 90 Mesh/β-lactose 75/25 (w/w)) and 
microcrystalline cellulose in a ratio of 80/20 (w/w) showed a sponge-like structure from 
which F4 fimbriae could be released. Coating of these pellets resulted in good enteric 
properties. To improve disintegration properties of the pellets, the lactose concentration was 
increased or sodium carboxymethyl starch was added. However, this resulted in poor enteric 
properties after coating. A dissolution test showed that F4 fimbriae were released from the 
optimised enteric-coated pellets but interactions between F4 fimbriae and the coating 
polymers were seen.  
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Het eerste doel (Hoofdstuk I) van dit onderzoek was het ontwikkelen van een orale, enterisch 
omhulde formulatie van leefbare, interleukine-producerende Lactococcus lactis voor de 
behandeling van de ziekte van Crohn (Hoofdstuk II) en voor het stimuleren van mucosale 
immuniteit (Hoofdstuk II) in zuigende biggen om zo de efficiëntie van orale vaccinatie tegen 
enterotoxigene Escherichia coli (ETEC) te verhogen. Deze veterinaire applicatie brengt het 
tweede doel van dit werk met zich mee nl. de ontwikkeling van een orale, enterisch omhulde 
formulatie van F4 fimbriae, aanwezig op ETEC stammen, voor orale vaccinatie van zuigende 
biggen tegen ETEC.  
In Hoofdstuk III werd een orale, enterisch omhulde formulatie van leefbare, interleukine-10 
producerende L. lactis Thy12 ontwikkeld (Hoofdstuk III.1). Aangezien bacteriën beschikbaar 
zijn als vloeibare suspensie na groei is de eerste stap in de ontwikkeling het drogen van deze 
vloeibare suspensie. In Hoofdstuk III.2 werd een gevriesdroogde formulatie van L. lactis 
Thy12 ontwikkeld met het behoud van zijn leefbaarheid en de hIL-10 producerende 
eigenschap. Er werd geconcludeerd dat het vriesdrogen van L. lactis GL1363, gegroeid tot 
zijn stationaire fase in magere melk, zonder een voorafgaande invriesstap, resulteerde in een 
aanvaardbare overleving (60%). Om de beste bewaaromstandigheden te bepalen van het 
gevriesdroogd poeder werd een korte en lange stabiliteitstudie uitgevoerd en deze toonde een 
significante invloed van bewaartemperatuur en -atmosfeer op leefbaarheid aan. Bewaring bij 
8°C/N2 resulteerde in de beste overleving. Er werd ook aangetoond dat de hIL-10 
producerende eigenschap bewaard bleef na vriesdrogen en bewaren. Om de belading van de 
bacteriën in het gevriesdroogd poeder te verhogen werden de bacteriën aangeconcentreerd 
door centrifugatie. Niettegenstaande L. lactis Thy12 deze procedure tolereerde was de 
concentratiefactor gelimiteerd tot 10. Verdere experimenten werden uitgevoerd om de 
vriesdroogmatrix te optimaliseren. Er werd aangetoond dat het incorporeren van 
voedingsstoffen nl. glucose en caseïne hydrolysaat in de matrix een negatieve invloed bleek te 
hebben op de leefbaarheid van L. lactis Thy12. Het incorporeren van 1.25% vitamine C, 10% 
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trehalose of 5% inuline in de magere melk matrix resulteerde in een significant betere 
leefbaarheid na bewaring.   
In Hoofdstuk III.3 werd de geschiktheid van polymeren voor enterische omhulling en ileum 
specifiek afgifte van recombinante L. lactis Thy12 in vitro geëvalueerd op basis van de 
vrijstelling van thymidine, het essentiële nutriënt van recombinante L. lactis Thy12. Enkel 
thymidine pellets omhuld met Eudragit FS 30 D en L30D-55 voldeden aan de specificaties 
van de Europese Farmacopee betreffende enterisch omhulde preparaten (< 10% vrijstelling na 
2 h in HCl 0.1N) zonder eisen van hoge curing temperatuur, terwijl pellets omhuld met 
Aqoat, Eudragit S of een mengsel van Eudragit FS 30 D/L30D-55 (8/2) faalden tijdens de 
dissolutie test in zuur milieu. Aqoat AS-HF, Eudragit L30D-55 en een mengsel van 
Eudragit FS 30 D/L30D-55 (8/2) losten op vanaf een pH lager dan 6.8, de pH ter hoogte van 
de specifieke afgifte plaats. Bijgevolg zal thymidine vrijgesteld en geabsorbeerd worden in 
het proximale deel van de dunne darm en zal de daarmee geformuleerde L. lactis blootgesteld 
worden aan de schadelijke galzouten aanwezig in het jejunum. Eudragit FS 30 D en S losten 
op vanaf een pH hoger dan de pH ter hoogte van de specifieke afgifte plaats. Bijgevolg zal 
thymidine en de daarmee geformuleerde L. lactis enkel vrijgesteld worden in het meest distale 
deel van het ileum. Dit brengt met zich mee dat de hIL-10 productie niet zal plaatsvinden in 
het ileum maar slechts in het colon.  
Hoofdstuk III.4 behandelt de ontwikkeling van een alternatieve methode voor de enterische 
omhulling van HPMC capsules waarbij de sluitingsstap wordt uitgesloten en die resulteert in 
enterisch omhulde capsules voor de incorporatie van gevriesdroogde L. lactis Thy12. De 
aparte omhulling van hoedjes en lichaampjes resulteerde, na manuele assemblage in enterisch 
omhulde HPMC capsules die voldeden aan de eisen gesteld door de Europese Farmacopee 
aan enterisch omhulde formulaties. De omhullingsamenstelling werd geoptimaliseerd om 
bewaring bij lage temperatuur en lage luchtvochtigheid en passage doorheen de maag toe te 
laten. De methode was reproduceerbaar en de omhulde capsules kunnen worden bewaard 
(enerzijds vóór het afvullen of reeds afgevuld) zonder de enterische eigenschappen te 
beïnvloeden. Daarbij is de methode toepasbaar voor een uitgebreid gamma van enterische 
polymeren (Eudragit® L30D-55 and FS 30 D, Aqoat® AS-HF and Sureteric®) en capsule 
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maten (nummer 4 tot 00). Gevriesdroogd L. lactis Thy12 werd afgevuld in deze kant-en-klare 
enterisch omhulde capsules enerzijds omhuld met Eudragit® L30D-55 en anderzijds met 
Eudragit® FS 30 D (7 mg/cm2). Deze formulatie beschermde L. lactis Thy12 tegen de 
schadelijke zure omstandigheden van de maag en na bewaring voor 1 jaar bij 8 en –20°C 
bleven de enterische eigenschappen, een aanvaardbare leefbaarheid en de hIL-10 
producerende eigenschap bewaard.  
In Hoofstuk III.5 werd een enterisch omhulde, multi-particulaire formulatie (~1 mm) van 
leefbare, hIL-10 producerende L. lactis ontwikkeld. Dit preparaat vertoont een versnelde 
maaglediging en zo een verkorte verblijftijd in de aanwezigheid van de schadelijke 
maagsappen en een eenvoudige toediening aan zuigende biggen aangezien het preparaat 
mengbaar is met hun voeder. In een eerste deel werd een geschikte productietechniek 
geselecteerd. Drie formulatietechnieken werden vergeleken. Vooreerst werd gevriesdroogde 
L. lactis gecompacteerd tot mini-tabletten. Daarnaast werd de vloeibare L. lactis cultuur 
gebruikt als granulatie vloeistof voor de productie van pellets door extrusie/sferonisatie. Als 
laatste werd de vloeibare L. lactis cultuur gelayerd op inerte pellets als alternatieve techniek 
voor de productie van pellets. De leefbaarheid viel terug naar 15.7% na compactie van de 
gevriesdroogde L. lactis en naar 1.0% na pelletisatie van de vloeibare L. lactis cultuur d.m.v. 
extrusie/sferonisatie. Na bewaring voor 1 week bij kamertemperatuur (Tk) en 10% relatieve 
vochtigheid (RV) verminderde de leefbaarheid in de mini-tabletten en de pellets tot 
respectievelijk 23 and 0.5% van de initiële leefbaarheid. Bewaring voor 1 week bij Tk en 60% 
RV resulteerde in een compleet verlies van leefbaarheid. Layering van L. lactis op inerte 
pellets resulteerde in een lage leefbaarheid (4.9%), maar na 1 week bewaring bij Tk en 10% 
RV bleef 68% van de initiële leefbaarheid behouden. Het verhogen van de 
producttemperatuur en de celdensiteit van L. lactis in de layeringsuspensie resulteerde niet in 
een significant gewijzigde leefbaarheid na layering of bewaring. De hIL-10 producerende 
eigenschap van L. lactis Thy12 bleef bewaard na layering. In een volgend deel werd de 
layeringsmatrix gewijzigd teneinde de leefbaarheid na layering en bewaring te verhogen. L. 
lactis Thy12 werd gelayerd in verschillende matrices (10% magere melk en/of 2.5, 5, 10% 
inuline). Na layering werd de hoogste leefbaarheid bekomen in de 10% magere melk matrix 
aangereikt met 5% inuline (8.7%). Maar na bewaring leverde de pure 10% magere melk 
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matrix de hoogste leefbaarheid op. Daarbij vertoonde L. lactis Thy12 gelayerd in 10% magere 
melk een superieure lange termijn stabiliteit in vergelijking met L. lactis Thy12 gevriesdroogd 
in 10% magere melk. Het layeringproces kon worden uitgevoerd gedurende 3 uur zonder 
technische problemen en de leefbaarheid bleef constant gedurende het volledige proces. 
Enterische eigenschappen van de gelayerde pellets werden bekomen met een 30% Eudragit 
L30D-55 of 15% Eudragit FS 30 D omhulling en bleven gehouden gedurende een bewaring 
van 6 maand (-20°C/20% RH). Na in vitro simulatie van de maagtransit bleef slechts 5% van 
de bacteriën in de Eudragit L30D-55 omhulde pellets leefbaar, in tegenstelling tot 85% in de 
Eudragit FS 30 D omhulde pellets. Na acht maand bewaring bij –20°C bleef 80% van de 
initiële L. lactis Thy12 leefbaarheid bewaard in de Eudragit FS 30 D omhulde pellets.  
Hoofdstuk IV beschrijft de ontwikkeling van een enterisch omhulde multi-particulaire 
formulatie van F4 fimbriae. Een eerste test toonde aan dat de incorporatie van F4 fimbriae in 
een desintegrerende pelletformulatie, bestaande uit 87.5% Pharmatose 200M, 2.5% Avicel 
CL 611 en 10% Explotab, door extrusie/sferonisatie en vervolgens wervelbed drogen een 
geschikte techniek is aangezien 69 ± 12% van de biologische activiteit bewaard bleef na 
productie. Maar de daarop volgende omhulling resulteerde in pellets met slechte enterische 
eigenschappen, alhoewel goede in vivo immunisatieresultaten werden bekomen na toediening 
aan biggen. Vanuit economisch standpunt werd deze pelletformulatie geoptimaliseerd om de 
dosis en de toedieningsfrequentie te verlagen. Na een desintegratie test vertoonden pellets,  
bestaande uit lactose (α-lactose monohydraat 90 Mesh/β-lactose 75/25 (w/w)) en 
microkristallijne cellulose in een ratio van 80/20 (w/w), een sponsachtige structuur waaruit F4 
zou kunnen worden vrijgesteld. Omhulling van deze pellets resulteerde in goede enterische 
eigenschappen. Om de desintegratie-eigenschappen van de pellets te verbeteren werd de 
lactose concentratie verhoogd of werd natriumcarboxymethylzetmeel toegevoegd. Maar dit 
resulteerde in slechte enterische eigenschappen na omhulling. Een dissolutie test toonde aan 
dat F4 fimbriae vrijgesteld werden uit de geoptimaliseerde enterisch omhulde pellets, maar 
een interactie tussen F4 fimbriae en het omhullingspolymeer werd vastgesteld.   
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Le premier objectif (Chapitre I) de cette thèse de doctorat était le développement d'une 
formulation orale à enrobage entérique et contenant le Lactococcus lactis viable, produisant 
de l'interleukine pour le traitement de la maladie de Crohn (Chapitre II) et pour la stimulation 
de l'immunité mucosale (Chapitre II) chez des cochons de lait afin d’augmenter l'efficacité de 
la vaccination orale contre l’ Escherichia coli (ETEC) entérotoxique. Cette application 
vétérinaire nous mène au second but de ce travail notamment le développement d'une 
formulation orale à enrobage entérique contenant des F4 fimbriae, présents sur des souches 
d'ETEC, pour la vaccination orale chez des cochons de lait contre l' ETEC.  
Au Chapitre III le développement de la formulation orale à enrobage entérique contenant de 
L. lactis Thy12 vivable, est décrit (Chapitre III.1). Comme les bactéries sont disponibles sous 
forme de suspension liquide, la première étape dans le développement était le séchage de cette 
suspension liquide. Dans Chapitre III.2 le développement d’une formulation lyophilisée de L. 
lactis Thy12 avec maintien de sa viabilité et de la possibilité de produire hIL-10, est décrit. Il 
fut conclu ce que la lyophilisation de L. lactis MG1363 en phase stationnaire dans du lait 
écrémé aboutit à un taux de survie acceptable (60%). Afin de définir les meilleures conditions 
de conservation de la poudre lyophilisée une étude de stabilité à long et moyen terme a 
confirmé une influence significative de la température et de l'atmosphère de conservation sur 
la viabilité. Une conservation à 8°C sous azote a fourni la meilleure viabilité. Ainsi on 
démontre que la capacité de produire du hIL-10 était conservée après lyophilisation et 
conservation. Pour augmenter la charge de bactéries dans la poudre lyophilisée les bactéries 
ont été concentrés par centrifugation. Bien que le L. lactis Thy12 supporte cette procédure, le 
facteur de concentration était limité à 10. Des expérimentations ont été réalisées pour 
optimiser la matrice de lyophilisation. On a démontré que l'incorporation de matières 
nutritives comme le glucose et l’ hydrolysat de caséine dans la matrice exerçait une influence 
négative sur la viabilité de L. lactis Thy12. L'incorporation de 1.25% de vitamine C, 10% de 
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tréhalose ou 5% d’ inuline dans la matrice de lait écrémé résultait en une viabilité 
significativement supérieure après conservation.   
Dans le Chapitre III.3 on a évalué différents polymères pour l’enrobage entérique et le ciblage 
entérique de L. lactis Thy12 recombinante évalué sur base de la libération in vitro de la 
thymidine, un élément nutritif essentiel pour le L. lactis Thy12 recombinante. Seulement des 
pellets contenant la thymidine et enrobés d'Eudragit FS 30 D et L30D-55 correspondaient 
aux spécifications de la Pharmacopée Européenne concernant les préparations gastro-
résistantes et entérosolubles (< 10% libération après 2 h dans HCl 0.1N) sans exiger des 
températures de maturation élevées. Au contraire, les pellets enrobés d’ Aqoat, Eudragit S 
ou un mélange d’ Eudragit FS 30 D/L30D-55 (8/2) ne répondaient pas aux critères pendant 
le test de dissolution dans un milieu acide. Aqoat AS-HF, Eudragit L30D-55 et un mélange 
de Eudragit FS 30 D/L30D-55 (8/2) se dissolvaient à partir d'un pH inférieur à 6.8, le pH 
cible et ainsi la thymidine serait libérée dans la partie proximale de l'intestin grêle et le L. 
lactis co-formulé serait exposé aux sels biliaires, présents dans le jéjunum. Eudragit FS 30 D 
and S se dissolvaient à partir d'un pH supérieur au pH au niveau du site ciblé. Par conséquent 
le thymidine et le L. lactis co-formulé se libéreront seulement dans la partie la plus distale de 
l'iléum. Cela implique que la production de hIL-10 ne se fera pas dans l'iléum mais seulement 
dans le colon.  
Chapitre III.4 traite le développement d'une méthode alternative pour l'enrobage entérique de 
capsules HPMC où l'on élimine l'étape de scellage ce qui fournit des capsules enrobées 
entériquement pour l'incorporation de L. lactis Thy12 lyophilisé. L'enrobage séparé des deux 
parties des capsules a résulté, après assemblage manuel, en des capsules d’HPMC enrobées 
entériquement qui correspondaient aux exigences de la Pharmacopée Européenne pour des 
formulations enrobées entériquement. La composition de l'enrobage a également été 
optimalisée pour permettre une conservation à des températures et humidité basses et un 
passage intact par l'estomac. La méthode était reproductible et les capsules enrobées peuvent 
se conserver sans influencer les qualités entériques. En plus, cette méthode est applicable à 
une gamme étendue de polymères entériques (Eudragit® L30D-55 and FS 30 D, Aqoat® AS-
HF and Sureteric®) et de tailles de capsules (numéro 4 à 00). L. lactis Thy12 lyophilisé a été 
RÉSUMÉ  195
rempli dans les capsules enrobées, alternativement une fraction des capsules fut enrobée avec 
l’Eudragit® L30D-55 et une autre avec l’Eudragit® FS 30 D (7 mg/cm2). Après conservation à 
8 et –20°C,  les qualités entériques, une viabilité acceptable et la capacité de produire hIL-10 
etaient conservées.  
Dans le Chapitre III.5 on a développé une formulation multi-particulaire (~1 mm) enrobée 
entériquement contenant le L. lactis viable produisant de l’hIL-10. Dans une première phase 
nous avons comparé trois techniques de formulation différentes. D'abord on a compacté le L. 
lactis lyophilisée en mini-comprimés. Ensuite on a utilisé la culture liquide de l’L. lactis 
comme liquide de granulation pour la production de pellets fabriqués par 
extrusion/sphéronisation. Enfin on a fixé la culture liquide de l’L. lactis sur des pellets 
neutres. Après compaction, la viabilité de L. lactis lyophilisé est retombée à 15.7% et à 1.0% 
après pelletisation par l'extrusion/sphéronisation. Après conservation durant une semaine à 
température ambiante (Ta) et 10% d'humidité relative (HR) la viabilité dans les mini-tablettes 
et les pellets a diminué jusqu’à une valeure de 23 et 0.5% de la viabilité initiale. La 
conservation durant 1 semaine à Ta et 60% HR a résulté dans une perte complète de la 
viabilité. La fixation de L. lactis sur des pellets neutres a résulté en une viabilité faible (4.9%). 
Après une semaine de conservation à Ta et 10% HR on a pu maintenir 68% de la viabilité 
initiale. L'élévation de la température du produit et la densité cellulaire de L. lactis dans la 
suspension n'a pas résulté en une viabilité significativement changée après layering ou 
conservation. La capacité de l’ L. lactis Thy12 a été conservée après layering. Finalement on a 
fait varier la matrice de layering afin d'augmenter la viabilité. L. lactis Thy12 a été fixé en 
employant différentes matrices (10% lait écrémé et/ou 2.5, 5, 10% inuline). Après layering on 
a obtenu la meilleure viabilité pour une matrice de 10% de lait écrémé enrichie de 5% d’ 
inuline (8.7%). Après conservation prolongée la matrice de lait écrémé pur 10% atteignait la 
viabilité la plus élévée. Le procédé de layering a pu se faire pendant 3 h sans problèmes 
techniques et la viabilité est restée constante pendant toute la durée du procédé. Les qualités 
entériques des pellets enrobées ont été obtenues avec un enrobage de 30% d’ Eudragit 
L30D-55 ou de 15% d’ Eudragit FS30D et ont été maintenues pendant une conservation 
initiale de 6 mois (-20°C/20% RH). Après simulation in vitro du transit gastrique seulement 
5% des bactéries dans les pellets enrobés d’ Eudragit L30D-55 étaient viables, contrairement 
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à 85% dans les pellets enrobés de Eudragit FS30D. Après conservation durant 8 mois à –
20°C,  80% de la viabilité initiale L. lactis Thy12 furent conservés dans les pellets enrobés d’ 
Eudragit FS30D.  
Chapitre IV décrit le développement d'une formulation multi-particulaire enrobée 
entériquement et contenant des F4 fimbriae. Un premier test a montré que l'incorporation de 
F4 fimbriae dans un pellet renfermant 87.5% Pharmatose 200M, 2.5% Avicel CL 611 et 
10% Explotab et fabriqué par extrusion/sphéronisation et séchage en lit d’air fluidisé est une 
technique valable vu que 69 ± 12% de l'activité biologique fut conservée après production. Un 
enrobage ultérieur a produit des pellets avec des mauvaises qualités entériques, même si de 
bons résultats d'immunisation in vivo furent obtenus après application sur des cochons de lait. 
D'un point de vue économique cette formulation en pellets a été optimalisée afin d’abaisser la 
dose et la fréquence d'administration. Après un test de désintégration les pellets, renfermant 
du lactose (α-lactose monohydrate 90 Mesh/β-lactose 75/25 (w/w)) et de la cellulose 
microcristalline dans un ratio de 80/20 (w/w), montraient une structure spongieuse de laquelle 
se libérait le F4. Afin d’améliorer les qualités de désintégration des pellets la concentration en 
lactose fut augmentée ou du carboxyméthylamidon fut ajouté. Malheureusement cette 
modification de la formulation a produit des mauvaises qualités entériques après enrobage. 
Un test de dissolution a montré que les F4 fimbriae étaient libérés à partir des pellets enrobés 
mais qu’ il existait une interaction entre les F4 fimbriae et le polymère d'enrobage.   
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LIST OF ABBREVIATIONS  A
LIST OF ABBREVIATIONS 
 
ABTS    2.2’-azino-bis-(3-ethylbenzthiazoline-6-sulfonic acid) 
alg     alginate 
APC    antigen presenting cells 
CFU    colony forming units 
CMIS    common mucosal immune system 
DBS    dibutyl sebacate 
dpm     dips per minute 
ELISA    enzyme-linked immunosorbent assay 
ETEC    enterotoxigenic Escherichia coli 
FAE    follicle-associated epithelium 
F4R    F4 receptor 
GALT    gut-associated lymphoid tissue 
GC-milk    10% skim milk with 0.5% glucose and 0.5% casitone added 
GCT-milk 10% skim milk with 0.5% glucose, 0.5% casitone and 50µg/ml 
thymidine added 
GI    gastrointestinal 
GM    genetically modified 
GMO    genetically modified organism 
GMP    good manufacturing practice 
GM17    M17 broth with 0.5% glucose added 
GMS    glyceryl monostearate 
GRAS    generally recognised as safe 
hIL-10    human interleukine-10 
HPMC    hydroxypropyl methylcellulose 
IBD    intestinal bowel disease 
ID    intradermal(ly) 
IFN    interferon 
Ig    immunoglobulin 
IL    interleukin 
LIST OF ABBREVIATIONS  B
IM    intramuscular(ly) 
LAB    lactic acid bacteria 
LEMS    liquid encapsulation microsealing spray 
L-HPC    low substituted hydropropyl cellulose 
L. lactis MG1363  plasmid free Lactococcus lactis subsp. cremoris 
L. lactis Thy12  hIL-10 producing Lactococcus lactis MG1363 
Mab    Mouse anti body 
M-cells   microfold cells 
(M)DSC   (modulated)differential scanning calorimetry 
MFT    minimal film-forming temperature 
PAGE    polyacrylamide gel electrophoresis 
PB     phophate buffer 
PBS     phosphate buffer saline  
PEI     polyethyleen imine 
PLG    poly (lactide-co-glycolide) 
PLL     poly-L-lysine 
PP    Peyer’s patches 
PVAP    polyvinyl acetate phtalate 
RH    relative humidity 
RSM    reconstituted skim milk 
RT    room temperature 
SC    subcutaneous(ly) 
SDS    sodium dodecyl sulphate 
SEM     scanning electron microscopy 
S. thyphi   Salmonella thyphi 
S. thyphi 21a   attenuated live strain of Salmonella thyphi 
TEC     triethyl citrate 
Tg    glas transition temperature 
thyA    thymidilate synthase gene 
T-milk    10% skim milk with 50µg/ml thymidine added 
TNF    tumor necrosis factor 
TTFC    tetanus toxin fragment C 
LIST OF ABBREVIATIONS  C
USP    United States Pharmacopoeia  
V. cholerae   Vibrio cholerae 
V. cholerae CVD 103 HgR attenuated live strain of Vibrio cholerae 
 
 
